 
Official Title:   
A Randomized, Double Blind, Placebo- Controlled,  Study to Assess the 
Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys 
With Duchenne Muscular Dystrophy  
Study ID: [REMOVED]  
Document  Date : Protocol  Version 4: 16-August -2018 
 
 
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
2/Protocol WN40227, Version 4  1. DOCUMENT HISTORY  
 
Document  Date  of Issue  Summary of Change s 
Revised Protocol 4 
(Version 4)  See electronic date stamp.   
Amendment 6  
See electronic date stamp.  • Deleted references to the previous  
Bristol -Myers Squibb protocol and 
product numb ers throughout the 
text, except in the Introduction, 
Schedule of  Assessments,  and 
Treatment sections  
• Change the primary endpoint from 
the 4 Stair Climb velocity to the 
North Star Ambulatory Assessment 
total score  
• Added a new inclusion criterion 
requiring a minimum NSAA score of 15 points at screening  
• Changed the 4SCV from the primary endpoint to a secondary endpoint  
• Added 95
th percentile stride velocity, 
as recorded using the ActiMyo as a 
secondary endpoint  
• Added the caregiver video assessment  
at selected sites as a new exploratory 
endpoin t 
• Added the Caregiver Global 
Impression of C hange  at selected 
sites as a new exploratory endpoint  
• Added the Pediatric Quality of Life 
Inventory Multidim ensional Fatigue 
Scale at selected sites as an 
exploratory endpoint  
• Shortened the Study Rationale section to include a high -level 
summary of available clinical data and to refer to the Investigator's 
Brochure for specific details  
• Updated the duration of the open -
label (OL) extension phase and the frequency of visits during the OL extension phase  
• Added the specific sites indicated for subcutaneous injection  
• Deleted the proposed interim an alysis  
• Updated the statistical analysis 
section to establish hierarchical 
testing of the doses  
• Added definitions for different 
situations of incorrect administration 
of study drug  
• Deleted urine biomarkers and miRNA biomarkers as exploratory 
endpoints  
• Added assessment of serum creatine 
kinase level in muscle to the exploratory pharmacokinetic, 
pharmacodynamic, and 
immunogenicity endpoints  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
3/Protocol WN40227, Version 4   
Document  Date  of Issue  Summary of Change s 
Revised 
Protocol 03  
  29 Jan 2018 Incorporates Amendment 05  
Amendment 05  29 Jan 2018.  – Added assessment of CGI -C. 
– Reduced pulmonary function tests  
– Reduced anthropometry assessments  
– Reduced myometry assessments  
– Reduced TFTs and 6MWT in the 
open- label phases  
– Clarified signature of informed 
consent prior to Day  −42 screening 
period  
– Clarified FVC in the exclusion criteria  
– Clarified contraception methods  
– Clarified GDF- 11 sample timepoint  
– Clarified ActiMyo assessments  
– Clarified use of videos  
– Updated requirement for safety 
reporting of overdose  
– Clarified monitoring of ADAs during 
24-week safety follow -up phase  
– Updated Medical Monitor information  
– Updated for consistency with IB, 
version  6 
– Corrected typographical errors  
Revised Protocol 
02 
  21-Aug -2017. Incorporates Amendment 04 
Amendment 04  21-Aug -2017. – Changed Spon sor from Bristol -Myers Squibb 
to F. Hoffmann -La Roche Ltd  
– Changed study drug name from BMS -986089 
to RO7239361 
– Updated Medical Monitor information 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
4/Protocol WN40227, Version 4  Revised  Protocol 
01 20-Apr-2017 Incorporates  Amendment 03 
Amendment 03 20-Apr-2017 – Added text defining significant change in 
dosage for  prednisone and deflazacort.  
– Added measurement of ulna length to baseline 
and on treatment time points.  
– Timing of on treatment  videotaping of 
functional  assessments has been clarified.  
– Timing of Health Care Resource  
Utilization  assessments has been 
clarified.  
– Added clarification that DXA scanning is not 
required  at early  termination.  
– History  of hypersensitivity  of the components 
of the study drug added as an exclusion.  
– Threshold for adjusting dosing weight tier increased  from 1 kg to 2 kg. 
– Text clarifying that malfunctions of pre-filled  
syringes  should be reported to the sponsor in 
accordance with  local regulations has been 
added.  
– Guidance regarding skin biopsy added.  
– Text describing  pharmacogenomics  removed.  
– Corrections of typographical errors.  
Original  Protocol  05-Dec-2016 Not Applicable  
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
5/Protocol WN40227, Version 4   
TABLE OF CONTENTS  
 
TITLE  PAGE  ................................................................................................................  1  
DOCUMENT  HISTORY.............................................................................................. 2 
TABLE  OF CONTENTS............................................................................................. 5 
PROTOCOL AMENDMENT ACCEPTANCE 
FORM ...........................................................................................................................  8 
1 SYNOPSIS.................................................................................................................  9 
2 SCHEDULE  OF ACTIVITIES..................................................................................  16 
3 INTRODUCTION .....................................................................................................  34 
3.1 Study Rational e.................................................................................................  35 
3.1.1 Rationale to Support Dose  Selection  .......................................................  36 
3.1.2 Rationale for Specific Inclusion/Exclusion Criteria  ................................  40 
3.1.3 Rationale for Primary  Endpoint ..............................................................  40 
3.1.4 Research  Hypothesis  ................................................................................  40 
3.2 Background .......................................................................................................  40 
3.3 Benefit/Risk  Assessment  ..................................................................................  42 
4 OBJECTIVES  AND ENDPOINTS  ...........................................................................  44  
5 STUDY DESIGN.......................................................................................................  46 
5.1 Overall  Design  ..................................................................................................  49 
5.1.1 Independent Data  Monitoring Committee  and Other  External   
Committees  ........................................................................................................  49 
5.2 Number of Participants  .....................................................................................  49 
5.3 End of Study Definition  ....................................................................................  49 
5.4 Scientific  Rationale  for Study Design...............................................................  49 
5.5 Justification  for Dose  ........................................................................................  49 
6 STUDY POPULATION ............................................................................................  49 
6.1 Inclusion Criteria  ..............................................................................................  49 
6.2 Exclusion Criteria  .............................................................................................  50 
6.3 Lifestyle  Restrictions  ........................................................................................  52 
6.3.1 Meals  and Dietary  Restrictions  ...............................................................  52 
6.3.2 Caffeine,  Alcohol and Tobacco................................................................  5
2 
6.3.3 Activity  .....................................................................................................  52 
6.4 Screen  Failures..................................................................................................  52 
6.4.1 Rescreening and Retesting  during Screening  Period  ...........................  52 
7 TREATMENT ...........................................................................................................  52 
7.1 Treatments  Administered..................................................................................  55  
7.2 Method of Treatment  Assignment ....................................................................  56  
7.3 Blinding.............................................................................................................  56 
7.4 Dosage  Modification.........................................................................................  57 
7.5 Preparation/Handling/Storage/Accountability..................................................  57 
7.5.1 Retained  Samples for Bioavailability  / Bioequivalence...........................  58 
7.6 Treatment  Compliance......................................................................................  58 
7.7 Concomitant Therapy........................................................................................  58 
7.7.1 Prohibited and/or Restricted  Treatments.................................................  58 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
6/Protocol WN40227, Version 4  7.7.2 Other  Restrictions  and Precautions.........................................................  59 
7.7.2.1 Management of Possible Acute Hypersensitivity Reactions to 
RO7239361 ........................................................................................... 59 
7.7.2.2 Imaging Restriction  and Precautions .............................................  59 
7.8 Treatment  after the End of the Study...............................................................  60 
8 DISCONTINUATION  CRITERIA  ...........................................................................  60 
8.1 Discontinuation from  Study Treatment  ............................................................  61 
8.1.1 Post Study Treatment  Study Follow-up....................................................  62 
8.2 Discontinuation from  the Study ........................................................................  62 
8.3 Lost to Follow-Up.............................................................................................  62 
9 STUDY ASSESSMENTS AND PROCEDURES.....................................................  63 
9.1 Efficacy  Assessm ents........................................................................................  63  
9.1.1 Functional Endpoint Assessment  .............................................................  63  
9.1.2 Myometry and Ankle Range of Motion (ROM)  ........................................  64  
9.1.3 Imaging Assessment  for the Study............................................................  64  
9.1.3.1 DXA.................................................................................................  64  
9.1.3.2 Cardiac MRI (cMRI).......................................................................  65  
9.1.4 Exploratory Genotyping...........................................................................  65 
9.1.5Acti Myo ....................................................................................................  65 
9.1.6 Caregiver Video Assessment ……… .................................................. 66 
9.1.7 Clinical Global Impression of Change (CGI -C) ............................... 66 
9.1.8 Caregiver Global Impression of Change (CaGI- C) ................................. 67 
9.1.9 Pediatric Quality of Life Inventory Multidimensional Fatigue 
Scale (PedsQL MFS)  .......................................................................................... 67 
9.2 Adverse Events  .................................................................................................  67 
9.2.1 Time  Period  and Frequency for Collecting  AE and SAE Information ....  68 
9.2.2 Method of Detecting  AEs and SAEs.........................................................  68 
9.2.3 Follow-up of AEs and SAEs.....................................................................  69 
9.2.4 Regulatory Reporting Requirements  for SAEs.........................................  69 
9.2.5 Pregnancy ................................................................................................  69 
9.2.6 Laboratory Test Result  Abnormalities .....................................................  69 
9.2.7 Potential
 Drug  Induced  Liver  Injury (DILI) ............................................  70 
9.2.8 Other  Safety Considerations ....................................................................  70 
9.2.8.1 Injection  Site Assessments...............................................................  70 
9.2.9 Overdose or Incorrect Administration of Study Drug .............................  71 
9.3 Safety  ................................................................................................................  71 
9.3.1 Physical  Examinations.............................................................................  72 
9.3.2 Vital Signs.................................................................................................  72 
9.3.3 Electrocardiograms and Echocardiograms.............................................  72 
9.3.4 Clinical Safety Laboratory Assessment s..................................................  73 
9.3.5 Imaging Safety Assessment  ......................................................................  74 
9.4 Pharmacokinetics................................................................................................  75 
9.5 Pharmacodynamics  ...........................................................................................  75  
9.6 Pharmacogenomics  ...........................................................................................  75  
9.7 Biomarker s........................................................................................................  75  
9.7.1 Additional Research  Collection  ...............................................................  76  
9.7.2 Immunogenicity Assessments...................................................................  77 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
7/Protocol WN40227, Version 4  9.7.3 RNA Transcriptome Research ……………….... .........................................  77 
9.7.4 RNA Expression  Research  of a Subset of RNA  Species ……………….... ... 77 
9.7.5 Proteome Research …………………..........................................................  77 
9.7.6 Metabolomic Research.............................................................................  77 
9.7.7 Other  Assessments .................................................................................... 78 
9.8 Health  Economics or Medical  Resource  Utilization  and Health  Economics… 78 
10 STATISTICAL  CONSIDERATIONS  ..................................................................... 78  
10.1 Sample  Size Determination.............................................................................  78 
10.2 Populations for Analyses  ................................................................................  78 
10.3 Statistical Analyses  ........................................................................................ .. 79 
10.3.1 Efficacy  Analyses  ..................................................................................... 80 
10.3.2 Safety Analyses.......................................................................................... 81 
10.3.3 Other  Analyses  .......................................................................................... 81 
10.3.4 Interim  Analyses........................................................................................ 81 
11 REFERENCES….. ................................... ......................................................................... 83 
12 APPENDICES …………………........................................................................................ 87 
APPENDIX 1 ABBREVIATIONS  AND TRADEMARKS  ........................................... 88 
APPENDIX 2 STUDY GOVERANCE  CONSIDERATIONS  ....................................... 94 
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW UP AND 
REPORTING................................................................................................................. 102 
APPENDIX
 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND METHODS 
OF CONTRACEPTION.................................................................................................. 106 
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
8/Protocol WN40227, Version 4  PROTOCOL  AMENDMENT  ACCEPTANCE FORM  
TITLE:  A RANDOMIZED, DOUBLE BLIND, 
PLACEBO -CONTROLLED, STUDY TO ASSESS 
THE EFFICACY,  SAFETY,  AND TOLERABILITY OF 
RO7239361 IN AMBULATORY BOYS WITH 
DUCHENNE MUSCULAR DYSTROPHY  
PROTOCOL NUMBER:  WN40227  
VERSION NUMBER:  4 
EUDRACT NUMBER:  2016- 001654- 18 
IND NUMBER:  120,702  
TEST PRODUCT:  Anti-Myostatin Adnectin (RO7239361)  
MEDICAL MONITOR S: , M.D. 
, M.D. , Ph.D.  
SPONSOR:  F. Hoffmann -La Roche Ltd  
 
I agree to conduct the study in accordance with the current protocol.  
   
Principal Investigator’s Name  (print)    
   
Principal Investigator’s Signature   Date  
Please retain the signed original of this form for your study files.  Please return a copy of 
the signed form as instructed by your study monitor.   

 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
9/Protocol WN40227, Version 4   
1 SYNOPSIS  
Protocol Title:  A Randomized, Double Blind, Placebo- Controlled,  Study to Assess the Efficacy,  
Safety,  and Tolerability  of RO7239361 in Ambulatory Boys  with Duchenne Muscular  Dystrophy 
Study Phase  2/3 Rationale 
The purpose  of this study  is to evaluate the efficacy,  safety  and tolerability  of weekly  subcutaneous 
(SC)  doses  of RO7239361 compared  to placebo  in ambulatory boys  with Duchenne m uscular  
dystrophy (DMD).  
Study Population:  
Key Inclusion Criteria:  
• Males,  ≥ 6 to < 12 years  of age at time of randomization  
• Diagnosis of DMD,  confirmed  by medical  history  (e.g., onset of clinical  signs  or symptoms  
before  5 years of age together  with an elevated  serum  creatine kinase level  observed before 
or after initial diagnosis)  and by genotyping 
• Participants  ≥ 15 kg 
• Ambulatory without  assistance  
• Participants  must  be receiving  corticosteroids  (CS; prednisone, prednisolone, or 
deflazacort)  for at least 6 months prior to the start of study drug,  with no significant change  
in dosage (> 0.2 mg/kg  prednisone or > 0.24 mg/kg  deflazacort)  or dosing regimen  
for at least 12 weeks  prior to the start of study drug, with the expectation  that dosage 
and dosing regimen will not change significantly  for the duration of the study 
• North Star Ambulatory Assessment  (NSAA) score ≥ 15 points at screening  
• 4SC ≤ 8 seconds at screening  
• Participants  must  agree to avoid major  changes  in their physical  or respiratory  therapy  
regimen during the double -blind phase, to the extent possible 
 
Key Exclusion Criteria:  
• Participants  with cognitive  impairment or behavioral issues that, in the judgement  of the 
investigator, will compromise  their ability  to comply  with study procedures 
• Participants  on intermittent CS regimens  with off periods of 20 days or longer (e.g.: 10 
days on, 20 days  off) 
• Any change (initiation,  change  in drug class,  dose modification  unrelated  to change in body  
weight, interruption  or re-initiation)  in prophylaxis/treatment for congestive heart  failure  
(CHF)  within  12 weeks  prior  to start of study  treatment 
• Any change (initiation,  change  in drug class,  dose modification  unrelated  to change in body  
weight,  interruption  or re-initiation)  in prophylaxis/treatment for bone  density within  
12 weeks  prior to start of study  treatment 
• Treatment  with exon  skipping therapies  within  6 months  prior to the start of study drug 
administration.  
• Treatment  with ataluren  currently or within 12 weeks prior to the start of study drug 
administration  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
10/Protocol WN40227, Version 4  • Treatment with  any other investigational drug (excluding deflazacort  in CS dose-finding 
trials ) currently  or within  12 weeks  prior  to the start of study drug administration   
• Concomitant or previous participation at any time in a gene therapy study  
• Participants  with a FVC  of < 50% of predicted value  (in participants able to produce a 
valid  FVC,  as judged by the clinical evaluator or respiratory  therapist)  
• Cutaneous  AEs  sustained  during participation in a prior  clinical trial  that resolved less  than  
12 weeks  prior to the start of study  drug administration  
• Current  or prior treatment  within  12 weeks  prior to the start of  study drug  administration  
with androgens or human growth hormone 
• Prior treatment  with RO7239361 or any  other anti -myostatin agent  
• History  of lower  limb fracture  within  12 weeks  prior to the start of study drug 
administration  
• History  of upper limb fracture  within  8 weeks  prior  to the start of study drug 
administration.  
• Any injury that may impact  functional  testing.  Previous  injuries  must  be fully healed  
prior to consenting. 
• Expectation  of major  surgical  procedure, such as scoliosis  surgery,  during the double- blind 
phase of  this study  
• Requirement  of daytime  ventilator assistance  
• Initiation  of nighttime  ventilation  less than 4 weeks  prior to the start of study drug 
administration  
• Expectation  that day time or nighttime ventilation  may be initiated during the double -blind 
phase of this study  
• Clinical signs or  symptoms of uncontrolled  congestive heart failure  (CHF ) (American 
College of Cardiology/American  Heart Associated Stage C or Stage D)  
• For participants participating  in cMRI  substudy:  implanted  ferromagnetic  metal  (implanted  
metal  that is not ferromagnetic, such as surgical steel or titanium implants may be allowed  
if the implants will not compromise  the quality of the cMRI) . 
• Unwilling or unable to administer study  drug at home  
  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
11/Protocol WN40227, Version 4  Objectives and Endpoints:  
 
Objectives  Endpoints  
Primary  
• To compare  the efficacy  of RO7239361  to 
placebo in ambulatory boys with Duchenne  
muscular  dystrophy  
• The change  from  baseline  in the North Star 
Ambulatory Assessment (NSAA) total score 
at Week  48 in RO723936 -treated  participants 
compared to  placebo -treated  participants.  
Secondary  
• To compare the efficacy  of RO7239361 to placebo  
using the following tests:   
− 4 stair climb velocity (4SCV)  
− Stand from supine velocity 
− 10 M walk/run velocity  
− PODCI transfers and basic mobility subscale  
− Proximal  lower  extremity  flexor  (knee  
extension  and knee flexion)  strength,  measured  
using manual myometry 
− 6 Minute Walk Distance  (6MWD)  
− Clinical Global Impression of Change 
(CGI -C) 
− Stride velocity recorded with ActiMyo   
• Change  from  baseline  at Week  48 in 
RO7239361- treated  participants  compared  to 
placebo -treated  participants  in the following   
− 4 stair climb velocity ( 4SCV)  
− Stand from supine velocity 
− 10 M walk/run velocity  
− PODCI transfers and basic mobility subscale  
− Proximal  lower  extremity  flexor  (knee  
extension  and knee flexion)  strength,  measured  
using manual  myometry  
− 6-Minute Walk Distance (6MWD)  
− Clinical Global Impression of Change 
(CGI -C) 
− 95th percentile stride velocity , as recorded with 
ActiMyo in a subset of the overall study 
population  
• To assess the safety  and tolerability  of RO7239361  in 
boys with DMD as reflected by new or worsening lab 
abnormalities  (as defined  by CTCAE  criteria),  
serious  adverse  events  (SAEs)  and adverse  events  
(AEs) leading to discontinuation.   • Tabulations  of the numbers  of unique  participants  
with new or worsening  laboratory  abnormalities,  
SAEs  and AEs leading to discontinuation,  in 
RO7239361 arms compared to the placebo arm.   
Tertiary/Exploratory  
• To assess the safety  and tolerability  of RO7239361  in 
boys with DMD as reflected  by vital signs,  
measures  of cardiac function   
• Summaries and listings  of vital signs,  ECG  
parameters, echocardiogram parameters.  
− Proportion of participants with on treatment  
adverse  events  in RO7239361 arms  
compared to the placebo arm  
– Proportion of participants with on treatment  
decrease in ejection fraction (EF), measured  
using echocardiography,  in RO7239361 
arms compared to the placebo arm  
  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
12/Protocol WN40227, Version 4   
Objectives  Endpoints  
  
• To compare the efficacy  of RO7239361 to placebo  
using the following tests:  
- Performance of upper limb (PUL) total score  • Change  from  baseline at Week  48 in RO7239361 
treated  participants  relative  to placebo  treated  
participants  in: 
– Performance of upper limb (PUL) total score  
• To evaluate  other  measures  of efficacy, quality  of 
life and health  care utilization  • Change  from  baseline  at Week  48 in RO7239361  
treated participants compared to placebo treated  
participants: 
− Pulmonary function tests, including FVC, 
% predicted FVC FEV 1, MEP, and MIP  
− PODCI total score  
−  Caregiver Global Impression of Change  
(CaGI -C) in a subset of the overall study 
population  
− Pediatric Quality of Life Inventory 
Multidimensional Fatigue Scale (PedsQL 
MFS) in a subset of the overall study 
population  
− Cardiac magnetic resonance imaging (cMRI)  
measures of ejection fraction, fractional strain, 
and volume of fibrosis in a subset of the overall 
study population  
• Strength of elbow flexors,  elbow extensors, and  
pinch, measured by manual myometry  
• Health Utilities Index III and PedsQL Family  
Impact  Module  scores 
• Assessments at select ed timepoints during the study  
of: 
− Dual x-ray absorptiometry  (DXA) measures  
of lean body mass, fat mass and bone mineral  
density  
− Activity levels in a subset of the overall study 
population, as recorded with ActiMyo 
− Scoring of functional assessments, as recorded 
by a subset of parents/caregivers participating in the caregiver video assessment  
− Number of falls during  treatment in the 
RO7239361 arms compared with the placebo 
arm 
  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
13/Protocol WN40227, Version 4   
Objectives  Endpoints  
• To evaluate  RO7239361 pharmacokinetics , 
pharmacodynamics , and immunogenicity  • Assessments at select timepoints during the study  
of: 
− Serum  RO7239361  concentrations  
− Serum free myostatin and myostatin drug 
complex  concentrations  
− Serum ADA concentrations  
− Serum creatine kinase  level in muscle  
• To explore the effect of genetic variation on target  
engagement, pharmacodynamic (PD)  effects  or 
functional test endpoints  • Assess the impact on genetic variation in the 
DYSTROPHIN  gene or in genes suspected to impact  
DMD disease expression (including but not limited  
to LTBP4, SPP1) in RO7239361 and placebo  
treated participants, on target  engagement,  
pharmacodynamic (PD) and functional endpoints  
 
 
Overall Design:  
This is a multi -center,  randomized, double-blind, placebo -controlled  study to  assess the efficacy,  
safety  and tolerability  of two different  weekly  SC doses of RO7239361 in ambulatory boys  with 
Duchenne muscular  dystrophy (DMD).  
Eligible  participants  will be randomized  to receive  doses of RO7239361 or placebo  (1:1:1 across 
the three treatment arms). The randomization  will be stratified by: 
• Age (6  through  7 and  8 through 11)  
• CS regimen : daily  (prednisone, prednisolone or deflazacort)  vs. intermittent  (any  
non-daily  dosing of prednisone, prednisolone or deflazacort) 
 
A separate randomization  will be conducted for Japan  (N∼15) with stratification  for age only 
(6 through 7 and 8 through 11) not CS regimen . 
RO7239361 or placebo  will be administered  weekly.  The first three  doses (Days  1, 8 and 15) of 
study drug must be administered at the site. Parents/caregivers will be trained to administer  SC 
injections  during the first three  dose administrations.  Parents/caregivers  can administer  the 
injection  at home  starting  at Day  22.  Site staff should ensure that the  parent  or caregiver is able to 
perform injections at home.  Parents/caregivers  will be dispensed an approximately  6- or 12 -week  
supply  of drug in pre-filled  syringes  (RO7239361 or placebo) , during the double -blind  phase  and 
open -label ( OL) extension  phase, respectively,  for weekly  study  drug/placebo administration to 
the participant.  
Study visits  and endpoint measurements  will occur as indicated  in Table  2-1 though Table 2-4.  
After  completion of this 48-week  double-bl ind phase,  participants  may enter  the OL phase in 
which  all participants  will receive active  RO7239361 study drug.  Participants  who discontinue 
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
14/Protocol WN40227, Version 4  the study drug at any time  (i.e., early  discontinuation  for subjects  who do not enter  the OL 
extension  phase or at completion of the OL extension  phase)  will enter  a 24 -week safety  follow -
up phase of the study.  Participants  will be monitored for safety  at three visits  during  the follow -up 
phase.   The participant will be requested to  provide immunogenicity  samples  at all follow-up visits  
during the 24 -week follow -up phase . 
Number  of Participants: 
Statistical Considerations:  
Sample  Size:  
Assuming the standard  deviation  of the NSAA is 4.4 points , with approximately 150 evaluable  
subjects,  the final analysis  will have 80% power to detect  a between  group difference of 
2.5 points . The number randomized  will be increased  to allow  for an approximate dropout 
rate on the order of 5% at the primary  analysis,  so approximately  159 participants  will be 
randomized. Approximately 15 of these participants will be randomized in Japan,  and the 
remaining  participants  will be randomized outside of Japan. 
The final analysis  will test for differences  between each RO7239361 treatment and placebo  in 
either  direction.  The doses will be tested against placebo in a hierarchical manner, with the high 
dose (Dose 2) tested versus placebo in the first step of the hierarchy. If the null hypothesis of no 
difference between the high dose and placebo is rejected in favor of t he RO7239361 dose at a two -
sided α level of 0.05, then the low dose (Dose 1) will be tested against placebo .   
The primary  analysis,  on the change  from  baseline in NSAA total score , will be conducted using  
a mixed model r epeated  measures  (MMRM) analysis  with treatment,  visit,  and the treatment -
by-visit interaction  entered  into the model as fixed  effects,  and participant entered  as a random 
effect.  The baseline value  of the NSAA total score  will be entered  into the model  as a covariate.  The 
stratification  factors will be entered into the model as blocks. 
Sensitivity analyses will include the following: an analysi s of covariance (ANCOVA) using the  
modified intent -to-treat ( mITT) data set; an  ANCOVA on the mITT  data set with missing  data 
imputed  using multiple  imputations; and an MMRM analysis using the per-protocol data.  
  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
15/Protocol WN40227, Version 4  Treatment Arms and Duration:  
 
OL=open label; SC=subcutaneous.  
Study Treatment:  
Each  participant will be administered weekly, SC doses of RO7239361 (previously , 
BMS -986089)  or placebo  for 48 weeks  in a randomized, double -blind  design. Participants  who 
complete the 48-week  double - blind phase  are eligible  to receive OL RO7239361 (active 
treatment)  as part of an OL extension  phase of this study. The OL extension  phase will last up to 
192 weeks or  until RO7239361 is commercially available in the subject' s country, per local 
regulations, or the study is terminated by the Sponsor, whichever comes first . Please refer to  Section 
7.8 for details regarding treatment after the end of study.   Doses  in the OL extension  phase  may 
be adjusted  based  on emerging data.  
  

 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
16/Protocol WN40227, Version 4   
Study  Drug  
Medication  Potency  IP/Non -IP 
RO7239361 7.5 mg dose 10.7 mg/mL (0.7mL/syringe)  IP 
RO7239361  15 mg dose  21.4 mg/mL (0.7mL/syringe)  IP 
RO7239361  35 mg dose  50 mg/mL (0.7mL/syringe)  IP 
RO7239361  50 mg dose  71.4 mg/mL  (0.7mL/syringe)  IP 
RO7239361  matching placebo  0 mg/mL (0.7mL/syringe)  IP 
 
 
Other  medications  used as support  medication  for preventative, diagnostic, or therapeutic reasons, 
as components of the standard  of care for a given  diagnosis, may be considered as 
non-investigational products. In this study,  corticoster oids are considered a non-investigational  
product and will not be provided by the sponsor. 
Study drug preparation and administration instructions will be provided in a separate manual.  
 
2 SCHEDULE OF ACTIVITIES  
Study procedures and assessments are present in  Table 2-1, Table 2-2, Table  2-3, and  Table 2-4. 
 
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
17/Protocol WN40227, Version 4  Table  2-1: Screening Procedural Outline  
 
Procedure  Screening  
Visit  
(Day  -42 to 
Day -1) Notes  
Eligibility Assessments  
Informed Consent  X A participant is considered enrolled only when a protocol specific informed consent is signed 
Informed consent may be signed prior to Day -42. 
Register / enroll participant in IWRS  X  
Inclusion/Exclusion Criteria  X  
Medical History  X Include disease history and any toxicities or allergies related to previous treatments.  
Concomitant Medications  X Include complete history of corticosteroids.  
Physical  Examination (PE)  X  
Physical  Measurements  X Includes height, weight, hand  circumference and  ulna length;  see Clinical Evaluator (CE)  
manual . 
Vital Signs  X Includes body temperature (recommend  using tympanic  thermometer), respiratory  rate, and  
seated blood pressure and heart rate. Blood pressure and heart rate should be measured after the  
participant has been resting quietly for at least 5 minutes.  
Electrocardiogram (ECG)  X ECG should be recorded after the participant has  been  supine  for at least 5 minutes.  See Eli 
150c/250c User Guide  
Echocardiogram  X See E CHO  Manual  
Laboratory  Assessments  X Section  9.3.4 
Urinalysis  X  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
18/Protocol WN40227, Version 4  Table  2-1: Screening Procedural Outline  
 
Procedure  Screening  
Visit  
(Day  -42 to 
Day -1) Notes  
Cardiac MRI  (At select  U.S. centers  only)  X See Section  9.1.3.2  and the imaging procedure manual . 
Baseline  cMRI  should  be obtained  between  Day -40 and Day  -14. The adequacy  of cMRI  scan 
should be confirmed by the imaging vendor prior to randomization.  
Subjects  enrolled at select U.S. centers will be required to attempt to complete the cMRI.  
DXA X See Section  9.1.3.1  and the imaging procedure manual;  
Baseline  DXA  should  be obtained  between  Day -42 and Day  -14. Adequacy  of DXA  scan 
should be confirmed by the imaging vendor prior to randomization.  
DXA is not required  for subjects  enrolled  at sites in Germany.  
NSAA  X See the Clinical Evaluator  Manual .  The NSAA  assessment  must  be performed to determine 
subject  eligibility (NSAA ≥ 15 total score i nclusion criteri on), videotaped for ATO M review and 
confirmed to be adequate prior to randomization  
TFTs  X Includes 4SC, 10 m walk/run, stand from supine  
At screening visit: 4SC must be  ≤ 8 seconds. See CE Manual;  
A videotape of screening TFTs must be reviewed by ATOM and confirmed adequate prior to  
randomization; see Bracket Videographer Manual  
6MWD  X A videotape of screening 6MWD must be reviewed by ATOM and confirmed adequate prior to  
randomization.  
PFTs  X To include  FVC,  % predicted  FVC,  FEV 1, MEP,  and MIP.  See PFT Site Manual.  
ActiMyo  X Subjects at selected  sites who agree to participate  will wear the ActiMyo device  from screening until 
Day 1 .  See the ActiMyo manual.  
Adverse Event Reporting  
Monitor for Serious Adverse Events  X All SAEs must be collected from the date of participant’s written consent  until 50  days post 
discontinuation of dosing in the present study. If the participant enters a separate rollover  
treatment  study  of RO7239361, the participant’s SAEs will be reported in that study.  
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
19/Protocol WN40227, Version 4  Table  2-2: On Treatment  Procedural  Outline, Double -Blind Phase  
 
Procedure  D1a D8 
± 1 day  
(Wk  1) D15 
± 1 day  
(Wk 2)  D29 
± 1 day  
(Wk 4)  Wk 6  
± 3 days  Wk 12   
± 3 days  Wk 18   
± 3 days Wk 24   
± 3 days  Wk 30   
± 3 days  Wk 36   
± 3 days  Wk 42   
± 3 days  Wk 48  or 
early D/C  
± 3 days  Notes  
Physical Examination 
(PE)      X  X    X  
Targeted PE  X X X X X  X  X X X  See Section 9. 3.1 
Monitor Injection Sites  X X X X X X X X X X X X Report findings as AEs, as appropriate. 
It is strongly recommended that 
photographs of injection site reactions without personally identifying 
information be obtained for submission 
to the sponsor or designee  
Some subjects with injection site reaction or rash may be asked to 
participate in additional procedures to 
determine type of immune reaction. See 
Section 9.2.8.1 . 
Weight  X     X  X  X  X See Study Procedure Manual  
Height  X     X  X  X  X See CE Manual  
Ulna Length X            See CE Manual   
Only to be measured instead of 
standing height if height cannot be 
measured  
Hand Circumference  X       X    X See CE Manual  
Vital Signs  X X X X X X X X X X X X See note in screening procedures.  
Con med assessment  X X X X X X X X X X X X Include corticosteroids  
Physical therapy and 
respiratory therapy 
assessment  X     X  X  X  X Assess current physical and respiratory therapy regimen  
Echocardiogram       X  X  X  X See ECHO  Manual  
 
 
   
Table  2-2: On Treatment  Procedural  Outline, Double -Blind Phase  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
20/Protocol WN40227, Version 4 
 Procedure  D1a D8 
± 1 day  
(Wk  1) D15 
± 1 day  
(Wk 2)  D29 
± 1 day  
(Wk 4)  Wk 6  
± 3 days  Wk 12   
± 3 days  Wk 18   
± 3 days Wk 24   
± 3 days  Wk 30   
± 3 days  Wk 36   
± 3 days  Wk 42   
± 3 days  Wk 48  or 
early D/C  
± 3 days  Notes  
Electrocardiogram 
(ECGs)  X       X    X ECGs should be recorded after the 
participant has been supine for at least 5 
minutes. See Eli 150c/250c User Guide  
Laboratory 
Assessments  X X  X  X  X  X  X Section 9. 3.4 
Placement of an intravenous lock is 
allowed for onsite visits when multiple 
blood draws are required.  
Urinalysis  X   X  X  X  X  X  
Blood PK Sampling  X X X X  X  X  X  X See section 9. 4 for the sample 
collection schedule. Must be collected 
prior to administration of study drug.  
Immunogenicity 
Sampling  X  X X  X  X  X  X Must be collected prior to administration of study drug.  
In the event of a positive 
immunogenicity response, additional 
neutralizing antibody (NAB) testing 
will be  conducted.  
Serum Free Myostatin 
and Myostatin -Drug 
Complex  X X X X  X  X  X  X Myostatin -drug complex will not be 
analyzed at baseline  
Must be collected prior to 
administration of study drug.  
Serum Biomarkers  X     X  X  X  X  
Additional Research 
Sample  X       X    X  
Exploratory 
genotyping sample  X             
TFTs  X     X  X  X  X See Clinical Evaluator Manual; TFT 
assessment must be videotaped for ATOM review at D1, Wk 24 and Wk 
48 visits  
 
 
   
Table  2-2: On Treatment  Procedural  Outline, Double -Blind Phase  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
21/Protocol WN40227, Version 4 
 Procedure  D1a D8 
± 1 day  
(Wk  1) D15 
± 1 day  
(Wk 2)  D29 
± 1 day  
(Wk 4)  Wk 6  
± 3 days  Wk 12   
± 3 days  Wk 18   
± 3 days Wk 24   
± 3 days  Wk 30   
± 3 days  Wk 36   
± 3 days  Wk 42   
± 3 days  Wk 48  or 
early D/C  
± 3 days  Notes  
6MWD  X     X  X  X  X See Clinical Evaluator Manual; 6MWD 
assessment must be videotaped for 
ATOM review at D1, Wk 24 and Wk 
48 visits  
ActiMyo  X 
(Scr to 
Day 1)     X 
(Wk 6 
to 
Wk 12)  X 
(Wk 18 
to 
Wk 24)  X 
(Wk 30 to 
Wk 36)  X 
(Wk 42 to 
Wk 48)  Subjects at selected  sites who opt in will 
wear ActiMy o device  at home and 
during visits . See ActiMyo manual.  
NSAA X     X  X  X  X See Clinical Evaluator Manual; NSAA 
assessment must be videotaped for ATOM review at D1, Wk 24 and Wk 
48 visits  
PFTs  X       X    X To include FVC, % predicted FVC, 
FEV1, MEP, and MIP. 
See PFT Site Manual  
Upper & Lower Extremity Myometry  X 
      X    X See Clinical Evaluator Manual; 
myometry assessment must be videotaped for ATOM review at D1, 
Wk 24 and Wk 48 visits  
Grip & Pinch Strength  X       X    X See Clinical Evaluator Manual  
PUL X       X    X See Clinical Evaluator Manual; PUL 
assessment must be videotaped for 
ATOM review at D1, Wk 24 and Wk 
48 visits  
Right Ankle Range of 
Motion  X       X    X See Clinical Evaluator Manual  
Caregiver video 
assessment  X     X  X  X  X Subjects at select ed sites who opt in  
will record videos at selected timepoints  of the study  (as specified),  
or at any applicable  visits after start 
date. The v isit window  is +2 weeks. 
See 
Section 9.1.6 and the 
parent/ caregiver manual.  
 
 
   
Table  2-2: On Treatment  Procedural  Outline, Double -Blind Phase  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
22/Protocol WN40227, Version 4 
 Procedure  D1a D8 
± 1 day  
(Wk  1) D15 
± 1 day  
(Wk 2)  D29 
± 1 day  
(Wk 4)  Wk 6  
± 3 days  Wk 12   
± 3 days  Wk 18   
± 3 days Wk 24   
± 3 days  Wk 30   
± 3 days  Wk 36   
± 3 days  Wk 42   
± 3 days  Wk 48  or 
early D/C  
± 3 days  Notes  
PODCI  X     X  X  X  X Completed by Parent/Caregiver (should 
be the same parent/caregiver at each 
visit) 
HUI-3 X       X    X Completed by Parent/Caregiver (should 
be the same parent/caregiver at each 
visit) 
Health Care Resource 
Utilization  X   X  X X X X X X X Protocol mandated procedures, test & 
encounters are excluded  
PedsQL Family 
Impact Module  X     X  X  X  X Completed by Parent/Caregiver (should 
be the same parent/caregiver at each 
visit) 
CaGI -C            X Completed by parent/caregiver (who 
has been involved in  the study from 
baseline) who opt in at selected sites  
CGI-C 
           X Completed by Clinician 
(e.g., Principal Investigator  or other 
clinician who has interacted with 
the individual from baseline)  
CaGI -C 
           X Completed by parent/caregiver (who 
has been involved in the study from 
baseline) who opt in at selected sites  
Pediatric Quality of 
Life Inventory 
Multidimensional 
Fatigue Scale (PedsQL 
MFS)   X     X  X  X  X Completed by parent/caregiver who opt 
in at selected sites (should be the same 
parent/caregiver at each visit)  
Cardiac MRI             X Visit window +/ - 1 week. Conducted at 
early termination if ≥ 24 weeks from 
previous cMRI.  
See Section 9.1.3.2  and the imaging 
procedure manual.  cMRI will be 
completed at select U.S. sites only. 
Subjects enrolled at select U.S. centers 
 
 
   
Table  2-2: On Treatment  Procedural  Outline, Double -Blind Phase  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
23/Protocol WN40227, Version 4 
 Procedure  D1a D8 
± 1 day  
(Wk  1) D15 
± 1 day  
(Wk 2)  D29 
± 1 day  
(Wk 4)  Wk 6  
± 3 days  Wk 12   
± 3 days  Wk 18   
± 3 days Wk 24   
± 3 days  Wk 30   
± 3 days  Wk 36   
± 3 days  Wk 42   
± 3 days  Wk 48  or 
early D/C  
± 3 days  Notes  
will be required to attempt to complete 
the cMRI.  
DXA        X    X Visit window +/ - 1 week. Not required 
at early termination visit. 
See Section 9.1.3.1  and the DXA 
Scanning Guide.  
DXA is not required for subjects 
enrolled at sites in Germany or for early 
termination visits.  
Monitor for Non - 
Serious Adverse 
Events  X X X X X X X X X X X X All participants administered study 
drug will be closely monitored for AEs 
including possible immunogenicity-
related AEs, such as rash, fever. Injection sites will be evaluated at each visit (see above).  
Falls should be assessed at each study 
visit b. 
Monitor  for Serious 
Adverse Events  X X X X X X X X X X X X All SAEs must be collected from the 
date of participant’s written consent 
until 50 days  
post discontinuation of dosing.  
Falls should be assessed at each study 
visit b. 
Randomize  X             
Access IWRS to obtain 
study drug kit 
assignment  X X X X X X X X X X X X Access IWRS as needed to obtain sufficient drug. Access IWRS as 
needed to replace kits. 
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
25/Protocol WN40227, Version 4  Table  2-3: Open -Label  Phase  Procedural  Outline  
 
Procedure  Wk 1a Wk 2  
± 1 day  Wk 3  
± 1 day  Wk 6  
± 3 days  Wk 12  
± 3days Wk 18  
± 3days Wk 24  
± 3days Wk 36  
± 3days Wk 48/ 
or early 
D/C 
± 3 days Wk 60  
±  5 days Wk 72  to 
Wk 192 
±  5 days Notes  
Week 1 of the open-l abel phase occurs 1 week 
after the end of the Week 48 double -blind visit  
After Week 24 visits to take place every 
12 weeks  
Safety Assessments              
Physical Examination 
(PE)         X    
Targeted PE X    X  X X   X See Section 9. 3.1; to be assessed every 24 weeks 
after Wk 48 of the OL phase  
Monitor Injection 
Sites X X X X X X X X X X X Report findings as AEs, as appropriate.  
It is strongly recommended that photographs of injection site reactions without personally 
identifying information be obtained for 
submission to the sponsor or designee.  
Some subjects with injection site reaction or rash may be asked to participate in additional procedures to determine type of immune 
reaction. See Section 9.2. 8.1 
Vital Signs  X   X X X X X X X X See note in screening procedures  
Con med assessment  X X X X X X X X X X X Include corticosteroid assessment  
Physical therapy and 
respiratory therapy 
assessment  X    X  X X X X X Assess current physical therapy and respiratory 
therapy  
Weight  X    X  X X X X X See Study Procedure Manual  
Height  X    X  X  X X X See CE Manual  
Ulna Length X          X See CE Manual   
Only to be measured instead of standing height if 
height cannot be measured.  
Hand Circumference        X  X  X See CE Manual; to be assessed every 24 weeks after 
Wk 48 of the OL phase 
Echocardiogram        X  X  X See E CHO  Manual; to be a ssessed every 24 weeks 
after Wk  48 of the OL phase  
 
  
 
Table  2-3: Open -Label  Phase  Procedural  Outline  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
26/Protocol WN40227, Version 4 
 Procedure  Wk 1a Wk 2  
± 1 day  Wk 3  
± 1 day  Wk 6  
± 3 days  Wk 12  
± 3days Wk 18  
± 3days Wk 24  
± 3days Wk 36  
± 3days Wk 48/ 
or early 
D/C 
± 3 days Wk 60  
±  5 days Wk 72  to 
Wk 192 
±  5 days Notes  
Week 1 of the open-l abel phase occurs 1 week 
after the end of the Week 48 double -blind visit  
After Week 24 visits to take place every 
12 weeks  
Safety Assessments              
Electrocardiogram 
(ECGs)          X  X ECGs should be recorded after the participant has 
been supine for at least 5  minutes. See Eli 
150c/250c User Guide; to be assessed every 24 
weeks after Wk 48 of OL phase. 
Laboratory Tests  X    X  X X X X X Placement of an intravenous lock is allowed for 
onsite visits when multiple blood draws are 
required.  
Urinalysis      X  X X X X X  
Monitor for Non -
Serious Adverse 
Events  X X X X X X X X X X X See notes above.  
Falls should be assessed at each study visit b. 
Monitor for Serious Adverse Events  X X X X X X X X X X X See notes above.  
All SAEs must be collected from the date of 
participant’s written consent until 50 days post discontinuation of dosing in the present  study. If 
the participant enters a separate rollover treatment study of RO7239361, the participant’s SAEs will 
be reported in that study.  
Falls should be assessed at each study visit b. 
Blood PK Sampling  X X X  X  X X X   Must be collected prior to administration of study 
drug. See  section 9. 4 for the sample collection 
schedule.  
TFTs  X      X  X  X See Clinical Evaluator Manual Functional 
measures at Open Label Week 1 Visit must be obtained prior to dosing; TFT assessment must be 
videotaped for ATOM review at Wk  24 and Wk 
48 visits. To be assessed every 24 weeks after Wk 
48 of the OL phase.  
 
  
 
Table  2-3: Open -Label  Phase  Procedural  Outline  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
27/Protocol WN40227, Version 4 
 Procedure  Wk 1a Wk 2  
± 1 day  Wk 3  
± 1 day  Wk 6  
± 3 days  Wk 12  
± 3days Wk 18  
± 3days Wk 24  
± 3days Wk 36  
± 3days Wk 48/ 
or early 
D/C 
± 3 days Wk 60  
±  5 days Wk 72  to 
Wk 192 
±  5 days Notes  
Week 1 of the open-l abel phase occurs 1 week 
after the end of the Week 48 double -blind visit  
After Week 24 visits to take place every 
12 weeks  
Safety Assessments              
6MWD  X      X  X  X See Clinical Evaluator Manual  
Functional measures at OL Week 1 visit must be 
obtained prior to dosing; 6MWD assessment must 
be videotaped for ATOM review at Wk 24 and 
Wk 48 visits. To be assessed every 24 weeks after 
Wk 48 of the OL phase.  
NSAA X      X  X  X See Clinical Evaluator Manual Functional 
measures at OL Week 1 visit must be obtained 
prior to dosing; NSAA assessment must be 
videotaped for ATOM review at Wk  24 and Wk 
48 visits. To be assessed every 24 weeks after Wk 
48 of the OL phase.  
ActiMyo      X 
(Wk 6 
to  
Wk 12)   X  
(Wk 18 
to  
Wk 24)  X 
(Wk 30 
to Wk 
36) X 
(Wk 42 
to  
Wk 48)    Subjects at selected sites who opt in during the 
double -blind phase of the study will wear the 
ActiMyo device at home and during visits of the 
OL phase. See the ActiMyo manual.  
PUL X      X  X  X See Clinical Evaluator Manual Functional 
measures at Open Label Week 1 Visit must be obtained prior to dosing; PUL assessment must be 
videotaped for ATOM review at Wk  24 and Wk 
48 visits. To be assessed every 24 weeks after Wk 
48 of the OL phase.  
PODCI        X  X   Completed by parent/ caregiver (should be the 
same parent/caregiver at each visit)  
CGI-C         X   Completed by clinician (e.g.,  Principal 
Investigator or other clinician who has 
interacted with the individual from baseline)  
Should be the same clinician at both visits.  
 
  
 
Table  2-3: Open -Label  Phase  Procedural  Outline  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
28/Protocol WN40227, Version 4 
 Procedure  Wk 1a Wk 2  
± 1 day  Wk 3  
± 1 day  Wk 6  
± 3 days  Wk 12  
± 3days Wk 18  
± 3days Wk 24  
± 3days Wk 36  
± 3days Wk 48/ 
or early 
D/C 
± 3 days Wk 60  
±  5 days Wk 72  to 
Wk 192 
±  5 days Notes  
Week 1 of the open-l abel phase occurs 1 week 
after the end of the Week 48 double -blind visit  
After Week 24 visits to take place every 
12 weeks  
Safety Assessments              
Immunogenicity 
Sampling  X X X  X  X  X  X Must be collected prior to administration of study 
drug. In the event of a positive immunogenicity 
response, additional NAB testing will be 
conducted. To be assessed every 24 weeks after Wk 
48 of the OL phase.  
Serum Free 
Myostatin and 
Myostatin -Drug 
Complex  X X X  X  X X X   Must be collected prior to administration of 
study drug.  
Serum Biomarkers      X  X X X    
PFTs  X      X  X  X To include FVC, % predicted FVC, FEV 1, MEP, 
and MIP  
See Clinical Evaluator Manual Functional 
measures at OL Week 1 visit must be obtained 
prior to dosing. To be assessed every 24 weeks after 
Wk 48 of the OL phase.  
Upper & Lower 
Extremity Myometry  X      X  X  X See Clinical Evaluator Manual Functional 
measures at OL Week 1 visit must be obtained 
prior to dosing; myometry assessment must be 
videotaped for ATOM review at Wk 24 and Wk 
48 visits. To be assessed every 24 weeks after Wk 
48 of the OL phase.  
Grip & Pinch 
Strength X      X  X   See Clinical Evaluator Manual Functional 
measures at OL Week 1 visit must be obtained 
prior to dosing.  
Right Ankle Range of 
Motion  X      X  X  X See Clinical Evaluator Manual Functional 
measures at OL Week 1 visit must be obtained 
prior to dosing. To be assessed every 24 weeks after 
Wk 48 of the OL phase.  
 
  
 
Table  2-3: Open -Label  Phase  Procedural  Outline  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
29/Protocol WN40227, Version 4 
 Procedure  Wk 1a Wk 2  
± 1 day  Wk 3  
± 1 day  Wk 6  
± 3 days  Wk 12  
± 3days Wk 18  
± 3days Wk 24  
± 3days Wk 36  
± 3days Wk 48/ 
or early 
D/C 
± 3 days Wk 60  
±  5 days Wk 72  to 
Wk 192 
±  5 days Notes  
Week 1 of the open-l abel phase occurs 1 week 
after the end of the Week 48 double -blind visit  
After Week 24 visits to take place every 
12 weeks  
Safety Assessments              
Caregiver video 
assessment        X  X   Subjects at selected sites who opt in to 
participate in the c aregiver video assessment 
during the double -blind phase will record 
videos at the specified timepoints. Visit 
window: + 2 weeks. See Sectio
n 9.1.6 and the 
Parent
/Caregiver manual.  
CaGI -C         X   Completed by parent/caregiver (who has been 
involved in the study from baseline) who opt in 
at selected sites. Should be the same 
parent/caregiver at each visit.  
HUI-3       X  X   Completed by parent/ caregiver (should be the 
same parent/caregiver at each visit)  
Health Care Resource 
Utilization  X      X  X   Protocol mandated procedures, tests, and 
encounters are  to be excluded.  
PedsQL Family 
Impact Module        X  X   Completed by parent/ caregiver (should be the 
same parent/caregiver at each visit)  
Pediatric Quality of 
Life Inventory 
Multidimensional Fatigue Scale 
(PedsQL MFS)        X  X   Completed by parent/caregiver who opt in at selected sites (should be the same 
parent/caregiver at each visit).  
Cardiac MRI 
(At select ed sites)         X  X* Visit window +/ - 1 week.  
Conducted at early termination if ≥ 24 weeks from 
previous cMRI.  
See the imaging procedure manual. * To be 
assessed every 48 weeks during the OL phase.  
 
  
 
Table  2-3: Open -Label  Phase  Procedural  Outline  
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
31/Protocol WN40227, Version 4 
 a Week 1 of the open-label (OL) phase  occurs one week after the end of the Week 48 double -blind visit. After W eek 24  of the OL phase, visits will take place every 
12 weeks , with some assessments performed every 12,  24, or every 48 weeks  as specified on the schedule of activities.  The OL phase will last up to 192  weeks or 
until RO7239361 is commercially available in the subject ’s country, per local regulations, or the study is terminated by the Sponsor , whichever occurs first. 
Please refer to Section 7.8  for details regarding treatment after the end of study.  
In the e
vent
 of multiple procedures are required at a single timepoint, the following is a list of procedures from highest priority to low: 
1) Safety  (ECG, echocardiogram)  
2) Safety  (clinical labs)  
3) Pharmacokinetic Sampling  
4) Biomarker Sampling  
b Falls will be reported only as an adverse event  if worsen ing (e.g., more frequent falls) compared with  pre-treatment . 
  
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
32/Protocol WN40227, Version 4 
 Table  2-4: Post Study Drug/Placebo Administration Follow- up Procedural Outline 
 
Procedure  Follow -up 
Week  8 
± 1 week  Follow -up 
Week  16 
± 1 week  Follow  up 
Week  24 
± 1 week  Notes  
NSAA  X X X For participants who discontinue  study  drug  before  Week  48 of the double -blind 
Phase, a follow -up visit will be schedule to coincide  with the date at which  the 
Week  48 visit of the double -blind phase would  have  occurred,  when  possible.  
Adverse Event Reporting      
Monitor injection site  X X X Report findings as AEs, as appropriate.  
It is strongly  recommended that photographs of injection site reactions without  
personally  identifying  information be obtained for submission to the sponsor or  
designee.  
Some  subjects  with injection site reaction or rash  may be asked to participate in  
additional  procedures  to determine  type of immune  reaction.  See Section  9.2.8.1  
Monitor  for previously  
reported or new onset of non- 
serious adverse events  X X X All non-serious adverse events must be collected until 50 days post discontinuation 
of dosing in the present study. If the participant enters a separate rollover treatment  
study  of RO7239361, the participant’s non- serious adverse events will be reported  
in that study  
Monitor  for previously  
reported  or new onset  of 
serious  adverse events (SAEs)  X X X All SAEs must be collected from the date of participant’s written consent until 
50 days post discontinuation of dosing in the present study. If the participant 
enters a separate rollover  treatment  study  of RO7239361, the participant’s SAEs 
will be  reported in that study.  
Safety  Assessments      
ECG    X Only required for participants who do not participate in a separate rollover study and  
who discontinue study drug due to cardiovascular concerns.  
Echocardiogram    X Only required for participants who do  not participate in a separate rollover study and  
who discontinued study drug due to cardiovascular concerns.  
  
  
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
33/Protocol WN40227, Version 4 
 Table  2-4: Post Study Drug/Placebo Administration Follow- up Procedural Outline 
 
Procedure  Follow -up 
Week  8 
± 1 week  Follow -up 
Week  16 
± 1 week  Follow  up 
Week  24 
± 1 week  Notes  
Laboratory  Assessments  X X X Only required for participants who do not participate in a separate rollover study and  
who discontinued study drug due to an abnormal  laboratory  result.  Lab result s should  
be followed until the participant’s lab values return to baseline or are considered 
stable  by the investigator . 
Immunogenicity  X X X Required for all patients who do not participate in a separate rollover study .   
In the event of a  positive immunogenicity response, additional NAB  testing  will be 
conducted.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
34/Protocol WN40227, Version 4    
3 INTRODUCTION  
DMD is  an X-linked  human disease that affects  1 in 3600- 6000 live male births,  with an estimated  
15,000 patients with the disease  in the United States . DMD results  from  mutations  in the 
DYSTROPHIN  gene (locus Xp21.2), that lead to absent  or defective dystrophin production The 
clinical manifestation  of this molecular  lesion  is progressive weakness  and limitation  in motor  
capacity,  with proximal  muscles  affected  initially  followed  by distal muscles.  Cardiac and 
respiratory  failure  typically  begin  to develop  in adolescence and lead to death  in the second  or 
third decade of life. Current  standard  of care is limited  to symptomatic  treatment,  including 
medical  and physical  therapies  to improve cardiac  and respiratory  function as well as 
corticosteroids  to improve  skeletal  muscle  strength  and function. However, corticosteroids  are 
associated  with significant adverse side effects,  including obesity, diabetes,  short stature,  
osteopenia, and fracture.2 Translarna (ataluren)  received  a conditional marketing  authorization in 
the European  Union with a restricted  indication  for the treatment  of DMD  specifically  resulting 
from  a nonsense  mutation  in the DYSTROPHIN  gene.  Exondys51 (eteplirsen)  received 
accelerated approval  by the U.S. FDA  for treatment  of DMD resulting  from  mutations  amenable  
to skipping exon 51. As both Translarna and Exondys51 target  restricted  populations with specific  
mutations, the unmet need  for safe and  effective treatments in DMD remains significant.  
Myostatin,  also known as growth  and differentiation  f actor -8 (GDF -8), is a member  of the 
transforming  growth  factor -β (TGF -β) superfamily  of secreted  growth  factors.  It is a negative  
regulator of skeletal  muscle  growth  and development  that is expressed  predominantly in skeletal  
muscle  beginning at  embryogenesis  and persisting  through  adulthood. Nonclinical models support 
the anti-myostatin  mechanism  as potentially  efficacious  in DMD.  Deletion  of the Myostatin  gene  
from  mdx mice, the  most  commonly used mouse  model of  DMD , which  carries  a premature stop 
codon  in exon  23 of DYSTROPHIN , resulted  in attenuation of the dystrophic  phenotype  relative  to 
mdx mice  with intact Myostatin  genes .3,4 Similarly,  weekly  administration  of anti-myostatin  
monoclonal antibodies to mdx mice resulted in increases in muscle size and strength .5 
RO7239361 (previously , BMS -986089)  is a bivalent human  anti -myostatin  adnectin,  which has 
been formatted  with a human IgG1  Fc tail to prolong its half-life in circulation.  RO7239361 is 
being developed as a once  weekly,  subcutaneously administered  therapeutic to increase muscle  
mass  and strength.  RO7239361 has a unique mechanism  of action  (MOA)  that includes  the 
competitive  inhibition  of Alk4/5  (signaling receptor)  recruitment  and binding  to free myostatin  or 
the myostatin -ActRIIb  complex. This MOA leads  to the inhibition  of downstream  pSMAD2/3  
intracellular  signaling with physiological consequences of  increased  muscle  volume and body 
weight.  54, 55 RO7239361  is being developed as a potential therapy  to improve  muscle  function  
in DMD.  As most  ambulatory DMD patients  are treated  with corticosteroids (CS),  in this 
study of ambulatory patients with DMD,  RO7239361 will be given to subjects on stable CS 
therapy.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
35/Protocol WN40227, Version 4   3.1 Study Rationale  
Study WN40227 is a multi- center,  randomized, double -blind,  placebo -controlled  study to assess  
the efficacy,  safety,  and tolerability  of two different  weekly  subcutaneous (SC)  doses  of 
RO7239361  in ambulatory boys  aged  ≥ 6 to < 12 years  with DMD.  
DMD is caused  by mutations  within  the DYSTROPHIN  gene  that result  in loss of the mRNA 
reading  frame,  severely  limiting  dystrophin protein production .6  The DYSTROPHIN  gene lies on 
the X chromosome and thus DMD is primarily  expressed  in boys.  The disease  manifests  as 
progressive weakness  of skeletal,  respiratory,  and cardiac  muscles  due to the absence of dystrophin 
in the subsarcolemmal  cytoskeleton.7 Progressive  weakness  and contractures  lead to loss of 
ambulation  by age 13 and death from cardiorespiratory  failure  by the late 20s to early 30s.8 In the 
absence  of supportive  treatment,  patients  rarely  survive beyond their teens .9 Advances  in 
management,  including CS use, physical  therapy  for contractures,  ventilatory  support, spinal  
surgery,  and cardiac management  have increased  the life expectancy  for patients  with DMD.9,10,11 
With  these advances,  aggressively  managed  patients  may ambulate  beyond 14 years of  age and 
survive  into their early  30s.9,10 
Although advances  in the management  of DMD have  improved survival, chronic  CS treatment  is 
associated  with adverse side effects  that contribute  to morbidity  in DMD.8,11 While  Translarna  
(ataluren)  has received a conditional marketing  authorization in the EU for the treatment of DMD  
resulting  from  a nonsense  mutation  in the DYSTROPHIN  gene,12 this treatment  is restricted  to the 
15% of patients  with DMD with this type of mutation  12,13 Similarly, Exondys51 (eteplirsen)  has 
received U.S. FDA  approval for treatment  of DMD  resulting  from  mutations  amenable  to exon  
51 skipping, roughly only 13%  of the DMD population. Thus,  there remains  a significant unmet 
medical  need for novel agents to treat DMD.  
Data from  prior  and ongoing clinical  studies suggest  that RO7239361 is generally  safe and well 
tolerated and  has expected  effects  on pharmacodynamic endpoints. 
A first-in-human  (FIH) assessment of RO7239361 ( Study CN001001), a combined single -
ascending  dose (SAD)/multiple -ascending  dose (MAD) study to investigate the safety, 
tolerability, pharmacokinetics , pharmacodynamics , and immunogenicity  in healthy  adult  subjects , 
showed that single and multiple doses ( of up to 180  mg weekly ) of RO7239361 were generally safe 
and well tolerated . The most  common  adverse events ( AEs) considered  by the investigator to be 
related  to study  drug were mild or moderate injection  site reactions, and  that, in most  cases,  did 
not require treatment.  There were no acute  hypersensitivity  reactions  during this study. The 
presence of a nti-drug antibodies ( ADAs ) did not appear to affect  the safety or exposure of 
RO7239361 in healthy subjects. Administration  of both single  and multiple  doses of RO7239361 
produced dose-dependent  reductions  in free serum  myostatin  and increases in myostatin -drug  
complex  consistent  with target engagement.  Findings supporting the expected pharmacodynamic 
(PD) effects of RO7239361 include increases in whole right thigh muscle volume (measured by 
magnetic resonance imaging)  and increases in  the change from baseline in the percentage of  lean 
body m ass (as measured by dual X -ray absorptiometry  [DXA] ). 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
36/Protocol WN40227, Version 4    
Study WN40226 is a Phase  1b/2, multi -center,  randomized,  placebo -controlled,  double -blind, 
multiple -ascending  SC dose study  in ambulatory boys ages ≥ 5 to < 11 years  with DMD who 
are receiving  CS. This study  was designed  as a dose-ranging study to characterize the safety,  
pharmaockinetics , target  engagement  (i.e., myostatin  suppression) and the relationship  between  
pharmaockinetics  and target  engagement  over at least 3 doses  in boys  with DMD. As of 8 
February 2018, all 43 patients randomized had completed the 24- week double- blind phase of the 
study. In all, 42 patients completed the 48- week OL phase and 41 entered into the OL extension 
phase. Two patients withdrew from the study for non- safety reasons .  The study met its primary 
objective of show ing safety and tolerability of RO7239361. The most common AEs  that were  
considered by the investigators to be related to study drug were mild to moderate injection -site 
reactions that resolved wit hout change to study treatment; there were no acute hypersensitivity 
reactions associated with study drug reported. Immunogenicity data from 43 g s showed a single 
value of low  positive ADA titer in 1 p atient who ha d received RO7239361 . 
Pharmacokinetic ( PK) data from Panels  1 to 3 ( which  includ ed all three  doses tested) show 
dose- related increases in peak and overall exposure, which appear to be dose proportional . 
Furthermore, an effect of body weight on the RO7239361 pharmacokinetics  has been such 
that with increasing body weight , the clearance  increases.  Preliminary target engagement 
data from Panels  1 to 3 show robust dose -related increases in free serum myostatin suppression. 
As shown by the population PK /PD model, the three different dose levels achieved 77%, 92%,  and 
97% reduction in serum -free myostatin.  
Further information  regarding the available clinical data  of RO7239361 in healthy volunteers 
and patients  with DMD can be found  in the Investigator's Brochure (IB). 
3.1.1  Rationale  to Support Dose Selection  
Two doses  of RO7239361 were selected for this  study  based on i nterim data from 
Study  WN40226 ; doses that are safe and were predicted to  produce a moderate level  of free 
myostatin  suppression ( ≥ 70% relative  to baseline)  and a second  dose that is safe and was predicted 
to produce a high er level of free myostatin  suppression ( ≥ 90% relative to baseline).  
Whereas statistically  signif icant increases in muscle volume were observed at >  80% suppression  
of free myostatin  levels  relative  to baseline in a dose ranging study in cynomolgus monkeys, 
numerical  but non statistically  significant increases  were observed at approximately 54%  
suppression relative  to baseline  following administration  of RO7239361 in that study. Similarly,  in 
Study CN001001, the multiple  dose study in normal healthy  subjects, statistically  significant  
increases  in muscle  volume were observed for RO7239361 versus  placebo  at doses  that sustained  
free serum  myostatin  suppression  above  68% at the time of MRI  assessment  (Day  57). In that same  
study,  no significant  increases  in muscle  volume were  observed at doses  or regimens  that 
generated  a suppression of approximately  42% or lower  on Day 57. The increase  in muscle  volume 
observed in monkeys  and humans following  RO7239361 administration  is expected  to correlate  
with an increase in thigh  muscle  to non-contractile tissue  fraction  in children with DMD.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
37/Protocol WN40227, Version 4   Given  that increase in muscle  mass  and strength  mediated  by RO7239361 induced  suppression  
of free myostatin  is the underlying mechanism  that is expected  to ultimately  drive the  efficacy  
of RO7239361 in patients  with DMD,  dose selection  for Study  WN40227 is based  on target  
engagement,  i.e., free myostatin  suppression. 
All available PK and free myostatin  data following administration  of 4 mg QW and 12.5 mg QW 
doses from  Study WN40226 were  analyzed  in an interim  analysis  (Interim  Analysis  1). Data were  
modeled using a population PK /PD model based on the concept of  target  mediated  drug 
disposition  (TMDD) . Using  the estimates  of the PK/PD  model parameters  and the associated  
variabilities,  the PK and free myostatin  suppression profile following various doses in an 
ambulatory DMD  population were obtained. The population of subjects in the simulations  reflected  
the age (6 to 12 years)  and weight  (≥15 kg) of ambulatory  DMD subjects  in Study  WN40227. 
Simulations  were  performed  for 1000 subjects  in each 5 kg weight  bin. Based  on the results  of the 
simulations,  a fixed  dose by weight  tier dosing  strategy  was chosen. Accordingly,  doses  for 
subjects  will be based  on their respective weight  tier, namely  Weight  Tier 1: ≥ 15 to ≤ 40 kg, 
or Weight  Tier 2: > 40 kg. This dosing  strategy  was intended to  provide similarity  in levels  of 
exposure and target  suppression  for subjects within  a given  weight  tier targeting  the achievement  
of either  ≥ 70% (Dose  Level  1) or ≥ 90% (Dose  Level  2) suppression  of free myostatin at trough.  
Doses selected for Study  WN40227 ar e as follows: 
 
Table 3.1.1-1: Dose Level 1, targeting moderate level of suppression: ( ≥ 70%  
suppression at trough)  
 
Dose Level  Body Weight tier Body Weight range  Dose  
1 1 ≥ 15 to ≤ 40 kg 7.5 mg QW  
1 2 > 40 kg 15.0 mg QW  
 
 
Table 3.1.1-2: Dose  Level 2,  targeting  high level of suppression: (≥ 90%  
suppression at trough)  
 
Dose Level  Body Weight tier Body Weight range  Dose  
2 1 ≥ 15 to ≤ 40 kg 35 mg QW  
2 2 > 40 kg 50 mg QW  
 
The dose may be adjusted when a subject’s weight exceeds or drops below the dosing weight tier 
to which he was originally assigned by > 2 kg, confirmed by repeat.  
The population PK /PD model was further developed utilizing more observations, including the 
top dose data from S tudy WN40226 (see  the IB). This model predicts similar reductions of free 
serum myostatin  of over 90% for both doses tested . In healthy subjects , the pre-filled syringe  ( PFS) 
achieved approximately 1.6- fold higher exposure than the vial formulation. If this would also be 
the case in patients with DMD, the exposure achieved in this study with the PFS at the top dose 
 
A nti -M y ost ati n A d necti n, ( R O 7 2 3 9 3 6 1) — F.  H off m a n n - L a R oc he Lt d 
3 8 /Pr ot oc ol W N 4 0 2 2 7, Versi o n 4   wo ul d still be lo wer t ha n t he e x pos ure ac hie ve d wit h 1 8 0 m g i n  healt h y s u bjects. T he dr u g was 
well tolerate d u p to doses of 1 8 0 m g Q W i n healt h y vol u nteers.  Alt ho u g h t he doses ma y gi ve hi g her 
ser u m m yostati n re d uctio n as i nitiall y e x pecte d, tiss ue le vel m yostati n re d uctio n is u nk no w n. 
T here ma y be mea ni n gf ul differe nces i n tiss ue effects , a n d t herefore t he co nti n ue d use of t he selecte d 
doses is j ustifie d.  
3. 1. 2  R ati o n al e f or S p e cifi c I n cl u si o n/ E x cl u si o n Crit eri a  
A ge R a n ge:  
A mi ni m u m  a ge  of i ncl usi o n of 6 years  is  pla n ne d, as  c hil dre n  y o u n ger t ha n  6 years  are less  li kel y 
t o c o nsiste ntl y u n derst a n d a n d  be  a bl e  t o  c o o perat e  wit h  perf or mi n g  t he  f u ncti o nal e n d p oi nts,  s uc h  
as  t he N S A A , relia bl y.  A n  u p per  a ge  li mit  f or  i ncl usi o n  of  < 1 2  years  is  pla n ne d  t o  e na ble   a f oc us  
o n c hil dre n  w h o  are  a ble  t o  perf or m  t he  f u nctio nal e n d poi nts  a n d  w h ose  l o wer  e xtre mities  ha ve  s o me 
i ntact  m uscle  tiss ue.  R O 7 2 3 9 3 6 1 is  e x pecte d  t o  preser ve  a n d  i m pr o ve m uscle  stre n gt h  pri maril y  
b y  i ncreasi n g t he size of e xisti n g  m uscle  fi bers.  T heref ore,  it  is  a ntici pate d  t hat  t he o pti mal  eff ect  
of R O 7 2 3 9 3 6 1 o n a m b ulat or y D M D  patie nts  will  be  bef ore  l o wer  e xtre mit y  m uscle  fi bers  ha ve  bee n  
c o m pletel y  re place d  b y  fat  a n d fi br osis.  A f urt her rati o nale f or li miti n g  t he a ge ra n ge i n t his st u d y  
is t o mi ni mize varia bilit y  wit h  res pect  t o  t he ti mi n g  a n d  e xte nt  of f u ncti o nal a n d p h ysical deficits,  
a n d  d u e t o  t he patie nt’s  a ge, gr o wt h, mat urit y,  a n d c o nc o mita nt  me dicati o ns.  B ot h  n at ural  hist or y 
a n d  cli nical  trial  dat a  ha ve  hi g hli g hte d  t he si g nifica nt  varia bilit y  i n   f u ncti o nal e n d p oi nts .1 6, 1 7, 1 8  
Ke y  a p pr o ac h es  t o  mi ni mizi n g  t his  varia bilit y  i ncl u de  restricti n g   t he a ge  ra n ge  f or   i ncl usi o n, 
t here b y re d uci n g varia bilit y  ste m mi n g fr o m  gr o wt h. 
N S A A Mi ni m u m Score : 
It was rece ntl y re porte d  2 6  t hat  i n a m b ula nt bo ys, a baseli ne total li neari ze d N S A A score of 
5 0 poi nts  ( ∼1 6 of t he ra w scale) i m plies  t hat t he bo ys are ver y u nlikel y to lose a m b ulatio n o ver t he 
co urse of a 2 - year st u d y. It has also bee n o bser ve d o n t he basis of  e mer gi n g data fro m  
St u d y  W N 4 0 2 2 6 i n a m b ula nt bo ys wit h D M D  a ge d 5- 1 0 year s at ra n do mizatio n t hat t here was 
a n i ncrease d rate of decli ne i n f u nctio n a n d i ncrease d rate of loss of a m b ulatio n for s u bjects wit h at 
a tot al score belo w 1 5  poi nts . A mi ni m u m N S A A score is pla n ne d  to li mit t he partici patio n to 
patie nts w ho  are not e x pecte d to lose a m b ulatio n d uri n g t he st u d y perio d  a n d  w ho  will be a ble to  
co nti n ue to partici pate i n ke y  f u nctio nal assess me nts. T he s pecific c utoff score of 1 5 poi nts at 
scree ni n g  will allo w  a foc us o n t he i ncl usio n of patie nts w ho are a ble to p artici pate i n  ke y st u d y 
assess me nts t hro u g ho ut t he st u d y , wit ho ut bei n g too stri n ge nt. It  is i nte n de d to mi ni mize 
varia bilit y  of t he f u nctio nal  assess me nts  a n d e x pecte d disease pro gressio n , gi ve n t hat t he patie nts 
are ver y u nlikel y to lose a m b ulatio n o ver t he co urse of  2 year s. 
Use of C ortic oster oi ds:  
As  C S   ha ve de m o nstrate d be nefit   o n m ot or  f u ncti o n  i n  b o ys  wit h  D M D 1 9 , b o ys   i ncl u de d i n  
t his   st u d y will   be re q uire d  t o  be   o n  a C S   ( e. g.,   pre d nis o ne/ pre d nis ol o ne  or deflazac ort)  f or  at  
least  6 m o nt hs  pri or  t o  t h e  start of  st u d y treat me nt,  wit h  n o si g nifica nt  c ha n ge  i n d osa ge or d osi n g 
re gi me n  f or  at  least 1 2  wee ks  pri or  t o  t he  start  of  st u d y  treat me nt.  T he  g oal of  t his  i ncl usi o n  
criteri o n  is  t o  c o ntr ol  varia bilit y  i n  m ot or   f u ncti o n a n d  stre n gt h  ste m mi n g  fr o m  C S  use.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
39/Protocol WN40227, Version 4   Both  prednisone/prednisolone and deflazacort  have been shown to be effective in increasing  and 
preserving  muscle  strength  in DMD19,20 supporting this pharmacotherapy  as an important  standard  
of care. Following  initiation  of CS, a period  of improvement  in muscle strength  is often  observed. 
To control  this potential  source of variance,  inclusion in this initial study will be restricted  
to patients who have been  taking CS for at least 6 months,  plan to continue CS for the duration 
of the double- blind  phase  of the clinical trial, and have not had a significant change in dose in the 
12 weeks  preceding initiation  of study treatment.  
Use of Translarna (Ataluren) , Exon -Skipping Therapies,  or Investigational Agents:  
Subjects receiving Translarna (ataluren) , exon skipping therapies (e.g., Exondys51 [ eteplirsen ]), 
or investigational agents  will not be eligible for this study. The magnitude and time course of 
treatment response to these agents in DMD is not well understood. Similarly, limited data are 
available regarding the safety and tolerability of investigational agents. These informatio n gaps 
render controlling for potential effects of these drugs challenging and thus could complicate interpretation of the data emerging from this study.  To avoid a potentially  confounding  impact  of 
poorly  understood effects  of ataluren , patients receiving  this treatment currently or  within  
12 weeks  prior to the start of study treatment will be excluded  from  participation.  Patients receiving 
treatment with any (approved or investigational) exon skipping therapies within 6 months prior to 
the start of study treatment will also be excluded from participation.  Treatment with deflazacort 
as part of CS  dose -finding trials is allowed, as long as the patient has been on treatment 
for 6 months without significant dose changes 12 weeks prior to study start.  
Heart Fa ilure : 
RO7239361 also binds to  growth and differentiation factor -11 (GDF -11), which has been 
implicated in heart failure associated with aging  in mice .
41 However, this finding is controversial .42 
43 44 Although the mechanism underlying the development of aging- related re -modeling of the heart 
likely differs from that underlying the development of heart failure in DMD, potential cardiac 
effects of RO7239361 will be monitored in  subjects enrolled in  this study using echocardiography. 
Notably, there have been no cardiac findings in animals that received RO7239361 in completed or ongoing toxicology studies.  In order to clearly differentiate any potential effects of RO7239361 on he art function from cardiac manifestations of disease progression, it is prudent to exclude 
patients with uncontrolled cardiac failure. It is requested that potential participants with ejection 
fraction <
 55% at baseline be discussed with the S ponsor 's Medic al M onitor.  
Use of Growth H ormone or Androgens: 
Growth hor
mone may exert effects on cardiac morphology and function, while androgens may 
alter skeletal muscle function in boys with DMD .21,22 To avoid potential confounding eff ects of 
growth hormone and androgens on the endpoints being measured in this study, patients receiving 
these treatments currently or within 12 weeks  or 5 half -lives (whichever is longer) prior to the start 
of study treatment will be excluded from participation.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
40/Protocol WN40227, Version 4   3.1.3  Rationale  for Primary Endpoint  
The primary  endpoint  for this study  is the change from b aseline in the NSAA total score at  Week  48 
in RO7239361- treated  participants  compared  with participants  treated with placebo . The NSAA is 
a validated clinician -reported outcome instrument  that has been widely  used in clinical  trials .  The 
instrument c onsis ts of 17 items designed to measure ambulatory function in boys with DMD.  The 
instrument has a 3 -point scale: 2="n ormal "no obvious modification of activity, 1= modified 
method but achieves goal independent of physical assistance from another, 0= unable to achieve 
independently. Therefore, higher scores represent greater functional abilities.47 
The NSAA has been demonstrated to have good inter -rater rel iability and test −retest reliability.56 
The NSAA correlates with key disease progression milestones, such as losing the ability to r ise 
independently from the floor ( a decline  in linearized score from 50 to 40 points) , loss of ability to 
stand still ( decline  in linearized score from 21 to 11 points) , and loss of ambulation .25,26 It has been 
reported that boys with DMD improve their motor function up to 7 years of age, as seen by an overall 
gain of 4 points/year in the linearized NSAA score, after which  they start to decline an average of 8 
linearized units/year.25,26 However, because age alone cannot serve as a predictor of loss of 
ambulation, it has been reported that the estimated mean lineari zed NSAA score at 12 and 24 
months prior to loss of ambulation (i .e., at ages  12 and 11 years, respectively)  is 34 and 42 units 
(approximately 9 and 13 on  the raw scale, respectively) .26 In addition, the NSAA has been 
demonstrated to have moderate to high construct validity based on  the 6MWD , 57, 58 and it has 
been shown to detect change in an interventional setting.25 Unlike  other functional tests, such as 
the 6MWD or  the 4SC, NSAA is a more reliable and comprehensive scale that captures both motor 
strength and quality of movement, in addition to being less susceptible to external motivations. 
Moreover,  while TFTs in DMD tend to remain stable until a point whe n they decline rapidly, the 
NSAA has been shown to decline more gradually.  Thus, the NSAA is  a reliable outcome measure 
to assess the efficac y of RO7239361 treatment in the study population.  
3.1.4  Research Hypothesis 
The hypothesis for this study is that in ambulant patients with DMD:  
• 48 weeks  of treatment with RO7239361, at either  or both doses, will be generally  safe and 
well tolerated  and will result  in improved NSAA total score relative  to 48 weeks  of placebo  
treatment.  
3.2 Background  
A detailed  description  of the chemistry,  pharmacology, efficacy,  and safety  of RO7239361  is 
provided in the  Investigator Brochure. 
RO7239361 is expected  to preserve and improve  muscle strength  primarily  by increasing the size of 
existing  muscle  fibers.  Several  investigators  have demonstrated  that either  genetic 
manipulation27,28,29 or pharmacologic treatments23,30,31,32,33 that reduce circulating  myostatin  
produce increases in muscle mass and measures of strength and motor function  in the mouse  mdx 
model and the golden retriever  model of DMD.34 Importantly, the relationship  between  myostatin  
reduction, increased  muscle  size, and increased  muscle  strength suggests  that muscle  volume 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
41/Protocol WN40227, Version 4   increases  induced  by this mechanism  result  in increased  muscle  function.  In contrast,  the 
pseudohypertrophic increases  in muscle size observed  in DMD reflect  increases  in non- contractile  
fat and fibrotic  tissue  within  the muscle,  and do not increase muscle strength.35 
RO7239361  has potential therapeutic utility  for conditions  such as DMD  as well as other 
muscle -wasting  diseases.  
A first-in-human combined  single  and multiple  ascending  dose (SAD/MAD)  study in normal  
healthy  volunteers (NHVs)  with RO7239361 has been completed (CN001001) .36 Data from  this 
study indicate  that single  doses up to 180 mg and multiple  weekly  (Q1W) doses up to 180 mg and 
every -2-week  doses  of 45 mg RO7239361 are generally  safe and well tolerated.  PK data indicate  
that plasma  concentrations  of total RO7239361 (serum  free RO7239361  plus RO7239361-
myostatin  complex) increase in a dose- related  fashion. Similarly,  the extent  and duration of 
serum  free myostatin  suppression increases  in a dose- related  fashion. Treatment  with 5 weekly  
doses of 45 mg or more  of RO7239361 was associated  with  increases  in thigh  muscle  volume and 
total lean body mass  in NHVs.   
A Phase  1b/2, multi- site, randomized, placebo -controlled  multiple  ascending  SC dose study to 
evaluate the safety,  tolerability  and PK of RO7239361 in ambulatory  boys  with DMD is ongoing.  
Preliminary  safety  data from  this study,  which  includes  ambulatory boys with DMD,  age ≥ 5 to 
< 11 years  on stable  CS treatment,  suggest  that RO7239361 is generally  safe and well tolerated  
in this population.  
There are no identified risks to date related to RO7239361 administration. Anti- drug antibodie s 
(ADAs) and mild or moderate  injection -site reactions  have been observed in studies of health y 
adults and patients with DMD.  The presence of ADAs did not appear to impact the safety or 
exposure of RO7239361.  
RO7239361 also recognizes  growth  and differentiation  factor -11 (GDF -11), which  is 
hypothesized to play roles  in inducing  mesoderm  in early  development and in anterior -posterior 
patterning of  axial skeleton.37,38,39,40  GDF -11 has also been  implicated  in heart  failure  associated  
with aging in mice .41 However, this  finding is controversial.42 43 44 While  the mechanism  
underlying the  development of aging related  re-modeling of the heart  likely  differs  from  that 
underlying the development of heart failure in DMD, potential cardiac effects of  RO7239361  will 
be monitored in this trial using echocardiography.  Notably, there have  been  no cardiac  findings in 
animals that received RO7239361 in the completed or ongoing toxicology  studies. No clinically 
significant treatment -related changes in ECG or echocardiogram parameters have been observed in 
RO7239361- treated patients with DMD to date.  
Potential  risks  include  hypersensitivity  reactions , injection -site reactions , immunogenicity , and 
findings from nonclinical studies or observations with the use of other anti -myostatin agents . These 
potential risks are described  in the current  Investigator Brochure.45 Appropriate clinical  
monitoring will be implemented  in all clinical  studies.  An independent  Data Monitoring 
Committee  (iDMC) will review data at intervals specified in the iDMC charter.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
42/Protocol WN40227, Version 4   3.3 Benefit/Risk Assessment  
More  detailed  information about the known and expected  benefits  and risks  and reasonably  
anticipated AEs of RO7239361 may be found in the  Investigator  Brochure. 
The potential benefits of treatment with RO7239361  have not been established. 
RO7239361  has been tested  in animals  including rats and monkeys. Serum  aminotransferase  
elevations  were  observed  in rats given  RO7239361 for 6 months. However, these elevations  were  
not associated  with microscopic  evidence  of liver or skeletal  muscle  damage and the animals  did 
not experience muscle weakness. In monkeys  that received RO7239361 for 6 months there were  
no serum  transaminase elevations even though systemic exposures were approximately 4 × higher 
than in rats. 
Taken  together,  the serum  transaminase increases  seen in rats in the 6-month  study  suggest  a time- 
dependent finding  that is likely  rat specific.  Regardless,  potential hepatotoxicity will be assessed  
by monitoring of aminotransferases  and bilirubin  in serum  and evaluations of clinical  signs  and 
symptoms.  The hepatocyte- specific  markers  GGT  and GLDH will also be monitored. 
In some  animals  treated  with RO7239361 a small  decrease in the IgG antibody response to 
primary  immunization  was observed. IgM antibody responses to primary  immunization were  not 
decreased in treated  animals.  Neither  IgG nor IgM antibody responses were decreased in response 
to subsequent (booster) immunizations  in those animals  tested.  Given  the small  size of the decrease  
in the IgG response to primary  immunization  and lack of effect  of RO7239361 treatment on IgM  
response or IgG response to booster, any potential  effect  of RO7239361 treatment on efficacy  of 
immunization  in humans is expected  to be minimal.  Caregivers  should  be advised  to ensure that 
their child’s immunizations are up to date prior to receiving study  drug.  
Among healthy  adult  huma ns who received  RO7239361 in study CN001001, the most  common  
AEs were mild or moderate  injection -site erythema . These AEs did not require  cessation  of study 
drug and  were not accompanied  by systemic  signs  or symptoms, such as fever  or eosinophilia.  In 
Study CN001001, 45.2% of SAD  phase participants developed  ADAs  at some point during  the 
study,  while  27.8% of MAD phase participants  developed ADAs.  Presence of ADAs  did not 
appear  to impact  exposure to RO7239361. Most  subjects  with injection -site or other skin 
reactions  were  ADA titer negative suggesting  a lack of relationship  between  the presence of 
ADAs and risk for cutaneous AEs . 
A Phase  1b/2 study of RO7239361  in ambulatory boys  with DMD (WN40226) is ongoing. 
Safety  data from  the completed  double -blind and 48 -week OL phases  of this study suggest  that 
RO7239361 is generally  safe and well tolerated  in this population. The most common related AEs 
were mild or moderate injection -site reactions that resolved without change to study treatment. 
Immunogenicity data from 43 patients showed a single value of low positive ADA titer in 1 patient 
who had received RO7239361.  
All participants  who are administered  study drug will be closely  monitored for possible 
immunogenicity -related  AEs,  such as rash,  fever,  and injection -site reactions.  Clinically  relevant  
immune  reactions  (e.g., hypersensitivity  reactions)  will be reported  as AEs and treated  according  to 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
43/Protocol WN40227, Version 4   current  standard  of care medical  practice.  If present, antibodies  will be assessed  for neutralizing  
activity  by assessment  of serum  free myostatin  levels  and a neutralizing  antibody (NAB)  assay.  
Subjects  completing  clinical  trials  of RO7239361  who do not enter  the Open  Label  Extension 
phase will enter the follow -up phase of the study.  Subjects  who enter  the follow-up phase will 
undergo ADA monitoring during the follow-up visits,  which  will occur  at regular  intervals  for 
24 weeks . Injection  sites will be rotated  and inspected regularly.  Injection  sites will be monitored 
from  Day 1 through the end of the study.  
Hypersensitivity  or acute allergic reactions  may occur  as a result  of the biologic  nature of 
RO7239361 . As of 8 Feb ruary  2018, no subject  receiving  RO7239361 has developed  an acute 
hypersensitivity  reaction  associated with study drug . Although  the risk of a subject  developing 
an acute hypersensitivity  reaction  to RO7239361 is considered  low, sites should be prepared  to 
manage possible acute hypersensitivity  reactions  to initial doses  of RO7239361 following accepted  
standards  of medical  care.  Qualified  personnel should administer  or supervise the administration  
by the caregiver  of the first 3 weekly  SC doses  of RO7239361 , and appropriate emergency  
equipment  should be available in the event  of a serious anaphylactic reaction.  Participants  and their 
parents/caregivers  will be provided with emergency  contact  information by the site. Participants  
and their parents/caregivers  will be instructed  to recognize  any signs and symptoms of 
hypersensitivity reaction and for  the need to seek  emergency medical care in case of an extreme 
reaction.   
 
  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
44/Protocol WN40227, Version 4   4 OBJECTIVES AND ENDPOINTS  
 
Table  4-1: Objectives and Endpoints  
 
Objectives  Endpoints  
Primary  
• To compare  the efficacy  of RO7239361  to 
placebo in ambulatory boys with Duchenne  
muscular  dystrophy  
• The change  from  baseline  in the North Star 
Ambulatory Assessment  (NSAA)  total score 
at Week  48 in RO7239361 -treated  
participants compared to  placebo -treated  
participants  
Secondary  
• To compare the efficacy  of RO7239361  to placebo  
using the following tests:  
− 4 Stair Climb Velocity  
− Stand from supine velocity 
− 10 M walk/run velocity  
− PODCI  transfers  and basic  mobility  subscale  
− Proximal  lower  extremity  flexor  (knee  
extension  and knee flexion)  strength,  measured  
using manual myometry 
− 6 Minute Walk Distance  (6MWD)   
− Clinical Global Impression of Change 
(CGI -C) 
− Stride velocity , as recorded by the 
ActiMyo  device  
 
• To assess the safety  and tolerability  of RO7239361 in 
boys with DMD as reflected by  new or worsening  lab 
abnormalities  (as defined  by CTCAE  criteria), 
serious  adverse  events  (SAEs)  and adverse  events  
(AEs) leading to discontinuation   
• Change  from  baseline  at Week  48 in 
RO7239361- treated  participants  compared  to 
placebo -treated  participants  in: 
– 4 Stair Climb Velocity  
– Stand from supine velocity 
– 10 M walk/run velocity  
– PODCI  transfers  and basic  mobility  subscale  
– Proximal  lower  extremity  flexor  (knee  extension  
and knee flexion)  strength,  measured  using  
manual myometry  
– 6 Minute Walk Distance (6MWD)  
– Clinical Global Impression of Change 
(CGI -C) 
– 95th percentile stride velocity , as recorded with 
the ActiMyo device in a subset of the overall 
study population  
 
• Tabulations  of the numbers  of unique  participants  
with new or worsening  laboratory  abnormalities,  
SAEs  and AEs leading  to discontinuation,  in 
RO7239361 arms compared to the placebo arm  
 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
45/Protocol WN40227, Version 4   Tertiary/Exploratory  
• To assess the safety  and tolerability  of RO7239361  in 
boys with DMD as reflected  by vital signs,  
measures of cardiac function.  
 
 
 
 
 
 
• To compare the efficacy  of RO7239361 to placebo  
using the following tests:  
- Performance of upper limb (PUL) total score  
 
• To evaluate other measures of efficacy, quality of life , 
and health care utilization   
• Summaries and listings  of vital signs,  ECG  
parameters,  echocardiogram  parameters.  
− Proportion of participants with on treatment  
adverse  events  in RO7239361 arms  
compared to the placebo arm  
– Proportion of participants with on treatment  
decrease in ejection fraction (EF), measured  
using echocardiography,  in RO7239361 
arms compared to the placebo arm  
• Change  from  baseline  at Week  48 in RO7239361 
treated  participants  relative  to placebo  treated  
participants  in: 
– Performance of upper limb (PUL) total score  
 
• Change  from  baseline at Week 48  in RO7239361 
treated participants compared to placebo treated  
participants: 
− Pulmonary Function Tests, including forced  
vital capacity  (FVC)  % predicted,  forced vital 
capacity  (FVC), forced expiratory volume in 
1 second  (FEV1), maximal  expiratory  pressure  
(MEP),  maximal inspiratory pressure  (MIP) . 
− PODCI total score  
− Caregiver Global Impression of Change  
(CaGI -C) in a subset of the overall study 
population at selected sites  
− Pediatric Quality of Life Inventory 
Multidimensional Fatigue Scale (PedsQL 
MFS ) in a subset of the overall study 
population  
− Cardiac magnetic resonance imaging (cMRI)  
measures of ejection fraction, fractional strain,  
and volume of fibrosis in a subset of the  
overall  study  population 
− Strength of elbow flexors,  elbow extensors, and  
pinch, measured by manual myometry  
− Health  Utilities  Index  III and PedsQL  Family  
Impact  Module  scores 
− Dual  x-ray absorptiometry  (DXA) measures  
of lean body  mass, fat mass, and bone mineral  
density  
  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
46/Protocol WN40227, Version 4    
Table  4-1: Objectives and Endpoints  
 
Objectives  Endpoints  
 
 
 
 
  
 
  
 
  
 
  
 
• To evaluate RO7239361 pharmacokinetics , 
pharmacodynamics , and immunogenicity • Assessments at select ed timepoints during the 
study  of: 
− Activity levels in  a subset of the overall 
study population , as recorded with 
ActiMyo  
− Scoring of functional assessments, as recorded 
by a subset of parents/caregivers participating in the caregiver video assessment  at selected 
sites  
− Number of falls while on treatment  in 
RO7239361 arms compared with the placebo 
arm 
• Assessments at select timepoints during the study  
of: 
− Serum  RO7239361  concentrations  
− Serum free myostatin and myostatin drug 
complex concentrations  
− Serum ADA concentrations  
− Serum creatine kinase level in muscle  
   
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
47/Protocol WN40227, Version 4   Table  4-1: Objectives and Endpoints  
 
Objectives  Endpoints  
• To explore the effect of genetic variation on target  
engagement, pharmacodynamic (PD) effects or 
functional  test endpoints  • Assess  the impact  on genetic  variation  in the 
DYSTROPHIN  gene or in genes suspected to impact  
DMD disease expression (including but not limited  
to LTBP4, SPP1) in RO7239361 - and 
placebo -treated participants, on target  engagement,  
pharmacodynamic (PD) and functional endpoints  
5 STUDY DESIGN  
5.1 Overall Design  
This is a multi- center,  randomized, double-blind, placebo -controlled  study to  assess the efficacy,  
safety  and tolerability  of two different weekly SC doses of RO7239361 in ambulatory  boys  with 
Duchenne muscular dystrophy (DMD).  
Eligible  participants  will be randomized  to receive  doses  of RO7239361 or placebo (1:1:1 across 
the three treatment arms). The randomization  will be stratified by: 
• Age (6 through 7 and 8 through 11) 
• CS regimen:  daily  (prednisone, prednisolone  or deflazacort)  vs intermittent (any non- daily  
dosing of prednisone, prednisolone or deflazacort) 
 
A separate randomization  will be conducted for Japan  (N∼15) with stratification  for age only 
(6 through 7 and 8 through 11), not CS regimen.  
RO7239361 or placebo  will be administered  weekly.  The first three  doses (Days  1, 8 and 15) of 
study drug  must be administered at the site. Parents/caregivers will be trained to administer  SC 
injections  during  the first three  dose administrations.  Parents/caregivers  who are comfortable with 
SC administration  can administer  the injection  at home  starting  at Day 22. Parents/caregivers  will 
be dispensed an approximately 6 week supply of drug in pre -filled syringes ( RO7239361  or 
matching placebo) for weekly  study drug/placebo administration  to the participant.  
After  completion of this 48-week  double-blind phase,  participants may enter  the OL phase  in 
which  all participants  will receive active RO7239361 study  drug.  Participants  originally  
randomized  to active  drug will continue to receive  the dose to which  they were originally  
randomized.  Participants  originally  randomized to placebo  will be randomized  to the high or low 
dose of RO7239361 on Day 1 of the OL phase.  Dose  assignment  in the OL phase may be 
modified  based  upon emerging  safety  findings. Subjects  entering the OL phase will remain 
blinded to their original dose assignment. Participants  who discontinue study treatment at any 
timepoint  (i.e., early  discontinuation  for patients  who do not enter the OL phase  or at termination 
of the OL phase)  will enter  the follow -up phase of the study.  The follow -up phase  of the study is 
24 weeks.  Participants  will be monitored  for safety  at three visits in the follow-up phase. 
Participants  should provide immunogenicity samples at all follow-up visits.  
The study design schematic  is present ed in Figure  5.1-1. 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
48/Protocol WN40227, Version 4    
Figure 5.1-1: Study Design Schematic  
 
OL=open label; SC=subcutaneous.  
Study visits  and endpoint measurements will occur  as indicated  in Table 2-1 through Table 2-4.  
5.1.1  Independent Data Monitoring Committee and Other External Committees  
There will  be an iDMC  for this study.  The iDMC  scope,  frequency of review,  membership,  
activities  and other specifications  are detailed  in the iDMC  charter.  
The iDMC  shall  have access  to partially  unblinded data (coded  treatment assignments)  including 
but not limited to the following: the frequency and spectrum of SAEs ; Grades 3 to 4 laboratory 
abnormalities; occurrence of malignancies, if any; and other select AEs of interest.  The iDMC  
shall  also review  aggregate data results  from  any interim analyses performed prior to the end of 
the double -blind treatment period . The iDMC  shall  have the right to request  full unblinding of 
the data (codes  will be decoded  to reveal  actual  treatment  assignments). The iDMC  shall act as 
an advisor to the sponsor and have responsibility  for safeguarding  the subjects’ interests.  The 
iDMC  shall  bring any safety  concerns  to the attention  of the sponsor  so that the sponsor  can review  
the data and prepare appropriate  communications  to the Regulatory  Authorities. 

 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
49/Protocol WN40227, Version 4   5.2 Number of Participants  
A total of approximately n=159 participants  randomized  will provide  for slightly  more  than 
80% power at the primary  analysis. This allows for roughly a 5%  dropout rate by  Week 48. 
Some  of the details behind sample size calculations are in  Section  10.1. 
5.3 End of Study Definition  
The start of the trial is defined  as the first visit for the first participant  screened.  End of trial is 
defined  as the last visit or scheduled  procedure shown in the Schedule of Activities  for the last 
participant.   
5.4 Scientific Rationale for Study Design 
See Section  3.1 
5.5 Justification for Dose  
See Section  3.1.1  
6 STUDY  POPULATION  
For entry  into the study,  the following criteria MUST be met.  
6.1 Inclusion Criteria  
1) Signed Written Informed Consent  
a) Prior  to study  participation, written  informed  consent  from  subjects,  and in the case of 
minors, written  permission (informed  consent) also from  parents,  guardians, or legally  
acceptable representatives must be obtained according to local laws and regulations.  
b) Assent  from  minor subjects  should  be obtained per local  laws and regulations  and should 
be documented in accordance with local  requirements . 
 
2) Type of Participant and Target Disease Characteristics  
a) Males,  ≥ 6 to < 12 years  of age at time of randomization  
b) Diagnosis  of DMD , confirmed  by medical history (e.g., onset of clinical  signs  or 
symptoms  before  5 years  of age together  with an elevated  serum  creatine  kinase level 
observed before or after initial diagnosis) and by genotyping 
c) Participants  ≥ 15 kg 
d) Ambulatory w
ithout  assistance  
e) Participants  must  be receiving  corticosteroids  (prednisone, prednisolone,  or deflazacort)  
for at least 6 months  prior  to the start of study  drug,  with no significant change in dosage 
(> 0.2 mg/kg  prednisone or > 0.24 mg/kg  deflazacort)  or dosing  regimen  for at least 12 
weeks  prior to the start of study drug, with the expectation  that dosage  and dosing  regimen  
will not change significantly  for the duration  of the study.  
f) NSAA score ≥ 15 points at screening  
g) 4SC ≤ 8 seconds at screening  
h) Subjects  must  agree to avoid  major  changes  in their physical  or respiratory  therapy  regimen  
during the double-blind phase, to the extent possible 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
50/Protocol WN40227, Version 4    
3) Age and Reproductive Status  
a) Males,  ≥ 6 to < 12 years  on day of randomization  
b) Subjects  who are sexually active must  agree to follow  instructions for method(s) of 
contraception  for the duration of treatment  with  study  treatment(s)  plus 5 half-lives of the 
study treatment  [RO7239361 ; 50 days]  plus 90 days (duration  of sperm  turnover) for 
a total of 140 days (5 months)  post-treatment completion.  
c) Azoospermic subjects  are exempt  from  contraceptive requirements. 
d) Subjects  must  be willing  to refrain  from  sperm  donation during the entire  study and for 5 
half-lives of  study treatment  plus 90 days  (duration of sperm turnover) 140 days  after 
dosing has been completed. 
 
Investigators shall provide appropriate and patient -centered counseling of adolescent trial subjects 
who are sexually active with WOCBP on the importance of pregnancy prevention and the 
implications of an unexpected pregnancy. Investigators shall advise subjects who are sexually  
active with WOCBP on the use  of highly effective methods of contraception in non-pregnant 
partner (Appendix 4) , and on the  use of condom in subjects with a pregnant partner . Highly 
effective methods of contraception have a failure rate of < 1% when used  consistently and 
correctly.  
6.2 Exclusion Criteria 
1) Medical  Conditions  
a) Participants  with cognitive  impairment or behavioral issues that, in the judgement  of the 
investigator, will compromise  their ability  to comply  with study procedures.  
b) Participants  with a FVC  of < 50% of predicted value  (in participants  able to produce a valid  
FVC,  as judged by the clinical evaluator or respiratory  therapist)  
c) Cutaneous  AEs sustained  during participation in a prior  clinical  trial that resolved  less than 
12 weeks  prior to the start of study  drug administration.  
d) History  of lower  limb fractu re within  12 weeks  prior to the start of study drug 
administration.  
e) History  of upper limb fracture  within  8 weeks  prior to the start of study drug 
administration.  
f) Any injury that may impact  functional  testing.  Previous  injuries  must  be fully healed  
prior to consenting. 
g) Expectation  of major  surgical  procedure,  such  as scoliosis  surgery, during the double -blind  
phase of this study.  
h) Requirement  of daytime ventilator assistance  
i) Initiation of nighttime ventilation less than 4 weeks prior to the start of study drug 
administration  
j) Expectation  that daytime or nighttime ventilation  may be initiated during the double -blind 
phase of this study.  
k) Clinical signs or symptoms of uncontrolled  congestive heart failure (American College of 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
51/Protocol WN40227, Version 4   Cardiology/American  Heart Associated Stage C or Stage D)  
l) For participants  participating  in cMRI  substudy:  implanted  ferromagnetic  metal  (implanted  
metal  that is not ferromagnetic, such as surgical steel or titanium implants may be allowed  
if the implants will not compromise  the quality of the cMRI)   
2) Prior/Concomitant Therapy  
a) Any change (initiation, change in drug class, dose modification unrelated to change in body 
weight, interruption or re -initiation) in prophylaxis/treatment for CHF within 12 weeks  
prior to start of study treatment 
b) Any change  (initiation,  change in drug class,  dose modification  unrelated  to change in body  
weight,  interruption  or re-initiation)  in prophylaxis/treatment for bone  density within  
12 weeks  prior to start of study  treatment  
c) Participants  on intermittent  CS regimens  with off periods of 20 days or longer (e.g., 
10 days on, 20 days  off) 
d) Treatment with exon skipping therapies within 6 months prior to the start of study drug 
administration.  
e) Treatment with ataluren  currently or within 12 weeks prior to the start of study drug 
administration  
f) Treatment  with any other investigational  drug (excluding deflazacort  in CS dose-finding 
trials ) currently or within 12 weeks prior to the start of study  drug administration  
g) Current  or prior treatment  within  12 weeks  prior to the start of  study drug administration  
with androgens or human growth hormone. 
h) Concurrent  or previous participation at any time in a gene therapy study  
i) Prior treatment  with RO7239361 or any  other  anti-myostatin  agent  
3) Physical and Laboratory Test Findings  
a) Evidence of organ  dysfunction or any clinically  significant  deviation from  normal in 
physical examination,  vital signs, ECG or clinical  laboratory determinations  beyond what  
is consistent with  the target  population 
4) Allergies and Adverse Drug Reaction  
a) History  of any significant drug allergy  (such as anaphylaxis or hepatotoxicity) 
b) History  of hypersensitivity  to components  of the study drug (histidine,  trehalose,  
diethylenetriaminepentaacetic  acid, polysorbate 80) 
5) Other Exclusion Criteria  
a) Particip
ants who are compulsorily  detained  for treatment of either  a psychiatric  or physical  
(e.g., infectious disease) illness  
b) Unwilling or unable to administer study  drug at home  
 
Eligibility  criteria  for this study have been carefully  considered  to ensure the safety  of the study 
participants  and that the results  of the study can be used.  It is imperative  that participants fully 
meet all eligibility  criteria.  
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
52/Protocol WN40227, Version 4   6.3 Lifestyle  Restrictions  
Not applicable   
6.3.1  Meals and Dietary Restrictions  
Not applicable  
6.3.2  Caffeine, Alcohol and Tobacco  
Not applicable  
6.3.3  Activity  
Not applicable  
6.4 Screen Failures  
Screen  failures  are defined  as participants  who consent to participate in the clinical  study but are 
not subsequently randomized.  A minimal set of screen  failure  information is required  to ensure 
transparent  reporting of screen  failure  participants,  to meet  the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements, and to respond to queries from  regulatory 
authorities.  Minimal  information includes date of consent, demography,  screen  failure  details,  
eligibility  criteria,  and any serious AEs. 
6.4.1  Rescreening and Retesting during Screening Period  
Participant re-screening : This study permits  one- time  re-screening  of a participant once that 
participant  has discontinued the study as a screen  failure  (i.e., participant has not been 
randomized). Laboratory testing that is repeated because of administrative or technical issues 
(e.g., breakage of a sample vial during transit to the central laboratory or degradation of a 
sample during transportation) is not consi dered to be rescreening.  If re-screened , the participant  
must  be re -consented.  
Retesting  of laboratory parameters  and/or other assessments within  any single  screening  or 
lead-in period will be permitted  (in addition  to any parameters  that require  a confirmatory value).  
The most  current  result  prior  to randomization is the value  by which  study inclusion  will be 
assessed, as it represents the participant’s  most  current, clinical state.  
Screening  Procedural  Outline  may be repeated  in an effort  to find all possible well-qualified  
participants.  Consultation with the Medical  Monitor may be needed  to identify  whether  repeat  
testing  of any  particular  parameter  is clinically  relevant.  
7 TREATME NT 
Study treatment is defined  as any investigational treatment(s),  marketed  product(s), placebo  or 
medical  device intended to be administered  to a study  participant  according  to the study 
randomization or treatment allocation  
Study treatment  includes both Investigational [Medicinal]  Product (IP/IMP)  and 
Non-investigational [Medicinal] Product (Non -IP/Non -IMP) and can consist of the following: 
• All products, active or placebo, being tested or used as a comparator in a clinical trial 
 
Anti -Myostatin Adnectin, (RO7239361) — F. Hoffmann -La Roche Ltd 
53/Protocol WN40227, Version 4   • Study required  premedication  
• Other  drugs administered  as part of the study  that are critical  to claims  of efficacy  
(e.g., background therapy, rescue medications)  
• Diagnostic  agents:  (e.g., glucose  for glucose  challenge)  given  as part of the protocol 
requirements  must  also be included in the dosing data collection.  
 
An investigational product, also known as investigational  medicinal  product in some regions,  is 
defined  a pharmaceutical  form  of an active substance or placebo  being tested  or used as a reference  
in a clinical study, including products already  with a marketing authorization but used or 
assembled  (formulated  or packaged)  differently  than the authorized  form,  or used for an 
unauthorized  indication, or when used  to gain further information about the authorized form. 
In this protocol, the investigational  product is RO7239361 (previously , BMS -986089)  
solution for injection  and matching  placebo  solution  for injection,  dispensed in pre -filled syringes.  
Other  medications  used as support  medication  for preventative, diagnostic, or therapeutic reasons,  
as components of the standard  of care for a given  diagnosis, may be considered as 
non-investigational products. In  this study,  CS are considered  non- investigational product and will 
not be provided by the sponsor . 
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
54/Protocol WN40227, Version 4 
  
 
Table  7-1: Study Treatments  
Product Description  
/Class and Dosage  
Form  Potency  IP/Non - 
IMP  Blinded or Open Label  Packaging / Appearance  Storage Conditions  
(per label)  
RO7239361 
injection  
7.5 mg/syringe  10.7 mg/mL  IP Blinded  (during  the 
48-week  double -blind  
phase) and Open  Label  
(during  the  
192-week  OL phase)  Solution packaged in a 1 cc glass  
syringe  equipped with a safety syringe  
device  
Secondary packaging is either a  
1 syringe carton or 4 syringe  carton  2-8° C (36-46° F), protect  from  
light,  protect  from  freezing  
RO7239361 
injection  
15 mg/syringe  21.4 mg/mL  IP Blinded  (during  the 
48-week  double -blind 
phase) and Open  Label  
(during  the 192-week  OL 
phase)  Solution packaged in a 1 cc glass  
syringe  equipped with a safety syringe  
device  
Secondary packaging is either a  
1 syringe carton or 4 syringe  carton  2-8° C (36-46° F), protect  
from light, protect from  
freezing  
RO7239361 
injection  
35 mg/syringe  50 mg/mL  IP Blinded  (during  the 
48-week  double -blind  
phase) and Open  Label  
(during  the 192-week  OL 
phase)  Solution packaged in a 1 cc glass  
syringe  equipped with a safety  syringe  
device  
Secondary packaging is either a  
1 syringe carton or 4 syringe  carton  2-8° C (36-46° F), protect  
from light, protect from  
freezing  
RO7239361 
injection  
50 mg/syringe  71.4 mg/mL  IP Blinded  (during  the 
48-week  double -blind  
phase) and Open  Label  
(during  the 192-week  OL 
phase)  Solution packaged in a 1 cc glass  
syringe  equipped with a safety syringe  
device  
Secondary packaging is either a  
1 syringe carton or 4 syringe  carton  2-8° C (36-46° F), protect  
from light, protect from  
freezing  
Placebo for  
RO7239361 
injection  0 mg/mL  IP Blinded  Solution packaged  in a 1 cc glass  
syringe  equipped with a safety syringe  
device  
Secondary packaging is either a  
1 syringe carton or 4 syringe  carton  2-8° C (36-46° F), protect  
from light, protect from  
freezing  
 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
55/Protocol WN40227, Version 4    
Oral CS will be obtained by standard prescribing procedures. 
7.1 Treatments Administered  
The selection and timing of dose for each participant is as follows:  
 
Table 7.1 -1: Selection and Timing of Dose  
 
Study Treatment  Unit dose  
strength(s)/Dosage  
level(s)  Dosage  formulation  
Frequency of  
Administration  Route  of Administration  
RO7239361 
injection  7.5 mg, 15  mg, 35 mg, 
or 50 mg syringe  Weekly  SC 
Placebo for  
RO7239361 
injection  0mg syringe  Weekly  SC 
 
 
Table 7.1 -2: Dose  Level  1, targeting  moderate level  of suppression:  (≥ 70%  
suppression at trough)  
 
Dose Level  Body Weight tier Body Weight  range  Dose  
1 1 ≥ 15 to ≤ 40 kg 7.5 mg QW  
1 2 > 40 kg 15.0 mg QW  
 
 
Table 7.1 -3: Dose Level 2, targeting high level of suppression: (90% suppression  
at trough)  
 
Dose Level  Body Weight tier Body Weight range  Dose  
2 1 ≥ 15 to ≤ 40 kg 35 mg QW  
2 2 > 40 kg 50 mg QW  
 
RO7239361  or placebo  will be administered  as a SC injection  in the  abdomen , thigh, or the  back of 
the upper arm . Injection sites should be rotated according to  the " instruction for use" (I FU).  
Refer to the current version of the IB for PK and safety data ) following single -dose administration 
across these injection sites in healthy subjects (Study WP40225 ) and for details on the 
recommended storage and use conditions for the PFS . 
Refer to current version of the IB for details on the recommended storage of and use conditions for  
the PFS . Do not use the PFS  after the labeled expiry date.  
Subjects  whose  weight  exceeds  or drops below the dosing weight  tier to which  they were assigned  
by > 2 kg (confirmed  by repeat)  should receive the new weight -based  dose in the subject’s  assigned  
dose level.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
56/Protocol WN40227, Version 4   7.2 Method of Treatment Assignment  
Subjects  will be randomized to receive either  low or high dose of RO7239361  or placebo  
according  to a computer -generated  randomization  scheme .  
During the screening  visit the investigative  site will enter  into the enrollment option of the 
Interactive Web  Response  System  (IWRS)  designated  by Roche for assignment  of a 5- digit subject 
number that will be unique across  all sites.  Enrolled  subjects,  including those not dosed, will be 
assigned  sequential subject  numbers  starting  with , (e.g., ).  
 
 
 Once  it is determined  that the subject  meets  the eligibility  criteria  following 
the screening  visit,  the investigative  site will enter  into the IWRS  to randomize  the subject  into 
the open dose panel.  
Study treatment  will be dispensed at the study  visits  as listed  in Schedule  of Activities  (Section  2). 
7.3 Blinding  
Blinding of treatment  assignment is critical  to the integrity  of this clinical  study.  However,  in the 
event  of a medical  emergency  or pregnancy in an individual  participant in  which  knowledge  of the 
investigational product is critical  to the participant's  management,  the blind for that participant  
may be broken by the investigator.  The participant’s safety  takes  priority  over any other  
considerations in determining if a treatment assignment should be unblinded.  
Before  breaking the blind of an individual  p articipant's  treatment,  the investigator  should 
determine that the unblinded  information  is necessary,  i.e., that it will alter the participant's  
immediate  management.  In many  cases,  particularly  when  the emergency  is clearly  not related  to 
the investigational product, the problem  may be properly  managed  by assuming  that the participant 
is receiving  active product. It is highly desirable that the decision to unblind treatment assignment  
be discussed  with the Medical  Monitor, but the investigator always  has ultimate  authority for the 
decision  to unblind.  The Principal  Investigator  should only call in for emergency  unblinding 
AFTER  the decision  to discontinue the participant  has been made.  
In case of an emergency,  the investigator(s)  has unrestricted  access  to randomization  information  
via the Interactive Web  Response System  (IWRS)  and is capable of breaking the blind  through the 
IWRS  system  without prior  approval  from  sponsor. Following the unblinding the Investigator shall  
notify the medical monitor and/or study director.  
In cases  of accidental  unblinding, contact the medical  monitor  and ensure every  attempt is made  
to preserve the blind. 
Any request  to unblind a subject  for non- emergency  purposes should be discussed  with the medical  
monitor. 
As this is a placebo -controlled,  double- blind  study,  all efforts  must  be maintained  by site staff,  
subjects and caregivers  in not making any assumptions on potential treatment  assignments  based  
on clinical presentations. 

 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
57/Protocol WN40227, Version 4   The randomization assignments  will be released  to the study  sites by the final study report  
generated for the study.  
7.4 Dosage Modification  
Dose  modifications are not allowed. 
7.5 Preparation/Handling/Storage/Accountability  
The investigational  product should  be stored  in a secure area according  to local  regulations.  It is 
the responsibility  of the investigator  to ensure  that investigational product is only dispensed  to 
study participants. The investigational product must  be dispensed  only from  official  study  sites by 
authorized personnel according to local regulations. 
The product storage  manager  should ensure that the study treatment is stored  in accordance  with 
the environmental  conditions  (temperature,  light,  and humidity)  as determined  by Roche. 
If concerns  regarding the quality or appearance of the study treatment  arise,  the study  treatment  
should not be dispensed and contact Roche immediately.  
Study treatment  not supplied by Roche will be stored in accordance with the package insert.  
Investigational product documentation  (whether supplied by Roche or not) must  be maintained  that 
includes all processes  required  to ensure  drug is accurately  administered.  This includes  
documentation of drug storage,  administration  and, as applicable,  storage temperatures,  
reconstitution, and use of required processes (e.g., required  diluents, administration sets).  
Study drug will be administered  in the clinical  facility  or off-site by the parent/caregiver.  The 
parent/caregiver  may administer  study drug on or after the Day 22 dose and once trained  and 
comfortable with SC injections  of study drug/placebo. For any dose administered  at the clinical  
facility,  the dose and location  of each SC injection  must be recorded in the source record. 
For any dose admin istered  off-site (off-site dosing allowed  starting  on Day 22 of double - blind 
phase  and at Week  4 of the OL phase),  the parents/caregivers  must  be trained  on proper 
administration of study drug. The site staff  will be provided with  a pharmacy  manual  that includes  
parent/caregiver  training  guidance and a training  checklist.  The parents/caregivers  will be provided 
with IFU on administration  of study drug.  The subjects and parents/caregivers  will be provided 
with a dosing diary to record administration of study drug and be instructed  to record  the location,  
time,  date,  etc. of each SC injection. Parents/caregivers  must  be instructed to bring the used and/or 
empty  syringes  in a Sharps container  and the dosing diary to each study visit;  this will allow  site 
staff to assess treatment compliance  and study drug accountability.  A diary  will also be provided 
to the parent/caregiver  to record  the subject’s  CS therapy,  AEs,  concomitant  medicine s, and 
falls.  Study drug  must  be transported to and from  the site in a cooler  with an ice pack  to maintain  
the appropriate storage temperature.  If approved by the local  IRB/EC,  the cooler  and ice pack for 
study  drug transport will be provided by the Sponsor or designee.  
Parents/caregivers must be instructed by the site staff on sharps handling procedures. 
Parents/caregivers should be instructed to return the sharps container to the study site for proper 
disposal. 
• Further guidance and information for final disposition of unused study treatment are provided  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
58/Protocol WN40227, Version 4   in Appendix 2  and the pharmacy  manual.  
7.5.1  Retained Samples for Bioavailability/ Bioequivalence  
Not applicable.  
7.6 Treatment Compliance  
Study treatment compliance  will be monitored by review  of dosing diary  cards.  Drug  
accountability  should be reviewed  by the site study staff at each visit to confirm  treatment  
compliance.  Sites  should discuss  discrepancies  with the participant  at each on-treatment study 
visit.    
Any overdose or incorrect administration of study drug should be reported as an adverse event and 
recorded on the Adverse Event electronic Case Report Form (eCRF) , and the Medical Monitor 
should be informed .  
7.7 Concomitant Therapy  
7.7.1  Prohibited and/or Restricted Treatments  
Prohibited  and/or restricted  medications  taken  prior  to study  drug administration  in the study  are 
described  below. Medications  taken  within  4 weeks  prior  to study  drug administration  must  be 
recorded  on the CRF.  Prior  therapies  to treat DMD, including  CS, should  be reported  on the 
CRF,  regardless  of when  the prior  therapy  was administered. Routine  standard of care 
immunizations  should be maintained throughout the study.  
Experimental  medications  to treat DMD  may be permitted  during the OL phase. This will be 
dependent upon results from the double- blind phase. 
1) Prior exposure to  RO7239361 or any  other anti -myostatin  agent.  
2) Treatment with ataluren  within 12 weeks prior to the start of study drug administration .  
3) Treatment with  any other  investigational drug (excluding deflazacort  in CS dose -finding 
trials ) currently or  within  5 half- lives  prior to the start of study  drug administration.  If the 
half-life of the prior treatment is unknown, the investigator must consult with the Roche 
medical monitor to determine the washout duration. 
4) Treatment with exon skipping therapies within 6 months prior to the start of study drug 
administratio
n 
5) Current or prior treatment within 12 weeks  of study drug administration with androgens or 
human growth hormone. 
6) Concomitant or previous participation at any time in a gene therapy study. 
7) Use of any other drugs, including over -the- counter medications and herbal preparations, within 
1 week prior to start of study drug administration or during study participation except those 
medications cleared by the Roche medical monitor.  
Any concomitant  therapies  must  be recorded on the CRF.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
59/Protocol WN40227, Version 4   7.7.2  Other Restrictions and Precautions  
7.7.2.1  Management of Possible Acute Hypersensitivity Reactions to  
RO7239361 
Hypersensitivity  or acute allergic  reactions  may occur  as a result  of the biologic  nature of 
RO7239361 . Qualified  personnel should administer  the first three weekly  SC doses of 
RO7239361  during both the double- blind phase and during the OL phase,  and appropriate  
emergency  equipment should be available in the event of a serious  anaphylactic reaction.  For the 
first three weekly  doses of both the double -blind  and OL phases,  subjects  should remain  on site for 
3 hours after drug administration for observation. Subjects and the parents/caregivers will  be 
provided with emergency  contact  information  by the site. Subjects  and the parents/caregivers  will 
be instructed to go to their local emergency care facility  in case of an  extreme  reaction.  
The following information  is provided to assist  in the recognition  of hypersensitivity  reactions  and 
in the management  of those reactions  should they occur during or after the administration  of 
RO7239361 . Care  should be taken  to treat any acute toxicity  expeditiously, should it occur.  When  
dosing  RO7239361, equipment  such as a portable tank or wall-source  of oxygen, endotracheal  
intubation  set, oral airway,  mask,  ambu -bag, syringes,  injectable epinephrine, injectable  
antihistamine,  and injectable  glucocorticosteriods  should be kept in the vicinity where the subject  
is dosed (for the first three weekly doses).  
Signs  of potential  acute hypersensitivity  reactions  include  symptomatic  hypotension; dyspnea;  
acute pain the chest, back or extremities/or chills, fever, urticaria; or generalized erythema.  
Clinically  relevant  hypersensitivity  reactions  will be reported  as AEs and treated  according to 
current standard of care medical practice. Management is as follows:  
Symptomatic  Hypotension:  Place subject  in the Trendelenburg position  and administer  
intravenous fluid.  Additional  medical  intervention  may also include  the use of epinephrine, 
glucocorticosteroids, antihistamines and pressor agents. 
Dyspnea: Observe  the subject  for worsening of the event  and for the appearance of additional 
signs  and symptoms of anaphylaxis. Antihistamines, epinephrine, and glucocorticosteroids may be 
administered  as indicated.  
Acute Pain  in the Chest,  Back  or Extremities: Observe subject  for worsening of the event  and 
for the appearance of additional  signs and symptoms of anaphylaxis . Antihistamines, epinephrine , 
and glucocorticosteroids  may  be administered as indicated.  
Chills, Fever, Urticaria or Generalized Erythema:  Treat these possible signs and symptoms  of 
an allergic reaction to biologic  products with  acetaminophen and antihistamines.  
The decision  whether  to continue  the subject  in the study  will be made by the investigator, in 
consultation with the Roche medical monitor. 
7.7.2.2  Imaging Restriction and Precautions 
The Principal  Investigator and/or the imaging  specialist  at the study  site imaging  facility  is 
responsible  for determining if a subject  is contraindicated from  having the imaging  procedures  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
60/Protocol WN40227, Version 4   specified  in the time and events  schedule (Table  2-2 and Table 2-3).  Imaging  contraindications 
and risks should be considered. 
The ultimate  decision  to perform  the imaging  should rest with the site radiologist, the investigator, 
and the standard set by the local  Ethics  Committee.  
7.8 Treatment  after  the End of the Study  
At the conclusion of the study,  participants who continue  to demonstrate clinical benefit  will be 
eligible to receive Roche- supplied study treatment. Study treatment will be provided via an 
extension of the study, a rollover study requiring approval by responsible health authority and 
ethics committee or through another mechanism at the discretion of Roche  and according to loca l 
legislation .  
Roche reserves  the right  to terminate  access  to Roche -supplied study treatment  if any of the 
following occur: a) the study is terminated  due to safety  concerns;  b) the development  of 
RO7239361 is terminated  for other reasons,  including but not limited  to lack of efficacy  and/or 
not meeting  the study objectives;  c) the participant can obtain  medication  commercially,  from  a 
government-sponsored program, or from a  private health  program. In all cases , Roche will follow  
local  regulations.  
8 DISCONTINUATION CRITERIA  
Clinical Criteria for  Dose Discontinuation:  
• Dosing  may be stopped until safety  information  can be reviewed in the event that:  
− Two (2) or more  subjects  experience  the same severe or very severe AE  that is 
considered related  to RO7239361 
• Dosing will be paused  within  a subject  until safety  information  is reviewed  and drug  induced 
liver injury  (DILI)  is ruled out in the event that: 
− ALT  > 5 x baseline AND no c orresponding increase in CPK  to indicate  muscle  origin  as 
the reason for the increase in ALT  
OR 
 
− ALT  > 10 x ULN  AND ALT  > 2 x baseline  AND no corresponding increase in CPK  to 
indicate  muscle  origin  as the reason for the increase in ALT  
OR 
− Total  bilirubin  > 2 x ULN  
OR 
− Symptoms  or signs  of hepatic inflammation  such as  nausea,  vomiting, right upper  quadrant  
pain or tenderness  with no other  immediately  apparent  possible  cause of these symptoms  
or signs, such as viral gastroenteritis or constipation. 
 
In addition  to the above  stopping  rules,  dosing  may be paused  or halted  within  a subject  if a review  
of safety  and tolerability  data,  or the clinical  judgment of the investigator, suggest the emergence  
of a new potentially serious safety  signal, including DILI. 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
61/Protocol WN40227, Version 4   The following categories and definitions of  intensity  as determined by a physician should be used  
for assessing the severity of  AEs:  
• Mild (Grade 1) - Awareness  of event  but easily  tolerated  
• Moderate (Grade 2)  - Discomfort  enough to cause some interference with usual activity  
• Severe (Grade 3)  - Inability to carry  out usual activity  
• Very  Severe (Grade 4) - Debilitating,  significantly  incapacitates  subject  despite symptomatic  
therapy  
Dosing  may not be resumed  until a thorough review  of safety  and tolerability  data has been  
completed  and the Roche medical  monitor, Roche  pharmacovigilance representative,  and the 
investigators agree that it is safe to proceed.  
Any subject  meeting  the above  stopping criteria  or otherwise  removed from  the study  for abnormal  
laboratory,  or echocardiogram  will be followed  until their abnormal laboratory result  and/or  
echocardiogram  values  return  to baseline.  Subjects  who discontinue  early  should enter  the 
post- treatment follow -up phase of the study for this follow-up. 
8.1 Discontinuation from Study  Treatment  
Participants  MUST immediately  discontinue  investigational  product (and non-investigational  
product at the discretion  of the investigator)  for any of the following reasons:  
• Participant’s  request  to stop study  treatment.  Participants  who request  to discontinue study 
treatment  will remain  in the study and must  continue  to be followed  for protocol specified  
follow-up procedures. The only  exception  to this is when a  participant specifically  withdraws  
consent for  any further contact  with  him/her  or persons previously authorized  by participant to 
provide this information  
• Any clinical AE, labora tory abnormality or intercurrent  illness  which, in the opinion of the 
investigator, indicates that continued participation in the study is  not in the best interest of the 
participant  
• Termination  of the study by Roche  
• Loss of ability  to freely  provide consent through imprisonment or involuntarily  incarceration  
for treatment of either  a psychiatric or physical  (e.g., infectious  disease)  illness  
• Unblinding a subject for any reason  (emergency  or non-emergency)  
• Inability  to comply  with protocol 
• Discretion  of the investigator  
 
Refer  to the Schedule of  Activities for data to  be collected  at the time  of treatment discontinuation 
and follow- up and for any further evaluations that can be completed  
All participants  who discontinue study treatment  should comply  with protocol  specified  follow-up 
procedures as outlined in Section  2. The only exception  to this requirement  is when  a participant  
withdraws  consent for all study procedures  including post- treatment study  follow-up or loses  the 
ability  to consent  freely  (i.e., is  imprisoned or involuntarily incarcerated  for the treatment of either  
a psychiatric or physical  illness).  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
62/Protocol WN40227, Version 4   If study  treatment is discontinued prior to the  participant’s  completion  of the study,  the reason for  
the discontinuation  must  be documented in the participant’s  medical  records  and entered  on the 
appropriate eCRF . 
8.1.1  Post Study Treatment Study Follow -up 
In this study,  safety  and the NSAA  are key endpoints of the study.  Post study follow-up is of 
critical  importance  and is essential  to preserving  participant  safety  and the integrity  of the study.  
Participants  who discontinue study treatment  must  continue to be followed  for collection  of 
outcome and/or survival  follow-up data as required  and in line with Section  5 until death  or the 
conclusion of the study.  There will be follow -up visits  up to 24 weeks  after the last dose of study  
drug (Table  2-4)  
8.2 Discontinuation from the Study  
Participants  who request  to discontinue  study treatment  will remain  in the study  and must  continue  
to be followed  for protocol specified  follow-up procedures ( Table 2-4).  The only exception  to this 
is when  a participant  specifically  withdraws  consent for any further contact  with him/her  or 
persons previously authorized by participant  to provide this information.  
• Participants  should notify the investigator of the decision to withdraw  consent  from  future  
follow-up in writing , whenever possible.  
• The withdrawal  of consent should be ex plained  in detail  in the medical  records by the 
investigator, as to whether the withdrawal is from further treatment with  study treatment only 
or also from  study procedures and/or post treatment  study follow -up, and entered  on the 
appropriate CRF page.  
• In the event  that vital status  (whether  the participant  is alive  or dead)  is being measured,  
publicly available information  should be used to determine  vital status  only as appropriately 
directed  in accordance with local  law. 
• If the participant withdraws  consent for disclosure of future  information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
8.3 Lost to Follow -Up 
• All reasonable efforts  must  be made to  locate participants  to determine and report  their ongoing 
status. This includes follow -up with persons authorized by the participant.  
• Lost to follow -up is defined  by the inability  to reach the  participant  after a minimum of three  
documented  phone  calls,  or emails  as well as lack of response  by participant  to one 
registered  mail  letter. All attempts should be documented in the  participant’s  medical  records.  
• If it is determined  that the participant has died, the site will use permissible  local  methods to 
obtain date and cause of death. 
• The site staff and representative will consult  publicly available sources,  such as public health  
registries  and databases, in order to obtain updated contact information.  
• If after all attempts,  the participant  remains  lost to follow-up, then the last known alive date as  
determined  by the investigator should be reported  and documented in the participant’s  medical  
records.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
63/Protocol WN40227, Version 4   9 STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and timing  are summarized  in the Schedule of Activities  (Table  2-1, 
Table 2-2, Table 2-3, and  Table 2-4).  
• Protocol waivers or exemptions are not allowed. 
• All immediate  safety  concerns must  be discussed  with the Sponsor immediately  upon 
occurrence or awareness  to determine  if the participant should continue  or discontinue 
treatment.  
• Adherence to the study design  requirements,  including those specified  in the Schedule of 
Activities,  is essential  and required  for study conduct. 
• All screening  evaluations  must  be completed  and reviewed  to confirm  that potential 
participants  meet  all eligibility  criteria before randomization.  The investigator will maintain  a 
screening  log to record  details  of all participants  screened  and to confirm eligibility  or record  
reasons for screening failure, as applicable.  
9.1 Efficacy Assessments  
9.1.1  Functional Endpoint Assessment  
Measurements  of function will be assessed at the timepoints specified in  Table  2-1 through Table 
2-4 and  includ e the follow ing:  
• TFTs  (4SC,  10 m walk/run, stand  from  supine)  
• 6 minute  walk  distance (6MWD)   
• NSAA scale  
• Performance  of Upper Limb  Scale  (PUL)   
Detailed  instructions  for performing  each of these  assessments  a re provided in the Clinical  
Evaluator (CE) Manual.  Functional  endpoints will be measured  by a clinical  evaluator  who 
has undergone study specific  training  on the administration  of these  assessments. The clinical 
evaluators who assess functional endpoints must be distinct from the clinicians who assess AEs of 
the study subjects. To ensure that clinical evaluators remain blind to study drug assignment, 
clinicians evaluating AEs should not c ommunicate the presence, absence or severity of AEs with 
clinical evaluators at the site unless such communication is required to ensure subject safety. 
TFTs  include  4SC, 10- meter  walk/run and stand  from  supine. The 6MWD  measures  the distance 
a patient is able to traverse while  walking for 6 minutes . TFTs , such as  the 4SC and  the 6MWD , 
are well validated and have been widely  used in clinical trials.19, 23, 24,  46 Data  delineating  the 
natural  history  of performance  of the 4SC and other  TFTs  in boys with DMD have been published . 
18, 25 A 2.2-second difference in 4SCV corresponds to a 30- meter difference on the 6MWD. A 30 -
meter difference on the 6MWD has been shown to be associated with a significantly heightened 
risk of loss of ambulation within the ensuing 2 years.26 Unlike the 6MWD, the 4SC is less reliant 
on endurance and is most reflective of lower extremity muscle power.  The 4SC velocity (the 
number of stairs  climbed  per second) is calculated as the ratio of the number of stairs climbed (4) 
divided by the  number of seconds taken to complete the 4-stair climb. Because children who are 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
64/Protocol WN40227, Version 4   or have become unable to perform this task , the time cannot be measured, conventionally a time 
equal or bigger than the worst performance in the group is subjectively given to indicate poor 
performance. In order to improve the  possibi lity of performing statistical analysis, the results will 
be converted into velocity (distance /time) rather than the conventional time as this would allow 
conver sion of  all the poor or failed results from a subjectively chosen number into a meaningful 
number.  
The PUL  includes  22 items  with  an entry  item to define the starting point of testing,  with  21 items  
subdivided into shoulder  level,  middle  level,  and distal level  dimension.  Each  dimension can be 
scored  separately .48 
Some of the functional endpoint assessment including the TFTs, NSAA, 6MWD and upper and 
lower extremity myometry will be video recorded at select study visits while the subject is 
completing the assessments. The videos will be uploaded by the site to a secure database, 
maintained by a separate vendor, and reviewed by master physiotherapists to assure quality or 
identify potential issues requiring re -training of clinical evaluators at the site.  In addition the videos 
may be used to explore additional assessment of timing of TFTs, and to grade the quality of the patient’s functional abilities, which could inform the feasibility of potential new outcome measures 
focused on move ment quality.  
9.1.2  Myometry and Ankle Range of Motion (ROM)  
Muscle  strength  will be assessed  using hand- held dynamometry  at the time points  specified  in 
Table 2-1 through Table 2-3, following procedures outlined in the CE Manual.  All measures  will 
be obtained with a calibrated hand -held dynamometer.   
Detailed  instructions for performing manual  myometry  and ankle  ROM  assessments will be 
provided in the CE Manual.  These  assessments will be performed  by a clinical  evaluator  who has 
undergone study specific training on the administration of these assessments. 
9.1.3  Imaging Assessment for the Study  
Images  will be submitted to an imaging core  lab. Sites should be trained prior to scanning the first  
study participant.  Image  acquisition  guidelines and submission  process  will be outlined  in the 
Imaging  Manual  provided by  the core lab. 
9.1.3.1  DXA  
DXA to collect  measures  of total lean body mass,  fat mass  and bone  mineral  density will be 
performed  at the time points indicated  in Table 2-1 through Table 2-3.  
DXA acquisition  guidelines and submi
ssion  processes  will be outlined in the DXA Scanning  
Guide.  
Adequacy of DXA scans  should be confirmed  by the central  imaging  vendor prior to 
randomization.  
Screening  DXA should be obtained  between  Day -42 and Day -14 to allow  for central  imaging  
vendor review. 
DXA is not required for subjects enrolled at sites in Germany.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
65/Protocol WN40227, Version 4   DXA is not required at the early termination  visit.  
Re-enrollment:  Repeat  of DXA is not required  if previously obtained within  3 months  of 
Day 1/randomization. 
Effective doses  for whole-body DXA examinations  were found  to be 0.0052, 0.0048, 0.0042 and 
0.0042 mSv for a 5-, 10-, 15-year old child  and adult respectively  for an examination  performed  
on the Hologic  Discovery  A device.  Corresponding values  for the Hologic  Discovery  W were 
0.0105, 0.0096, 0.0084 and 0.0084 mSv .49 
9.1.3.2  Cardiac MRI  (cMRI) 
cMRI  with gadolinium enhancement  wi ll be performed  in a subset  of participants at select  U.S. 
centers at the time points indicated in  Table 2-1 through Table
 2-3. Su bjects enrolled  at select U.S. 
centers  participating  in the cMRI  substudy will be required  to attempt to complete  the cMRI.  
Subjects  participating at sites where the cMRI  substudy is being performed  who have an allergy  
to gadolinium may  undergo cMRI scanning without gadolinium.  
cMRI  acquisition  g
uidelines, protocols, contrast  agent  type and dose, and image  submission 
processes  are outlined in the imaging  manual  provided by the core imaging lab.  
Adequacy of cMRI  scans  should be confirmed  by the central  imaging  vendor prior to 
randomization.  
Screening  cMRI  should be obtained between  Day -42 and Day -14 to allow  for central  imaging  
vendor review. cMRI  will be conducted at early  termination  visits  if ≥ 24 weeks  has elapsed  from  
previous  cMRI.  
Re-enrollment:  Repeat  of cMRI  is not required  if p reviously  obtained within  6 months  of 
Day 1/randomization. 
9.1.4  Exploratory Genotyping 
A 2-mL whole blood 9.1.7 s ample w ill be drawn  (as indicated  in Table  2-2) for
 potential  analysis  
of g
enetic variation  in genes  suspected  to impact  DMD  disease  expression  (including but not 
limited  to LTBP4,  SPP1).  Human  leukocyte antigen  (HLA)  genotyping may be conducted  to 
better  understand immunogenicity risk if ADAs  are detected  and it is determined  that ADA  
impacts  safety  or efficacy.  Further details  of blood collection  and processing will be provided to 
the site in the laboratory procedure manual.  The exploratory  genotyping samples  will be used 
for up to 2 years  after the study  is closed  and will be used for analyses  between  genotype  and 
endpoints evaluated in this study.  
9.1.5  Acti Myo 
Subjec
ts enrolled at selected sites will be a sked to wear a device  called ActiMyo. The w earing of 
the ActiMyo is optional. Hence, refusal to wear ActiMyo will not affect  the eligibility of a subjec t 
to be enrolled  in the study. The  purpose of the ActiMyo device is to measure the daily movement 
and activity levels of subj ects with  a degree of  high accuracy. Unlike consumer-grade activity 
trackers and mobile phone applications, the  endpoints of the ActiMyo device are clinically 
validated. Therefore, the activity data collected by ActiMyo  will be analyzed  to provide deep 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
66/Protocol WN40227, Version 4   insights into the ability of subjects  to ambulate (i.e. , walking distance, walking speed, ability to 
climb stairs, speed of climbing stairs , etc.) and allows for the determination of the clinical 
meaningfulness  of RO7239361 in the treatment of DMD , and refusal will not exclude a subject  
from the study. The purpose of the ActiMyo device is to accurately measure the daily movement 
and activity levels of the subject. The device consists of two sensors, to  be worn on each ankle. 
Subjects will wear the de vices each day during specified periods of the study and during TFTs and 
6MWT at specified site visits. As the ActiMyo device battery requires recharging overnight, the 
device will not be worn at night. The subject and parent/caregiver will be trained on  how  to use the 
device, including correct fitting and wearing of the device, how to dock the device on the battery 
chargin g station, and when to return ActiMyo materials to the site. As a CE -marked device, the 
possibility of allergic reactions and skin irrit ation has been addressed and are thus unlikely to 
occur. Nevertheless, should any skin reaction be observed, the subject should remove the strap and 
sensor and contact the study team as soon as possible. Detailed instructions as to use of the 
ActiMyo devic e are provided in the ActiMyo User Manual and Quick Start Guide. 
9.1.6  Caregiver  Video Assessment  
Subjects enrolled at selected sites will be invited to  participate in the c aregiver video assessment . 
Participation is optional , and refusal  to participate will not exclude a subject  from the main study. 
The aim of the c aregiver video assessment  is to provide additional insight into a subject's  physical 
functioning and motor strength  during the study. A video application will be used to capture a  
range of  standardized  tasks in a real -world environment, external to the clinic . 
The video application will ask caregivers to record the subject  completing selected tasks every 
12 weeks according to pre- specified instructions read aloud by the caregiver. These tasks include  
sitting up, st anding up, walking, running,  climbing  stairs, and one additional task personally 
chosen by the caregiver. The caregiver is allowed to skip the recording of any of these tasks if not 
appropriate  or applicable. In addition,  the application  will allow caregivers to record a new ability 
at any point during the study. 
If the subject and caregiver agree to participate, they will sign a sep arate Informed Consent Form at 
baseline ( for newly enrolled  subjects ) or at a future  study visit ( for subjects  who are already enrolled 
in the main study  only). Detailed instructions regarding the c aregiver video assessment  are 
provided in the parent/caregiver m anual.  
9.1.7  Clinical Global Impression of Change (CGI- C)  
The CGI -C is a single item that clinicians will complete at the end of the double -blind phase (Week 
48 of the study) and at Week 48 of the  OL phase ( Week 96 of the study ) to rate change in the 
patient’s global impression of change in DMD from the start of each phase (i.e., from baseline for  
the double -blind phase and from Week 4 9 for the OL phase) .  There are seven response options: 
“Very much improved”, “Much improved”, “Minimally improved”, “No change”, “Minimally 
worse”, “Much wor se”, and “Very much worse”.  It  is a widely used endpoint in clinical trials 
across a variety of disease areas. To enhance inter -rater consistency, an instruction document 
(developed with input from clinical experts) will be provided in the user manual, which includes 
examples for each of the response options. 
The item should be completed by a clinician (e.g., Principa l Investigator or study coordinator) who  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
67/Protocol WN40227, Version 4   has interacted with the individual since baseline. The same clinician should complete the CGI -C 
at all s pecified visits for an individual patient. If there is no clinician at the site who is able to 
reflect on the patient’s health status, an alternative clinician should make the rating using existing 
study notes, and sites should record this. 
9.1.8  Caregiver Global Impression of Change (CaGI -C)  
The CaGI -C comprises six  item s that caregivers will complete at the end of the 
double -blind phase  (Week 48 of the study)  and at Week 48 of the OL phase  (Week 96 of 
the study)  to rate the change in a subj ect's symptoms, physical abilities, daily activities, 
social life, emotions and mental well- being , and overall health  from  the start of each phase  
(i.e., from baseline of  the double -blind phase and from Week 49 of  the OL phase) . There are seven 
response options: “Very much improved, ” “Much improved, ” “Minimally improved ,” 
“No change ,” “Minimally worse ,” “Much worse ,” and “Very much worse .” It is a widely 
used endpoint in clinical trials across a variety of disease areas.  
To enhance intra - and inter -consistency, descrip tions of each level of change have been 
developed and domain level global impression items have been created with input from 
patients with DMD  and their  caregivers.  The item s should be completed by the parent or 
caregiver who has been involved in the study since baseline. The same parent or caregiver 
should complete the CaGI -C for his or her child at the end of each study phase to reflect 
the subject' s health status from basel ine for the double -blind phase  and Week 49 of the 
OL phase . The CaGI -C will be a ssessed at selected sites only.  
9.1.9  Pediatric Quality of Life Inventory Multidimensional Fatigue Scale 
(PedsQL MFS)  
The PedsQL MFS parent proxy measures the severity and impact of fatigue on the subject  
from the caregiver’s perspective.  The recall period is the last 4 weeks.  The instrument is 
appropriate for individuals aged 2- 18 years old and captures six items on g eneral fatigue, 
six items on sleep/rest fatigue, and six items on cognitive fatigue.  A total fatigue score 
can be calculate d from the 18 items that  ranges from 0  to 100, with higher scores 
indicating less fatigue. The PedsQL MFS takes  approximately 10 minu tes to complete.  
The Ped sQL MFS will be a ssessed at selected sites only.  
9.2 Adverse Events  
The definitions of an AE or SAE can be found in Appendix 3.  
AEs will be reported  by the participant (or, when  appropriate, by a caregiver,  surrogate,  or the 
participant's  legally  authorized  representative).  
Malfunctions of the pre-filled syringes containing study drug should be reported to the sponsor 
via designated form (electronic system)  in accordance with local  regulations.  
The investigator and any designees  are responsible  for detecting,  documenting,  and reporting 
events  that meet  the definition  of an AE or SAE  and remain  responsible for following up AEs  that 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
68/Protocol WN40227, Version 4   are serious, considered related to the study treatment or the study, or that caused the participant to  
discontinue  before completing the study.  
The clinical evaluators who assess functional endpoints must be distinct from the clinicians who 
assess AEs of the study subjects. Clinicians evaluating AEs should not communicate t he presence, 
absence or severity of AEs with clinical evaluators at the site unless required to do so to ensure 
subject safety.  
Contacts for SAE reporting are specified in Appendix  3. 
9.2.1  Time Period and Frequency for Collecting AE and SAE Information 
The collection  of nonserious  AE information  should begin  at initiation  of study  treatment  until 50 
days of discontinuation  of dosing .  Nonserious AE information should also be collected  from  
the start of a placebo  lead-in period  or other observational period intended to establish a baseline 
status for the participants.  
Section  6.4 in the IB represent  the Reference Safety  Information  to determine expectedness  of 
serious  AEs for expedited  reporting. Following the participant’s  written  consent to participate  in 
the study,  all SAEs,  whether  related  or not related  to study drug,  must  be collected,  including  
those thought to be associated  with protocol- specified  procedures. 
All SAEs  must  be collected  that occur  during the screening  period and within  50 days  (5 half-lives)  
of discontinuation of dosing.  If applicable,  SAEs must  be collected  that relate  to any later 
protocol -specified  procedure (e.g., a follow -up skin biopsy).  
The investigator must  report  any SAE  that occurs  after these time periods and that is believed  to 
be related to study  drug or protocol- specified  procedure. 
• Medical  occurrences  that begin  before  the start of study treatment  but after obtaining  informed  
consent will be recorded  on the appropriate section of the eCRF section.  
• All SAEs  will be recorded  and reporte d to Sponsor or designee  within  24 hours, as indicated  
in Appendix 3.  
• The investigator will submit any updated  SAE data to the sponsor  within  24 hours  of this being 
available.  
 
Investigators are not obligated  to actively  seek AEs or SAEs  in former study participants.  
However,  if the investigator learns  of any SAE,  including a death,  at any time after a participant 
has been  discharged  from  the study,  and he/she considers  the event  reasonably related  to the study  
treatment  or study participation, the investigator  must  promptly  notify the sponsor. 
The method of evaluating  and assessing the seriousness, severity, and  causality  of AEs and the 
procedures  for completing  and reporting/transmitting SAE reports are provided in  Appendix 3 . 
Guidance fo
r assessing severity of AEs  is also  provided in S ection 8. 
9.
2.2 Method  of Detecting  AEs and SAEs  
Adverse events  can be spontaneously reported  or elicited  during open-ended questioning, 
examination,  or evaluation of a subject. (In order to prevent reporting bias, subjects should not be  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
69/Protocol WN40227, Version 4   questioned regarding the specific occurrence of one or more AEs.) 
9.2.3  Follow -up of AEs and SAEs  
• Nonserious  AEs should be followed to resolution  or stabilization,  or reported  as SAEs  if they 
become serious (see Appendix 3).  
• Follow-up is also required  for nonserious AEs that cause interruption  or discontinuation of 
study treatment and for those present at the end of study treatment as appropriate. 
• All identified nonserious  AEs must be recorded  and described  on the nonserious AE page of 
the CRF (paper  or electronic).  Completion  of supplemental  CRFs  may be requested  for AEs 
and/or laboratory abnormalities that are reported/identified  during the course of the study.  
 
After the initial AE/SAE report, the investigator is required to proactively follow  each participant 
at subsequent visits/contacts.  All SAEs  will be followed until resolution, until the condition 
stabilizes,  until the event is otherwise  explained,  or until the participant  is lost to follow- up (as 
defined in Section  8.3).  
Further information  on follow -up procedures is  given  in Appendix 3. 
9.2.4  Regulatory Reporting Requirements for SAEs  
• Prompt  notification  by the investigator  to the Sponsor of SAEs  is essential  so that legal  
obligations and ethical  responsibilities  towards the safety  of participants and the safety  of a 
product under clinical investigation are met.  
• An investigator who receives  an investigator safety  report describing  SAEs  or other specific  
safety  information (e.g., summary or listing  of SAEs)  from  the Sponsor will file it along with 
the Investigator Brochure and will notify the IRB/IEC,  if appropriate according  to local  
requirements.  
 
Sponsor or design
ee will be reporting AEs to regulatory authorities and ethics  committees  
according  to local  applicable  laws including European  Directive 2001/20/EC  and FDA Code of 
Federal  Regulations  21 CFR  Parts  312 and 320. A SUSAR  (Suspected,  Unexpected  Serious  
Adverse Reaction)  is a subset of SAEs  and will be reported  to the appropriate regulatory 
authorities and investigators  following local  and global guidelines and  requirements.  
9.2.5  Pregnancy  
Any pregnancy that occurs  in a female partner  of a male  study participant should be reported  to 
Sponsor or designee.  In order for Sponsor or designee  to collect  any pregnancy surveillance  
information from  the female partner,  the female partner  must  sign an informed  consent form  for 
disclosure of this information. Information on this pregnancy  will be collected  on the Pregnancy  
Surveillance Form.  
9.2.6  Laboratory Test Result Abnormalities  
The following laboratory test  result  abnormalities  should be reported as an AE  and captured  on 
the nonserious AE eCRF  page or SAE  Report Form  electronic,  as appropriate. Paper  forms  are 
only intended  as a back -up option when the electronic system is not functioning.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
70/Protocol WN40227, Version 4   • Any laboratory  test result that is clinically significant or meets the definition  of an SAE  
• Any laboratory test result  abnormality that required  the participant to have study treatment  
discontinued or interrupted 
• Any laboratory test  result  abnormality that required  the participant to receive specific 
corrective therapy  
It is expected  that wherever  possible, the clinical  rather  than laboratory  term would  be used by the 
reporting investigator (e.g., anemia versus low hemoglobin value). 
Laboratory  abnormalities that are reported  as AEs or SAEs  should be reported  utilizing  the 
Common  Terminology Criteria  for Adverse Events (CTCAE), version 4.0. 
9.2.7  Potential Drug Induced Liver Injury (DILI)  
• Dosing will be paused  within  a subject  until safety  information  is reviewed  and drug  induced 
liver injury  (DILI)  is ruled out in the event that: 
− ALT  > 5 x baseline AND No corresponding increase in CPK  to indicate  muscle  origin  as 
the reason for the increase in ALT  
OR 
− ALT  > 10 x ULN  AND ALT  > 2 x baseline  AND no corresponding increase in CPK  to 
indicate  muscle  origin  as the reason for the increase in ALT  
OR 
− Total  bilirubin  > 2 x ULN  
OR 
− Symptoms  or signs  of hepatic inflammation  such as nausea,  vomiting, right upper  quadrant  
pain or tenderness  with no other immediately  apparent  possible  cause of these  symptoms  
or signs, such as viral gastroenteritis or constipation. 
Wherever  possible, timely  confirmation of initial liver-related  laboratory abnormalities  should 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting  
the defined  criteria,  must  be reported  as SAEs  (see Section  9.2 and Appendix  3 for report ing 
details).  
Criteria  for initiating  an evaluation  for potential DILI are defined in  Section  8. 
9.2.8  Other Safety Considerations  
Any significant worsening noted during interim or final physical  examinations, electrocardiogram,  
x-ray filming,  any other potential  safety  assessment  required  or not required  by protocol should 
also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly. 
9.2.8.1  Injection  Site Assessments 
Subjects  will be monitored  for injection -site reactions  from  Day 1 through the last study visit.  
Report  injection -site reactions  as AEs, as appropriate. It  is strongly recommended  that non- subject  
identifying  photographs of injection  site reactions  be taken  for submission to the sponsor or 
designee.  Some  subjects  with injection -site reaction  or rash may be asked  to participate  in 
additional procedures to determine  the type of immune reaction  associated  with the injection -site 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
71/Protocol WN40227, Version 4   reaction  or rash. Potential  subjects will be identified  in consultation with the medical  monitor.  
The additional procedures include a blood sample  and skin biopsy  to assess the type of 
immune  reaction.  The blood sample  will be used to assess ADA titers,  serum  mast  cell 
tryptase/histamine, and  compliment  activation  products ( e.g., C3D, C3G). The  skin biopsy  should 
be collected  in a sterile  manner in accordance with local procedures, using a 3 mm punch biopsy 
instrument and formalin  fixation,  and will assess  mast cell, eosinophil, and neutrophil infiltration.  
The Draize Scale for erythema  and edema will be used as a guide for  reporting injection  site 
reaction  AEs50 (see Table 9.2.8.1-1).  
 
Table 9.2.8.1-1: Grading Injection Site Reactions  
 
Erythema  Edema  
Description  AE Grade  Description  AE Grade  
No erythema  - No edema  - 
Very  slight  erythema,  barely  
perceptible Mild  Very  slight edema, barely  perceptible  Mild  
Well defined erythema  Moderate Moderate  edema, raised  approximately  
1 milimeter (mm)  Moderate 
Severe erythema 
Beet redness to slight eschar  
formation  Severe  Severe edema, raised  more  than 1mm  
and beyond exposure area  Severe  
 
9.2.9  Overdose  or Incorrect Administration of Study Drug 
An overdose is defined as the accidental or intentional administration of the drug in an amount 
higher than the assigned  dose. Definitions of other incorrect administration of study drug 
(including medication error, drug abuse, and drug misuse) are provided in Appendix 3.  
Any overdose or incorrect administration of study drug must be reported as  an AE.  
If the associated AE fulfills seriousness criteria, the event should be reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event ). Any AE 
associated with an overdose or incorrect administratio n of study drug should be reported as a 
separate AE as well  (see Section  9.2).  
9.3 Safety  
Planned  time points for all safety  assessments are listed in the Schedule of Activities.  
The data from  the safety  assessments required  in this protocol (laboratory  tests,  ECGs,  
echocardiograms) will  be transferred to Roche or designee  from  the relevant  vendor. The site staff 
are not  required  to report these  procedures  in the CRF.  Any  findings  of potential clinical  relevance 
should be evaluated  and managed  by the investigator per standard  medical/clinical judgment  in 
consultation with the Roche medical monitor. Site staff are required to report to the sponsor on the  
CRF any AE that is identified  during safety  assessments.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
72/Protocol WN40227, Version 4   9.3.1  Physical Examinations  
Targeted  physical  exams  to be guided by review  of systems  and include  assessment  of heart,  lungs  
and abdomen. 
9.3.2  Vital Signs  
Refer to Schedule of Activities.  
9.3.3  Electrocardiograms and Echocardiograms  
Refer to Schedule of Activities.  
A central  core lab will perform  all imaging  analyses.  Sites  will be informed  of quality issues or 
needs for repeat scanning via queries from  the core lab.  
Any findings of potential  clinical  relevance that are not directly  associated  with the objectives  of 
the protocol should be evaluated  and handled by the study investigator as per standard  
medical/clinical judgment.  
Reports (electrocardiogram  and echocardiogram)  from  the central  core lab will be provided to sites 
for inclusion  in the subject’s medical  record  and to provide  to subject caregivers.  Availability  of 
reports will be determined by  the central  core lab. 
Electrocardiograms  and echocardiogram  should be  repeated  in subjects  with  new  cardiac  
symptoms.  
9.3.4  Clinical Safety Laboratory Assessments  
Investigators must document their review of each laboratory  safety  report.  
 
  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
73/Protocol WN40227, Version 4   Table 9.3.4-1: Laboratory Assessments 
 Screening  On Treatment  Follow -up 
Hematology    
Hemoglobin X X X 
Hematocrit  X X X 
Total leukocyte count, including 
differential  X X X 
Platelet count X X X 
Serum  Chemistry     
Alanine  aminotransferase (ALT)  X X X 
Aspartate aminotransferase (AST)  X X X 
Gamma -Glutamyl transferase (GGT)  X X X 
Total bilirubin  X X X 
Direct bilirubin  X X X 
Alkaline phosphatase  X X X 
Lactate dehydrogenase  (LDH)  X X X 
BUN  X X X 
Creatinine  X X X 
Creatine kinase  X X X 
Total Protein  X X X 
Albumin X X X 
Sodium  X X X 
Potassium  X X X 
Chloride  X X X 
Calcium  X X X 
Phosphorus  X X X 
Magnesium  X X X 
Iron X X X 
Plasma Chemistry     
Glutamate  Dehydrogenase  (GLDH) X (D ay -1 or -2) X X 
Urine  test    
Urinalysis  (including protein,  glucose,  
blood, leukocyte esterase, specific  
gravity)   
X X (only  required at visits  
specified in  Table  2-2 and 
Table 2-3 )  
 
 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
74/Protocol WN40227, Version 4   Table 9.3.4-1: Laboratory Assessments 
 Screening  On Treatment  Follow -up 
Other  sample  collections     
Serum Biomarkers   X (see Table  2-2  
and Table  2-3)  
Immunogeni city  X (see Table  2-2  
and Table  2-3) X (see Table  2-4) 
Free and  myostatin drug complex  X (see Table  2-2  
and Table  2-3)  
Exploratory  genotyping  X (see Table  2-2)  
Creatine kinase -muscle  (CK-MM)   X (Day  1, Weeks  12, 24 
 and 48 in double -blind phase)   
GDF -11  X (see myostatin collection  
schedule in  Table  2-2 
 and Table  2-3)  
 
9.3.5  Imaging Safety Assessment  
Any incidental findings  of potential  clinical  relevance that are not directly  associated  with the 
objectives of the protocol should be evaluated  and handled by the Study  Investigator as per 
standard  medical/clinical  judgment. 
9.4 Pharmacokinetics  
The PK data obtained  in this study will be combined with data from  other studies  in the clinical  
development program to develop a population PK model. This model will be used to evaluate the 
effects of intrinsic and extrinsic covariates on the PK of RO7239361 and to determine measures  
of individual  exposure (such  as steady -state trough, and time-averaged  concentration). Model  
determined exposures will be used for exposure -response analyses of selected  efficacy  and safety  
end points. Results of population PK and exposure- response analyses will be reported separately.  
Table 9.4-1 lists the sampling schedule to be followed  for the assessme nt of pharmacokinetics.  
Further details  of blood collection  and processing will be provided to the site in the procedure 
manual  and laboratory  manual.  
Serum samples  will be analyzed  for 
RO7239361 using a validated  ligand binding assay.  
Pharmacokinetic samples  collected  from a subject who received placebo will not be analyzed.  
 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
75/Protocol WN40227, Version 4   Table 9. 4-1: Pharmacokinetic Sampling Schedule for RO7239361 
 
Study  Day of Sample  
Collection  Event  Time  (Relative To 
RO7239361  Dose)   
Hour:  Min RO7239361 
Blood  Sample  for Serum  
Day 1 of the  double -blind phase  
 predose  00:00  X 
Day 8 of the  double -blind phase  predose  00:00  X 
Day 15 of the  double -blind phase  predose  00:00  X 
Day 29 of the  double -blind phase  predose  00:00  X 
Week 12 of the  double -blind phase  predose  00:00  X 
Week 24 of the  double -blind phase  predose  00:00  X 
Week 36 of the  double -blind phase  predose  00:00  X 
Week 48 of the  double -blind phase  predose  00:00  X 
Week  1 of the  open-label phase  predose  00:00  X 
Week  2 of the  open-label phase  predose  00:00  X 
Week 3 of the  open-label phase  predose  00:00  X 
Week  12 of the  open-label phase  predose  00:00  X 
Week  24 of the  open-label phase  predose  00:00  X 
Week  36 of the  open-label phase  predose  00:00  X 
Week  48 of the  open-label phase  predose  00:00  X 
 
 
9.5 Pharmacodynamics 
Not applicable  
9.6 Pharmacogenomics  
Not applicable.  
9.7 Biomarkers  
Blood will be drawn at the times indicated in  Table 2-1 through  Table 2-3 for the measurement of  
target engagement biomarkers (free myostatin and myostatin -drug complex). 
Blood will be drawn at the times indicated in  Table 2-1 through  Table 2-3 for the measurement of  
exploratory biomarkers. Serum  samples  may be used to evaluate  the levels  of exploratory 
biomarkers  known to be involved in muscle  growth , function , and/or myostatin  signaling  (e.g., 
sTNI, MYL3, FABP3 ). 
Creatine kinase- muscle  (CK-MM)  will be analyzed  during the double blind  phase of the study to 
examine concentrations associated with muscle atrophy  in boys  with DMD.  
Reports of the exploratory serum  biomarkers  will not be provided to sites as this is a research  
measure.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
76/Protocol WN40227, Version 4   9.7.1  Additional Research Collection  
Additional  research  collections  and retention  are optional for all subjects, except where prohibited  
by local  laws or regulations.  
This protocol will include both sample  collection  and residual sample  storage for additional  
research (AR).  
This serum  collection  for additional research  is intended  to expand  the translational R&D  
capability  at Roche, and will support as yet undefined  research  aims that will advance our 
understanding of disease  and options for treatment.  For example,  this sample  may have potential 
in exploration of diagnostic  or prognostic biomarkers contingent on scientific  developments 
in the field of myostatin  biology,  DMD pathophysiology or unanticipated results in the study.  
This collection  for additional research  may also be used to support health  authority requests for 
analysis, and advancement of pharmacodiagnostic development to better target  drugs to the right 
patients.  This may  also include  genetic/genomic exploration aimed  at exploring  disease pathways, 
progression and  response to  treatment  etc. 
All requests  for access  to samples  or data for additional research will  be vetted  through a diverse 
committee  of the study sponsor’s senior  leaders  in Research  and Development to ensure  the 
research supports appropriate and well -defined scientific  research  activities.  
 
• Prospective samples of serum  for Additional Research  will be collected  at selected  time points 
(see Table 9. 7.1-1) 
• Residual seru
m from  serum  biomarker collections (see Table 9.7.1 -2) will also be retained for  
additional research  purposes 
• Residual  whole blood or DNA  derived   from   the  whole   blood  sample   from   exploratory  
genotyping  analysis  (Table 9.7.1 -2) will also be retained for additional research purposes 
Samples will be securely stored by the Roche Research Biosample Repository or at a Roche 
approved third party storage management facility. 
Samples  will be stored in a coded fashion, and no researcher will have access to the key. The key 
is securely held  by the investigator at  the clinical  site,  so there is no direct ability  for a researcher  
to connect a sample to a specific individual  
Additional  research  samples  will be retained  for 15 years  or the maximum allowed  by applicable  
law. No additional  sampling is required for residual collections. 
Further details  of sample  collection  and processing will be provided to the site in the procedure 
manual . 
  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
77/Protocol WN40227, Version 4   Table 9.7.1-1: Additional Research Sample Schedule  
 
 
Study Day  Time  
(Event)  
Hour  Time  
(Relative To Dosing)  
Hour: Min  
Blood  Sample  
Baseline Day  1 0 (predose)  00:00  X 
Week 24  0 00:00  X 
Week 48  0 00:00  X 
 
 
Table 9.7.1-2: Residual Sample Retention for Additional Research Schedule  
 
Sample  Type  Timepoints for which residual samples will be  
retained  
PK All 
Residual serum from serum biomarkers  All 
Residual  whole  blood  or DNA derived from the whole  
blood sample from exploratory genotyping Day 1 
Residual  serum  from  ADA analysis  All 
Residual serum from myostatin and myostatin -drug 
complex  All 
 
9.7.2  Immunogenicity  Assessments  
Serum  samples  from  all treated  subjects will be analyzed  by a validated  immunogenicity  assay.  
Individual time  points are considered positive  if confirmed as specific against RO7239361. The  
subject  will be called  positive for immunogenicity  as defined  in the Statistical  Analysis  Plan (SAP).  
The number and percentage of subjects  will be listed  and summarized  by treatment  and by time,  
and the corresponding antibody titer values  will be listed.  If ADAs  are observed, subgroup 
analyses  may be conducted to compare AEs,  labs, biomarker  data,  and PK results  across  treated  
subjects  with and without ADAs.  In the event  a subject has a positive  immunogenicity  response, 
additional NAB  analyses  may be conducted. 
9.7.3  RNA Transcriptome Research  
Not applicable.  
9.7.4  RNA Expression Research of a Subset  of RNA Species  
Not applicable.  
9.7.5  Proteome Research  
Not applicable.  
9.7.6  Metabolomic Research  
Not applicable.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
78/Protocol WN40227, Version 4   9.7.7  Other Assessments  
Not applicable.  
9.8 Health Economics or Medical Resource Utilization and Health 
Economics  
This study includes  a number  of patient reported  outcomes,  such as pediatric  data collection  
instrument  (PODCI), health utilities index (HUI III), and PedsQL family impact module (PedsQL  
FIM)  that provide  additional information to the clinician -reported  outcomes. In addition, several  
questions will be included to collect  presenteeism  and absenteeism  data,  along with health  care 
resource utilization.  
Health  care resource utilization  data associated  with medical  encounters, will be collected  in the 
CRF by the investigator  and study -site personnel for all participants  throughout the  study.  
Protocol- mandated procedures, tests, and encounters are excluded. 
The data collected may be used to conduct exploratory economic analyses and will include: 
• Number and duration of medical  care encounters, including surgeries,  and other selected  
procedures (inpatient and outpatient) 
• Duration  of hospitalization  (total days length  of stay, including duration by wards , 
e.g., intensive care unit)  
• Number and character of diagnostic  and therapeutic tests and procedures 
• Outpatient  medical  encounters and treatments (including physician or emergency room visits, 
tests and procedures, and medications)  
10 STATISTICAL CONSIDERATIONS  
10.1 Sample Size Determination  
Statistical Considerations:  Sample Size  
The sample size of 159 patients (53 patients per arm) will provide 80% power for testing the null 
hypothesis of no difference between a dose of RO7239361 and placebo in the change from baseline 
in the NSAA total score at 48 weeks under the following assumptions:  
• A true treatment difference (RO7239361 minus placebo) of 2.5 points  
• A standard deviation of 4.4 points  
• A treatment discontinuation rate of 5%  
10.2 Populations for Analyses  
For purposes of analysis, the following populations are defined: 
 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
79/Protocol WN40227, Version 4   Population  Description  
Enrolled  All participants  who sign informed  consent  and are assigned  a 
participant  identification  number. 
Randomized  Enrolled  participants  who receive  a randomization  treatment  
assignment.  
Treated  Enrolled subjects who receive at least 1 dose of study  therapy.  
• If a subject received  the same  incorrect treatment throughout the  
study, then the participant  will be analyzed  based  on the treatment  
received.  
• If a subject received  study drug from  more  than one treatment  
group, and none  of the administrations  were consistent  with the 
assigned randomized treatment group, then the participant will be  
analyzed based on the first treatment received.  
Modified  Intention  to Treat  
(mITT)  Randomized  subjects  that received  at least one dose of study  
drug. For change from baseline analyses,  this includes  only those 
subjects that had at least one efficacy assessment.  
Per-Protocol  mITT subjects with no major protocol violations , as described in 
the Statistical Analysis Plan  
 
10.3 Statistical Analyses  
The SAP  will be developed and finalized  before  database lock and will describe  the selection  of 
participants  to be included  in the analyses,  and procedures  for accounting  for missing,  unused, 
and spurious data.  Below  is a summary  of planned  statistical  analyses  of the primary  and 
secondary endpoints. 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
80/Protocol WN40227, Version 4   10.3.1  Efficacy Analyses  
 
Endpoint  Statistical Analysis Methods  
Primary  The primary analysis, on the change from baseline in NSAA total score , will be 
conducted using a Mixed Model Repeated Measures (MMRM) analysis with 
treatment, visit, and the treatment- by-visit interaction entered into the model as fixed 
effects, and participant entered as a random effect. The baseline NSAA total score  will 
be entered into the model as a covariate. The stratification factors will be entered into 
the model as blocks.  
For each RO7239361 dose group, the null hypothesis of the no treatment difference 
between the dose group and placebo will be tested using the estimates from this 
MMRM model at the end of the 48 -week double- blind treatment period. In order to 
control the overall type I error rate for the analysis, the following hierarchical testing 
of doses will be implemented:   
1. Comparison of the RO7239361 high dose (35/50 mg) to placebo at a two -sided 
α level of 0.05 is performed. 
2. If the null hypothesis for the high dose is rejected (comparison of the high dose 
to placebo in the previous step is statistically significant), then a comparison of the RO7239361 low dose (7.5/15 mg) to placebo at a two -sided α  level of 0.05 
will be  perfo rmed. If the null hypothesis for the high dose is not rejected, then 
the testing of the low dose versus placebo will not be performed.  
Sensitivity analyses will include the following: an analysis of covariance 
(ANCOVA) using the mITT data set; an ANCOVA on  the mITT data set with 
missing data imputed using multiple imputations; and an MMRM analysis using the 
per-protocol data.  
Secondary  Following testing of the primary endpoint, the key secondary endpoints will be 
analyzed using a hierarchical testing procedure in order to maintain the overall type 
I error rate at  0.05. This procedure will be specified in the S tatistical Analysis Plan 
prior to database lock.  
Most secondary endpoints will be tested using a MMRM that is similar in structure 
to the primary analysis. Proximal lower extremity flexor strength will be tested using 
a MANOVA of the 2 component variables: knee extension and knee flexion. 
If a dose fails to reach significance against placebo in any stage of the testing 
hierarchy, any further tests will be considered as exploratory . 
Exploratory  Will be described in the Statistical  Analysis Plan finalized  before database lock  
 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
81/Protocol WN40227, Version 4   10.3.2  Safety Analyses  
All safety analyses will be performed using treated subjects. 
 
Endpoint  Statistical Analysis Methods  
Primary  Not applicable  
Secondary  Tabular summaries of SAEs, AEs leading to discontinuation  and Grade 3 to 4  
laboratory abnormalities will present the number and percentage of unique 
subjects  with  treatment  emergent  events. Adverse event summaries will be  
presented by system organ class  (SOC) and preferred term (PT).  All SAEs  
since  enrollment will be listed. Grade 3 to 4 laboratory abnormalities will be 
summarized as proportions by baseline toxicity  grade.  
Endpoint  Statistical Analysis Methods  
Exploratory  Will be described in the Statistical  Analysis Plan finalized before database  lock 
 
10.3.3  Other Analyses  
PK, PD, biomarker and exploratory  analyses will be described in the SAP  finalized  before 
database  lock. The population PK analysis  and PD  analyses will be presented separately from  the 
main  clinical study  report.  
10.3.4  Interim Analyses  
Schedule of Analyses  
In addition to the primary analysis (to be conducted when all patients have completed  Week 48, the 
end of the double -blind treatment period), the following analyses may be conducted during the 
course this study:  
• When at least 20% of the total number of patients ha ve completed 24 weeks of double -blind, 
placebo- controlled treatment  
• When at least 20% of the total number of patients has completed 48 weeks of double-blind, 
placebo- controlled treatment  
• An analysis conducted at Week 96  (at the end of the first 48 weeks of the OL phase of the study) 
• A final data analysis when the study has been completed  
The SAP  will further describe the planned interim analyses.  
Interim SAPs (iSAPs) will contain detailed information about  the conduct of the futility analyses, 
which will be performed by an independent data coordinating center with results reviewed by the 
iDMC. Because  these futility analyses will be conducted prior to the primary efficacy analysis, the 
unblinded data will n ot be shared with the Sponsor in order to maintain the integrity of the study 
blind.   
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
82/Protocol WN40227, Version 4   For the primary efficacy endpoint ( the change from baseline in NSAA total score), additional 
analyses may be performed , incorporating the first 96 weeks of exposure to RO 7239361 (48 weeks 
of double -blind treatment ) followed by 48 weeks of OL treatment). The data will be compared with  
data from  one or more control cohorts from external data sources (e.g. , disease registries) that 
include at least 96 weeks of follow -up data. 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
83/Protocol WN40227, Version 4    
11 REFERENCES  
 
1 Emery  AE. Population  frequencies  of inherited  neuromuscular  disease - a world  survey. 
Neuromuscular  Disord, 1991; 1:19-29. 
2 Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular  
dystrophy. Cochrane Database Systematic Review, 2008; 1:CD003725. 
3 Wagner  KR, McPherron  AC, Winik  N, et al. Loss  of myostatin  attenuates  severity  of muscular  
dystrophy in mdx mice. Ann Neurol, 2002; 832-836. 
4 Grounds MD, et al. Towards developing standard operating procedures for pre-clinical  testing  
in the mdx mouse  model of Duchenne muscular  dystrophy.  Neurobiol Dis 2008; 31(1):  1-
19. 
5 Bogdanovich S, Krag, TO, Barton ER,  et al. Functional improvement of dystrophic muscle by  
myostatin  blockade. Nature, 2002; 420: 418- 421. 
6 Guiraud S, Aartsma -Rus A, Vieira NM, et al. The Pathogenesis  and Therapy  of Muscular 
Dystrophies. Annu  Rev Genomics  Hum  Genet  2015;ePub  ahead  of print. Accessed : 23 July 
2015. 
7 Hoffman  EP, Brown  RH, Kunkel  LM. Dystrophin: the protein  product of the Duchenne 
muscular  dystrophy locus.  Cell 1987:51:919-28. 
8 Manzur  AY, Kuntzer  T, Pike M, Swan  AV. Glucocorticoid  corticosteroids  for Duchenne 
muscular  dystrophy.  Cochrane Database Syst Rev 2008;1.  
9 Eagle  M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular  dystrophy:  
improvements in life expectancy  since 1967 and the impact of home  nocturnal ventilation.  
Neuromuscul  Disord 2002;12:926-9. 
10 Lynn  S, Aartsma -Rus A, Bushby K, et al. Measuring  clinical  effectiveness  of medicinal  
products for the treatment  of Duchenne muscular  dystrophy.  Neuromuscul  Disord  
2015;25:96-105. 
11 Moxley RT 3rd, Pandya S, Ciafaloni  E, et al. Change in  natural history  of Duchenne muscular  
dystrophy with long- term corticosteroid  treatment:  implications  for management.  J Child  
Neurol 2010;25:1116-29. 
12 Translarna (ataluren)  Summary  of Product Characteristics.  Almac Pharma  Services.  31 July 
2014. 
13 Dent  KM, Dunn DM, von Niederhausern  AC, et al. Improved molecular  diagnosis  of 
dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 2005;134:295–8. 
14 Wright  MA,  Yee AS,  et al. Consider Muscle  Disease  in Children  with  Elevated  Transaminase.  
JABFM 2012; 25: 536-540. 
15 McMillan  HJ, Kang  PB, et al. Serum  Transaminase Levels  in Boys  with Duchenne and Becker  
Muscular Dystrophy. Pediatrics  2011; 127: e132 -e136. 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
84/Protocol WN40227, Version 4   16 Mcdonald  CM, Henricson  EK, Abresch  RT, et al. The 6-minute  walk  test and other clinical  
endpoints in duchenne muscular  dystrophy:  Reliability,  concurrent  validity,  and minimal  
clinically  important differences  from  a multicenter  study.  Muscle and Nerve  
2013;48(3):357-68 
17 Bushby K, Finkel R, Wong  B, et al. Ataluren  treatment  of patients  with nonsense  mutation  
dystrophinopathy. Muscle  & Nerve 2014;50:477-487. 
18 Pane M, Mazzone ES, Sivo S, et al. Long term natural  history data in ambulant boys with 
duchenne muscular dystrophy:  36-month changes. PLOS ONE 2014;9:e108205. 
19 Griggs  RC et al. Prednisone in Duchenne muscular  dystrophy:  a randomized,  controlled  trial 
defining the time course and dose response. Archive of Neurology 1991; 48:383-388. 
20 Manzur  AY, Kuntzer  T, Pike M, Swan  AV. Glucocorticoid  corticosteroids  for Duchenne 
muscular  dystrophy.  Cochrane Database  of Systematic  Reviews  2008, Issue  1. Art. 
No.: CD003725. 
21 Cittadini A,  Comi  LI, Longobardi  S, et al. A preliminary  randomized  study  of growth  hormone  
administration in becker and duchenne muscular dystrophies. Eur Heart J 2003;24(7):664- 72. 
22 Fenichel  GM,  Griggs  RC, Kissel  J, et al. A randomized efficacy  and safety  trial of oxandrolone 
in the treatment of duchenne dystrophy.  Neurology 2001;56(8):1075-9. 
23 Griggs,  R, Moxley,  R, Mendell, J, Fenchel,  G, Brooke, M, Pestronk, A, Miller,  J. Prednisone 
in Duchenne Dystrophy.  Arch Neurol. 1991; 48:383-388. 
24 Bushby K, Finkel R, Wong  B, et al. Ataluren  treatment  of patients  with nonsense  mutation  
dystrophinopathy. Muscle Nerve 2014; 50: 477-487 
25 Mayhew A, Cano S, Scott E, et al . Detecting meaningful change using the North Star 
Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med  Child N eurol  
2013;55:1046-52. 
26 Ricotti V, Ridout D, Pane M, et al . The North Start Ambulatory Assessment in Duchenne 
muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg  
Psychiatry 2016;87:149-55.   
27 McDonald  C, Henricson E, Abresch  R, et al. The 6-minute  walk  test and other endpoints  in 
duchenne muscular dystrophy: longitudinal natural  history observations over  48 weeks  from  a 
multicenter study.  Muscle Nerve 2013; 48: 343-356. 
28 McDonald  C, Henricson  E, Abresch  R, et al. The 6-minute  walk  test and other clinical  
endpoints in Duchenne muscular  dystrophy:  reliability,  concurrent validity,  and minimal  
clinically important differences from  a multicenter  study.  Muscle Nerve 2013; 48: 357 -368. 
29 Nakatani  M, Takehara Y, Sugino H, et al. Transgenic  expression of a myostatin  inhibitor 
derived  from  follistatin  increases  skeletal  muscle  mass  and ameliorates  dystrophic pathology 
in mdx mice. FASEB J 2008;22:477 -87. 
30 Morine KJ, Bish LT, Pendrak  K, et al. Systemic  myostatin  inhibition via liver targeted  gene 
transfer in normal and dystrophic mice. PLoS  One 2010;5:e9176.  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
85/Protocol WN40227, Version 4   31 Wagner  KR, McPherron AC, Winik  N, Lee SJ. Loss of myostatin  attenuates  severity  of 
muscular  dystrophy in mdx mice. Ann Neurol 2002;52:832 –6. 
32 Bogdanovich S, Krag TO, Barton ER, et al. Functional  improvement of dystrophic muscle by 
myostatin  blockade. Nature 2002;420:418-21. 
33 Morine KJ, Bish LT, Selsby  JT, et al. Activin  IIB receptor  blockade attenuates  dystrophic 
pathology in a mouse  model  of Duchenne  muscular  dystrophy.  Muscle Nerve 2010;42:722- 30. 
34 Murphy  KT, Ryall  JG, Snell  SM, et al. Antibody -directed  myostatin  inhibition improves 
diaphragm  pathology in young but not adult dystrophic mdx mice.  Am J Pathol 
2010;176:2425- 34. 
35 Pistilli EE, Bogdanovich  S, Goncalves  MD, et al. Targeting  the activin  type IIB receptor  to 
improve muscle  mass  and function in the mdx mouse  model  of Duchenne  muscular  dystrophy.  
Am J Pathol 2011;178:1287-97. 
36 Bish LT, Sleeper  MM,  Forbes SC, et al. Long -Term  Systemic  Myostatin  Inhibition via Liver - 
Targeted  Gene Transfer  in Golden Retriever  Muscular Dystrophy. Hum  Gene  Ther  
2011;22:1499-509. 
37 Kornegay JN, Childers MK, Bogan DJ, et al. The paradox of muscle hypertrophy  in muscular  
dystrophy. Phys Med Rehabil Clin N Am 2012;23:149-72. 
38 Clinical Study Report for Study CN001001. A Randomized, Placebo -Controlled,  Single  and 
Multiple  Ascending  Subcutaneous Dose  Study  to Evaluate the Safety,  Tolerability,  
Pharmacokinetics,  and Pharmacodynamics  of BMS -986089 in Healthy  Adult Subjects. 
Bristol- Myers  Squibb Company; 2016. Document Control No. 930103114. 
39 Gamer,  LW, Wolfman  NM, Celeste  AJ, et al. A novel  BMP  expressed  in developing mouse  
limb,  spinal  cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev.  
Biol 1999;208:222–232. 
40 McPherron  AC, Lawler,  AM, Lee  S-J. Regulation  of anterior/  posterior  patterning of the 
axial skeleton by  growth/differentiation factor 11. Nat. Genet. 22:260–264. 
41 , BMS -986089: Sc ientific  Report In Vitro  Potency  and Selectivity  of 
BMS -986089 in Cell -based  Luciferase Reporter Assays. Bristol -Myers Squibb Company;  
Jan 22, 2014. Document Control No. 930074468. 
42 . BMD -986089:  Sc ientific  Report. An in Vitro  Selectivity  Study 
Testing  BMS -989089 Blockade of GDF -8 and GDF -11 Cellular  Signaling.  Bristol- Myers  
Squibb Company; Jun 1, 2015. Document Control No. 930090594. 
43 Loffredo  FS, et al. Growth  differentiation  factor  11 is a circulating  factor  that reverses  
age-related  cardiac hypertrophy.  Cell,  2013;153:828-839. 
44 Egerman  MA, et al. (2015). "GDF11  Increases  with Age and Inhibits Skeletal  Muscle  
Regeneration."  Cell Metab. 22, 164–174. 
45 Rodgers  BD, and J. A. Eldridge JA. Reduced  Circulating  GDF11  Is Unlikely Responsible  
for Age-Dependent  Changes  in Mouse  Heart,  Muscle,  and Brain.  Endocrinology 
201; 156(11): 3885- 3888. 

 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
86/Protocol WN40227, Version 4   46 Smith,  S. C., et al. (2015). "GDF11  Does  Not Rescue Aging- Related  Pathological  
Hypertrophy."  Circ Res 117(11): 926-932. 
47 Investigator Brochure:  Anti-Myostatin  Adnectin,  RO7239361. F. Hoffmann- La Roche Ltd . 
Version  07, July 2018. 
48 Henricson  E et al. The Cooperative International Neuromuscular  Research  Group Duchenne 
Natural  History  Study:  Glucocorticoid treatment  preserves  clinically  meanintful functional 
milestones and reduces rate of disease progression as measured by manual muscle testing and 
other  commonly used clinical trial outcome measure s. Muscle and Nerve; July 2013:55- 67. 
49 Mazzone  ES et al. Reliability  of the North  Star Ambulatory Assessment  in a multicentric  
setting.  Neuromuscular Disorders 2009; 19:458-461. 
50 Pane  M, et al. Reliability  of the Performance  of Upper  Limb  Assessment in Duchenne 
muscular  dystrophy.  Neuromuscular Disorders  2014; 24: 201-206 
51 Damilakis  J et al. Radiation  exposure  in X-ray-based  imaging  techniques used  in osteoporosis.  
Eur Radiol 2010; 20: 2707-2714. 
52 Haschek  W, Rousseaux  C, Wallig  M. 2010.  Fundamentals of Toxicologic  Pathology. 2nd 
Edition.  London: Elseviers,  Inc. 
53 Food and Drug  Administration,  FDA  Briefing  Document,  Peripheral  and Central  Nervous 
System  Drugs  Advisory  Committee  Meeting,  NDA 206031, Drisapersen,  November 24, 2015. 
54 Rodriguez J, Vernus B, Chehl I, et al.  Myostatin and the skeletal muscle atrophy and 
hypertrophy signaling pathways. Cell Mol Life Sci 2014;71:4361-71. 
55 Tando T, Hirayama A, Furukama M, Sato Y, et al.  Smad2/3 proteins are required for 
immobilization -induced skeletal muscle atrophy. J Biochem 2 016;291:12184- 94. doi : 
10.1074/jbc.M115.680579. 
56 Scott E, Eagle M, Mayhew A, et al. Development of a functional assessment scale for mbulatory boys with Duchenne muscular dystrophy and the North Star Clinical Network for Paediatric Neuromuscular Disease. Physio Res Int 2012;17:101-9. 
57 Mazzone E, Martinelli D, Bardinelli A, et al. North Star Ambulatory Assessment, 6 -minute 
walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010;20:712-6. 
58 Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 2011;364:1513–22. 
 
 
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
87/Protocol WN40227, Version 4    
12. APPENDICES  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
88/Protocol WN40227, Version 4   APPENDIX 1 A BBREVIATIONS AND TRADEMARKS  
 
Term  Definition  
4SC 4 stair climb  
6MWD  6 minute walk distance  
AE adverse event  
ACLS  advanced cardiac life support  
ADA  anti-drug antibody  
AI accumulation  index  
AI_AUC  AUC  Accumulation Index; ratio  of AUC(TAU)  at steady  state to 
AUC(TAU) after the first dose  
AI_Cmax  Cmax  Accumulation Index; ratio of Cmax at steady state to Cmax after  
the first dose  
AI_Ctau  Ctau Accumulation  Index; ratio of Ctau at steady  state to Ctau after the  
first dose 
ALT  alanine  aminotransferase  
ANC  absolute  neutrophil  count  
ANOVA  analysis of variance  
AST aspartate aminotransferase  
AT amino  transaminases  
ATOM  Advancing Trial Outcome Measures International , Ltd. 
AUC  area under the concentration -time curve  
AUC(INF)  area under the concentration -time curve from time  zero extrapolated to  
infinite time 
AUC(0 -T) area under the concentration -time curve from time zero to the time of the  
last quantifiable concentration  
AUC(TAU)  area under the concentration -time curve in one dosing interval  
A-V Atrioventricular  
BID,  bid bis in die, twice daily  
BLQ  below limit of quantification  
BMI body  mass  index  
BMS  Bristol -Myers  Squibb  
BP blood pressure  
BUN  blood urea nitrogen  
C Celsius  
C12 concentration at 12 hours  
24 concentration at 24 hours  
Ca++ calcium  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
89/Protocol WN40227, Version 4   Term  Definition  
Cavg  average  concentration  
CBC  complete  blood count  
Cexpected -tau expected concentration in a dosing interval  
CFR Code of Federal Regulations  
CGI-C Clinical Global Impression of Change  
CHF  Congestive  heart  failure  
CI confidence interval  
C1- chloride  
CLcr  creatinine clearance  
cm centimeter  
Cmax,  CMAX  maximum observed concentration  
Cmin, CMIN  minimum  observed concentration  
cMRI  Cardiac  magnetic  resonance imaging  
CPF Cough peak flow  
CRC  Clinical  Research  Center  
CRF Case Report Form, paper or electronic  
CS Corticosteroid  
Ct Expected concentration  at a certain time,  usually at the end of an  
expected future dosing interval ( e.g., concentration at 24 hours, 
concentration at 12 hours, etc.)  
Ctau  Concentration in a dosing interval ( e.g., concentration at 24 
hours, concentration at 12 hours, etc.)  
CTCAE  Common  Terminology  Criteria  for Adverse Events  
Ctrough  Trough observed plasma concentration  
CV coefficient of variation  
D/C discontinue  
dL deciliter  
DMD  Duchenne muscular dystrophy  
DXA  Dual -energy  X-ray absorptiometry  
ECG  electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
EF Ejection  fraction  
e.g. exempli gratia (for example)  
EOSI  events of special interest  
ESR Expedited Safety  Report  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
90/Protocol WN40227, Version 4   Term  Definition  
FDA  Food and Drug Administration  
FEV 1 Forced expiratory  volume  in 1 second  
FVC  Forced Vital Capacity  
g Gram 
GCP  Good Clinical Practice  
GGT  gamma -glutamyl  transferase  
GFR  Glomerular  filtration  rate 
GDF -8 Growth and differentiation  factor -8 
GLDH  Glutamate  dehydrogenase  
h Hour 
HBsAg  hepatitis  B surface antigen  
HBV  hepatitis  B virus  
HCV  hepatitis  C virus  
HCO  - 
3 Bicarbonate 
HIV Human  Immunodeficiency Virus  
HR heart rate  
HRT  hormone  replacement  therapy  
HUI-3 Health  Utility  Index -3 
IA interim analysis  
IB Investigator’s Brochure  
ICD International Classification of Diseases  
ICH International Conference on Harmonisation  
iDMC  independent Data Monitoring Committee  
i.e. id est (that is)  
IEC Independent Ethics Committee  
IFU instructions for use  
IMP investigational  medicinal product  
IND Investigational New Drug  
IP Investigational product  
IRB Institutional  Review  Board  
IRT Interactive Response Technology  
IU International  Unit 
IV Intravenous  
IWRS  Interactive web response system  
K slope  of the terminal phase of the log concentration -time curve  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
91/Protocol WN40227, Version 4   Term  Definition  
K3EDTA  potassium  ethylenediaminetetraacetic acid  
K+ Potassium  
kg Kilogram  
L Liter 
LC liquid chromatography  
LDH  lactate dehydrogenase  
ln natural  logarithm  
LTBP4  Latent  transforming  growth  factor  beta binding  protein  4 
MAD  Multiple ascending dose  
MEP  Maximum expiratory  pressure  
MIP Maximum inspiratory  pressure  
mg Milligram  
Mg++ Magnesium  
min Minute  
mITT  Modified  intent  to treat  
mL Milliliter  
mmHg  millimeters of mercury  
MMRM  Mixed  model  repeated  measures  
MR medical research  
MRI Magnetic  resonance  imaging  
MRT  mean residence time 
MS Mass spectrometry  
MTD  maximum tolerated dose  
µg Microgram  
N number of  subjects or observations  
Na+ Sodium  
NA not applicable  
NAB  Neutralizing antibodies  
ng Nanogram  
NIMP  non-investigational  medicinal products  
NOAEL  No observed adverse event level  
NSAA  North Star Ambulatory  Assessment  Scale  
NSAID  non-steroidal  anti-inflammatory drug  
OL Open  label  
pAUCe  Extrapolated partial AUC from last quantifiable  concentration  to infinity  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
92/Protocol WN40227, Version 4   Term  Definition  
Pb percent of bound drug  
PD pharmacodynamic  
PE Physical exam  
PedsQL  FIM Pediatric Quality  of Life Family Impact Module  
PFR Peak  flow rate 
PFS pre-filled syringe  
PFTs  Pulmonary  function  tests 
PK pharmacokinetic  
PODCI  Pediatric  Outcome  Data  Collection  Instrument  
PO per os (by mouth  route of administration)  
PT prothrombin  time 
PTT partial  thromboplastin  time 
Pu percent of unbound drug  
PUL  Performance  of Upper Limb  
QC quality  control  
QD, qd quaque  die, once daily  
R2 coefficient of determination  
RBC  red blood  cell 
SAE serious adverse event  
SAP Statistical Analysis Plan  
SC Subcutaneous  
SOP Standard Operating Procedures  
SPP1  Secreted  phosphoprotein 1 
t Temperature  
T Time 
TE Target engagement  
TFTs  Timed function  tests 
TGF -β transforming growth factor -β 
T-HALF  Half life  
Tmax, TMAX  time of maximum observed  concentration  
Vss/F (or Vss)  apparent volume of distribution  at steady  state 
W Washout  
WBC  white blood cell  
WHO  World  Health  Organization  
WOCBP  women  of childbearing potential  
 
Anti-Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
93/Protocol WN40227, Version 4   Term  Definition  
x g times  gravity  
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
94/Protocol WN40227, Version 4    
APPENDIX 2 STUDY GOVERANCE CONSIDERATIONS  
The term "Participant" is used in the protocol to refer to a person who has consented to participate  
in the clinical  research  study.  The term "Subject " used in the eCRF  is intended  to refer to a person 
(Participant)  who has consented to participate in the clinical research study.  
REGULATORY and ETHICAL CONSIDERATIONS  
GOOD  CLINICAL  PRACTICE  
This study will be conducted in accordance with:  
• Good Clinical Practice (GCP),  
• as defined by  the International  Council on Harmonisation (ICH)  
• in accordance with the ethical  principles underlying European Union Directive 2001/20/EC  
• United States Code of Federal Regulations, Title  21, Part 50 (21CFR50)  
• applicable local requirements.  
 
The study will be conducted  in compliance with the protocol. The protocol and any amendments  
and the participant  informed  consent will receive approval/favorable opinion  by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC), and regulatory  authorities  according  to 
applicable local regulations prior  to initiation of the study.  
All potential serious  breaches  must  be reported  to Sponsor or designee  immediately.  A serious  
breach  is a breach  of the conditions  and principles of GCP  in connection with the study or the 
protocol, which  is likely  to affect,  to a significant  degree,  the safety  or physical  or mental  integrity  
of the subjects of the study or the scientific value of the study. 
Personnel  involved in conducting this study will be qualified  by education, training,  and 
experience to  perform  their  respective tasks.  
This study  will not use t he services  of study personnel where  sanctions have  been invoked or where  
there has been scientific  misconduct or fraud (e.g., loss of medical licensure, debarment). 
 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS  COMMITTEE  
Before  study initiation,  the investigator must  have written  and dated  approval/favorable opinion 
from  the IRB/IEC  for the protocol, consent form,  participant recruitment  materials  
(e.g., advertisements), and any other written information to be provided  to subjects.  The 
investigator or Roche should also provide the IRB/IEC  with a copy  of the Investigator  Brochure  or 
product labeling  information to be provided to subjects and any updates. 
The investigator,  Sponsor or designee should provide the IRB/IEC  with reports,  updates and other  
information (e.g., expedited  safety  reports, amendments,  and administrative  letters)  according  to 
regulatory  requirements  or institution  procedures. 
 
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
95/Protocol WN40227, Version 4   COMPLIANCE WITH THE PROTOCOL AND PROTOCOL  REVISIONS  
The investigator  should not implement any deviation or change to the protocol without prior  
review  and documented  approval/favorable  opinion of an amendment  from  the IRB/IEC  (and if 
applicable, also by local  health  authority)  except  where  necessary  to eliminate  an immediate  
hazard(s) to study subjects.  
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to  
obtaining relevant  approval/favorable opinion(s)  the deviation or change will be submitted,  as 
soon as possible to: 
• IRB/IEC for  
• Regulatory  Authority(ies), if applicable  by local  regulations (per national requirements) 
 
Documentation of approval/favorable  opinion signed  by the chairperson  or designee  of the 
IRB(s)/IEC(s) and if applicable, also by local health  authority must  be sent to Roche. 
If an amendment  substantially  alters  the study design  or increases  the potential risk to the 
participant:  (1) the consent form  must  be revised  and submitted  to the IRB(s)/IEC(s) for review  
and approval/favorable opinion; (2) the revised  form  must  be used  to obtain  consent from  subjects  
currently enrolled  in the study if they are affected  by the amendment;  and (3) the new form  must  
be used to obtain consent from new subjects prior to enrollment. 
If the revision is done via an administrative letter, investigators must inform  their IRB(s)/IEC(s).  
 
FINANCIAL DISCLOSURE  
Investigators and sub-i nvestigators  will provide the Sponsor with sufficient,  accurate financial  
information in accordance  with local  regulations  to allow  the Sponsor to submit  complete  and 
accurate financial  certification  or disclosure statements  to the appropriate health  authorities.  
Investigators are responsible  for providing information on financial  interests  during the course of 
the study and for 1 year after completion  of the study.  
 
INFORMED CONSENT PROCESS  
Investigators must  ensure that subjects are clearly and fully informed about the purpose, potential  
risks,  and other critical  issues regarding clinical studies in which they  volunteer to participate.  
In situations  where consent  cannot  be given  to subjects,  their legally  acceptable representatives  
(as per country guidelines) are clearly and fully informed about the purpose, potential risks, and 
other critical  issues  regarding clinical studies in which the participant volunteers to participate.  
Sponsor or designee will provide the investigator  with an appropriate  (i.e., Global  or Local)  sample  
informed  consent form , which  will include  all elements  required  by ICH,  GCP  and applicable  
regulatory  requirements.  The sample  informed  consent  form  will adhere to the ethical  principles 
that have their origin in the Declaration of Helsinki.  
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
96/Protocol WN40227, Version 4   Investigators must:  
• Provide  a copy  of the consent form and written information about the study in the language in  
which  the participant is most  proficient  prior to clinical  study  participation. The language must  
be non- technical  and easily  understood. 
• Allow  time necessary  for participant or participant's legally  acceptable  representative to 
inquire about the details of the study.  
• Obtain an informed consent signed and personally dated by  the participant  or the participant's  
legally  acceptable representative and by the person who conducted the informed  consent  
discussion.  
• Obtain  the IRB/IEC’s  written  approval/favorable opinion of the written  informed  consent  form  
and any other information  to be provided  to the subjects, prior  to the beginning of the study,  
and after any revisions are completed  for new information.  
 
If informed consent is initially  given by a participant’s  legally  acceptable representative or legal  
guardian,  and the participant subsequently  becomes capable of making and communicating  his or  
her informed  consent during the study, consent must  additionally  be obtained from  the participant. 
Revise  the informed  consent  whenever important new information  becomes  available that is 
relevant  to the participant's  consent. The investigator,  or a person designated  by the investigator, 
should fully inform  the participant  or the participant's legally  acceptable  representative  or legal  
guardian,  of all pertinent aspects  of the study and of any new information  relevant to  the 
participant's  willingness  to continue participation  in the study.  This communication  should be 
documented. 
The confidentiality  of records  t hat could  identify subjects  must  be protected,  respecting  the privacy 
and confidentiality  rules applicable to regulatory  requirements, the subjects'  signed  ICF and, in the 
U.S., the subjects’ signed HIPAA Authorization.  
The consent form  must  also include  a statement that Roche and regulatory  authorities  have direct  
access to participant records.  
For minors,  according  to local  legislation,  one or both parents  or a legally  acceptable representative  
must be  informed  of the study procedures and must  sign the informed  consent form  approved for 
the study prior  to clinical  study participation.  The explicit wish  of a minor,  who is capable of 
forming  an opinion  and assessing  this information  to refuse  participation  in, or to be withdrawn  
from,  the clinical  study at any time should be considered by  the investigator. 
Minors who  are judged to  be of an  age of reason  must also  give  their  written  assent.  
The rights,  safety,  and well-being of  the study subjects  are the most  important considerations and 
should prevail  over interests of science and society.  
 
SOURCE DOCUMENTS  
The investigator is responsible for ensuring that the source data are accurate,  legible,  
contemporaneous, original  and attributable, whether the data are hand- written  on paper or entered  
electronically.  If source data are created (first entered), modified, maintained, archived, retrieved,  
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
97/Protocol WN40227, Version 4   or transmitted  electronically  via computerized  systems  (and/or any other kind of electronic 
devices)  as part of regulated  clinical  trial activities,  such systems  must  be compliant with all 
applicable laws and regulations  governing use of electronic records  and/or electronic signatures.  
Such  systems  may include,  but are not limited  to, electronic medical/health  records  (EMRs/EHRs),  
adverse event  tracking/reporting, protocol required  assessments,  and/or drug accountability 
records).  
When  paper records  from  such  systems  are used in place of electronic  format  to perform  regulated 
activities,  such paper  records  should be certified  copies.  A certified  copy  consists  of a copy of 
original information that has been verified,  as indicated  by a dated  signature, as an exact  copy  
having all of the same attributes and information as the original.  
 
STUDY TREATMENT  RECORDS  
Records  for study treatments  (whether  supplied by Roche , its vendors, or the site) must  
substantiate  study  treatment  integrity  and traceability  from  receipt,  preparation, administration,  
and through destruction  or return.  Records  must be  made available for review  at the request  of 
Roche /designee or a Health Authority.   
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
98/Protocol WN40227, Version 4   If Then  
Supplied by Roche  (or its vendors):  Records  or logs must  comply  with applicable  
regulations and guidelines and should include: 
• amount  received and placed in storage 
area 
• amount  currently  in storage  area  
• label identification  number or batch  
number 
• amount  dispensed to and returned by each 
participant,  including  unique participant 
identifiers  
• amount  transferred to another area/site for  
dispensing or storage 
• nonstudy disposition  (e.g., lost, wasted)  
• amount  destroyed  at study site, if 
applicable 
• amount  returned to Roche 
• retain samples for  
bioavailability/bioequivalence, if  
applicable 
• dates  and initials  of person responsible for 
Investigational Product 
dispensing/accountability, as per the  
Delegation  of Authority Form.  
Sourced  by site, and not supplied  by Roche  or 
its vendors (examples include IP sourced from  
the sites stock  or commercial  supply, or a 
specialty  pharmacy)  The investigator  or designee  accepts  
responsibility  for documenting traceability  and 
study drug integrity  in accordance with 
requirements  applicable  under law and the 
SOPs/standards of the sourcing pharmacy. 
These records should include: 
• label identification  number or batch 
number 
• amount  dispensed to and returned by each 
participant,  including unique participant 
identifiers  
• dates  and initials  of person responsible for 
Investigational Product  
dispensing/accountability, as per the  
Delegation  of Authority Form.  
Roche  or designee will provide  forms  to facilitate  inventory  control  if the investigational site does not have  an 
established system that meets these requirements.  
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
99/Protocol WN40227, Version 4   CASE REPORT FORMS  
An investigator  is required  to prepare and maintain  adequate and accurate case histories designed  
to record  all observations and other data pertinent  to the investigation  on each individual treated  
or entered  as a control  in the investigation.  Data that are derived  from  source documents and 
reported  on the CRF must be consistent with the source documents or the discrepancies  must  be 
explained. Additional  clinical  information may be collected  and analyzed  in an effort  to enhance 
understanding of product safety. CRFs  may be requested for AEs and/or laboratory  abnormalities  
that are reported or identified during the course of the study.  
For sites using the Sponsor or designee  electronic data capture  tool, electronic  CRFs  will be 
prepared  for all data collection  fields except  for fields  specific to SAEs  and pregnancy,  which  will 
be reported  on the electronic SAE  form  and Pregnancy  Surveillance form,  respectively.  
If electronic  SAE  form  is not available,  a paper  SAE  form  can be used.  Spaces  may be left 
blank  only in those circumstances  permitted  by study- specific CRF  completion  guidelines  
provided by Sponsor or designee.  
The confidentiality  of records  that could  identify  subjects  must  be protected,  respecting  the privacy 
and confidentiality  rules  in accordance with the applicable regulatory  requirement(s).  
The investigator will  maintain a signature sheet to document signatures and initials of all persons 
authorized  to make entries  and/or corrections on CRFs. 
The completed CRF, SAE/pregnancy CRFs, must be promptly reviewed , signed,  and dated by the  
investigator  or qualified  physician  who is a subinvestigator and who is delegated  this task on the 
Delegation  of Authority  Form. Subinvestigators in Japan may not be delegated the CRF approval  
task. For electronic CRFs,  review  and approval/signature is completed  electronically  through the 
Roche electronic data capture  tool. The investigator  must  retain  a copy  of the CRFs  including 
records of the changes and corrections.  
Each  individual electronically  signing electronic CRFs  must  meet  Sponsor or designee  training  
requirements  and must  only access  the Roche electronic  data capture  tool using  the unique user 
account  provided by  Sponsor or designee.  User accounts  are not to be shared  or reassigned  to other 
individuals. 
 
MONITORING  
Sponsor or designee  representatives  will review  data centrally  to identify  potential  issues  to 
determine a schedule of on-site visits  for targeted review of study records. 
Representatives of Roche  must be allowed to visit all study  site locations  periodically to assess the  
data quality and study integrity.  On site they will review  study records and directly compare  them  
with source documents, discuss the conduct of the study with the investigator, and verify that the  
facilities  remain  acceptable.  Certain  CRF  pages  and/or electronic  files may serve as the source 
documents  such as quality of life questionnaires. 
 
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
100/Protocol WN40227, Version 4  In addition, the study may be evaluated  by Sponsor or designee internal auditors and government  
inspectors who must  be allowed  access  to CRFs,  source documents, other study files,  and study 
facilities. Roche audit reports will be kept confidential. 
The investigator must  notify  Roche promptly of any inspections  scheduled  by regulatory  authorities,  
and promptly forward  copies  of inspection reports to  Sponsor or designee. 
 
RECORDS RETENTION 
The investigator (or head of the study site in Japan) must  retain  all study  records  and source 
documents  for the maximum period required  by applicable regulations and guidelines, or 
institution  procedures, or for the  period specified  by Roche or designee,  whichever  is longer. The 
investigator (or head of the study site in Japan) must contact Roche prior to destroying any records 
associated  with the study.  
Roche or designee will notify  the investigator (or head of the study site in Japan)  when  the study 
records are no longer needed. 
If the investigator  withdraws  from  the study (e.g.,  relocation, retirement),  the records  shall be 
transferred  to a mutually  agreed  upon designee  (e.g., another investigator, study site, IRB).  Notice  
of such transfer will be given in writing  to Roche or designee.  
 
RETURN OF STUDY TREATMENT  
For this study, study treatments  (those supplied by  Roche , a vendor or sourced by  the investigator)  
such as partially  used study  treatment  kits, vials and syringes may be destroyed on site.  
 
If Then  
Study  treatments  supplied  by Roche  
(including its vendors) Any unused  study  treatments  supplied  by 
Roche  can only be destroyed after being  
inspected  and reconciled  by the responsible 
Study Monitor unless  study treatments  kits 
must  be immediately  destroyed  as required  
for safety,  or to meet  local  regulations (e.g., 
cytotoxics or biologics).  
If study treatments  will be returned, the return  
will be arranged  by the responsible  Study 
Monitor. 
Study  treatments  sourced  by site, not supplied  
by Roche (or its vendors) (examples  
include study treatments  sourced  from  the 
sites stock  or commercial supply, or a 
specialty  pharmacy)  It is the investigator’s  or designee’s  
responsibility  to dispose  of all kits 
according  to the institutional  guidelines  and 
procedures. 
 
It is the investigator’s or designee’s  responsibility  to arrange for disposal, provided that procedures  
 
Anti -Myostatin Adnectin (RO7239361)— F. Hoffmann -La Roche Ltd 
101/Protocol WN40227, Version 4  for proper disposal  have been established  according  to applicable federal,  state,  local,  and 
institutional  guidelines and procedures, and provided  that appropriate records  of disposal  are kept. 
The following minimal standards must be met:  
• On-site disposal practices  must not expose humans to risks from  the drug. 
• On-site disposal practices  and procedures are in agreement  with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.  
• Written  procedures for on- site disposal  are available  and followed. The procedures must  be 
filed with the site’s SOPs and a copy  provided to Roche upon request. 
• Records are maintained  that allow  for traceability  of each container, including  the date 
disposed of, quantity disposed, and identification  of the person disposing the kits. The method  
of disposal, incinerator, licensed  sanitary landfill,  or licensed  waste  disposal vendor must be 
documented. 
• Accountability and disposal records are complete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period. 
 
It is the investigator’s  or designee’s responsibility  to arrange for disposal  of all empty  kits. 
If conditions for destruction  cannot  be met  the responsible  Study  Monitor will  make  arrangements  
for return  of study treatments  provided by Roche (or its vendors). Destruction  of non- study  
treatments  sourced  by the site, not supplied by Roche , is solely  the responsibility  of the investigator  
or designee.  
 
CLINICAL STUDY REPORT  AND PUBLICATIONS  
A Signatory Investigator must be selected to sign the clinical study report.  
For this protocol, the Signatory  Investigator will be selected  as appropriate  based  on the following 
criteria:  
• External Principal  Investigator designated at protocol development 
• National  Coordinating Investigator  
• Study Steering Committee chair or their designee  
• Participant  recruitment  (e.g., among the top quartile of enrollers) 
• Involvement in trial design 
• Regional  representation  (e.g., among  top quartile  of enrollers  from  a specified  region  or country)  
• Other criteria (as determined by  the study team)  
 
The data collected  during  this study are  confidential  and proprietary to Sponsor or designee.  Any 
publications or abstracts  arising  from  this study  must adhere to the publication  requirements  set 
forth  in the clinical  trial agreement  (CTA)  governing [Study  site or Investigator] participation  in 
the study.  These  requirements  include, but are not limited to, submitting proposed publications to  
Sponsor or designee  at the earliest  practicable  time prior to submission  or presentation and 
otherwise  within the time period set forth in the CTA.  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
102/Protocol WN40227, Version 4 
  
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS:  
DEFINITIONS AND PROCEDURES FOR RECORDING,  
EVALUATING, FOLLOW UP AND REPORTING  
 
ADVERSE EVENTS  
 
Adverse Event Definition:  
An Adverse  Event  (AE)  is defined  as any new untoward  medical  occurrence  or worsening  of a 
preexisting medical  condition in a clinical  investigation  participant  administered  study  drug and 
that does not necessarily have a causal relationship  with  this treatment.  
An AE can therefore  be any unfavorable  and unintended  sign (such  as an abnormal  laboratory  
finding), symptom,  or disease temporally  associated  with the use of study drug, whether  or not 
considered related to the study drug.  
 
 
SERIOUS ADVERSE EVENTS  
 
Serious  Adverse  Event  (SAE)  is defined  as any untoward  medical  occurrence  that,  at any 
dose:  
Results in death  
Is life-threatening  (defined  as an event  in which  the participant  was at risk of death  at the time 
of the event;  it does not refer to an event  which  hypothetically  might  have caused  death  if it were  
more  severe)  
Requires  inpatient  hospitalization or causes prolongation of existing  hospitalization (see NOTE  
below)  
NOTE:  
The following hospitalizations are not considered  SAEs in Roche clinical studies:  
o a visit to the emergency  room  or other hospital department  < 24 hours, that does  not 
result  in admission  (unless  considered  an important  medical  or life- threatening 
event)  
o elective surgery, planned prior to signing consent 
o admissions as per protocol for a planned medical/surgical procedure 
o routine health  assessment  requiring  admission  for baseline/trending  of health  status 
(e.g., routine colonoscopy)  
o medical/surgical  admission other than to remedy  ill health  and planned prior  to entry  
into the study.  Appropriate documentation  is required  in these cases  
 
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
103/Protocol WN40227, Version 4 
 o admission  encountered  for another  life circumstance  that carries  no bearing  on health  
status  and requires  no medical/surgical intervention  (e.g., lack of housing, economic  
inadequacy,  caregiver  respite,  family  circumstances,  administrative  reason)  
o admission  for administration  of anticancer  therapy  in the absence of any other SAEs 
(applies to oncology protocols) 
Results in persistent  or significant  disability/incapacity  
Is a congenital anomaly/birth defect  
is an important  medical  event (defined  as a medical  event(s)  that may not be  immediately  life- 
threatening  or result  in death  or hospitalization  but, based  upon appropriate medical  and 
scientific  judgment, may jeopardize  the participant or may require intervention  [e.g., medical,  
surgical]  to prevent one of the other serious  outcomes listed in the definition above.) Examples  
of such events  include, but are not limited  to, intensive  treatment in an emergency  room  or at 
home for allergic  bronchospasm; blood dyscrasias  or convulsions  that do not result  in 
hospitalization.) Potential drug induced liver injury (DILI)  is also considered  an important  
medical event. (See  Section  9.2.7 for the definition  of potential DILI.)  
 
Suspected  transmission  of an infectious  agent  (e.g., pathogenic  or nonpathogenic) via the study 
treatment  is an SAE.  
Although  pregnancy, cancer,  and potential  drug induced liver injury  (DILI)  are not always  
serious by regulatory  definition,  these  events must  be handled as SAEs.  (See Section  9.2.5 for 
reporting pregnancies). 
Any component of a study  endpoint that is considered related to study  therapy  should be reported  
as SAE  (e.g., death  is an endpoint, if death  occurred  due to anaphylaxis,  anaphylaxis must  be 
reported).  
 
EVALUATING AE s AND SAE s 
 
Assessment of Causality  
The causal relationship to study  drug is determined by  a physician  and should  be used to assess  
all adverse events (AE). The causal relationship can  be one of the following:  
Related:  There  is a reasonable  causal  relationship between  study  drug administration  and 
the AE.  
Not related:  There  is not a reasonable causal  relationship  between  study  drug 
administration and the AE. 
The term "reasonable causal relationship" means  there is evidence to suggest a causal  
relationship. 
 
  
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
104/Protocol WN40227, Version 4 
 Assessment of severity  
The following  categories and definitions of severity  as determined by a physician should be 
used for assessing severity of adverse events: 
• Mild (Grade 1) :  Awareness of  event  but easily  tolerated  
• Moderate (Grade 2) :  Discomfort  enough to cause some interference with usual activity  
• Severe (Grade 3) :  Inability  to carry  out usual  activity  
• Very  severe (Grade  4):  Debilitating,  significantly  incapacitates  subject  despite  
symptomatic  therapy  
 
 
Follow -up of AEs and SAEs  
If only limited  information  is initially  available,  follow -up reports  are required.   
(Note:  Follow- up SAE reports must include the same investigator  term(s)  initially  reported.) 
If an ongoing SAE  changes  in its intensity  or relationship to study drug or if new information  
becomes  available,  the SAE  report must  be updated and submitted  within  24 hours to Roche 
(or designee) using the same procedure used for transmitting the initial SAE report.  
All SAEs must be followed  to resolution  or stabilization.  
 
OVERDOSE, MEDICATION ERROR, DRUG MISUSE AND DRUG ABUSE  
 
Definition:  
Accidental overdose :  accidental administration of a drug in a quantity that is higher than the 
assigned dose.  
Intentional overdose :  intentional administration of a drug in a quantity that is higher than the 
assigned dose.  
Medication error :  accidental deviation in the administration of a drug (in some cases, a 
medication error may be intercepted prior to administration of the drug).  
Drug abuse :  intentional excessive use of a drug that may lead to addiction or dependence,   
physical harm, and/or psychological harm.  
Drug misuse :  intentio nal deviation in the administration of a drug that does not qualify as drug 
abuse (drug misuse could involve the drug being administered to someone other than the patient).  
 
 
   
REPORTING OF SAE s TO SPONSOR OR DESIGNEE 
 
Anti -Myostatin Adnectin (RO7239361) —F. Hoffmann -La Roche Ltd 
105/Protocol WN40227, Version 4 
  
 • SAEs, whether related or not related to study  drug, and pregnancies must be reported to 
Roche (or designee)  within  24 hours of awareness  of the event.  
• SAEs   must   be  recorded  on  the  SAE   Report  Form;   pregnancies  on  a  Pregnancy  
Surveillance Form (electronic or paper forms). 
• The preferred method for SAE data reporting collection  is through the eCRF. 
• The paper  SAE/pregnancy  surveillance forms  are only intended  as a back -up option 
when the eCRF system is not functioning.  
o In this case,  the paper forms  are to be transmitted  via email or  confirmed  
facsimile (fax) transmission  to: 
SAE Email Address: Refer to Contact Information list.  
SAE  Facsimile  Number:  Refer to  Contact Information list.  
For studies capturing  SAEs through electronic data capture (EDC), electronic submission is the 
required  method for reporting.  In the event  the electronic system  is unavailable  for transmission,  
paper forms must be used and submitted immediately. When paper forms are used, the  original 
paper  forms  are to remain  on site.  
SAE  Telephone  Contact  (required  for SAE  and pregnancy  reporting):  Refer  to Contact  
Information list 
 
Anti-Myostatin Adnectin  (RO7239361) —F. Hoffmann- La Roche Ltd  
106/Protocol WN40227, Version 4 
  
APPENDIX 4 WOMEN OF CHILDBEARING  POTENTIAL DEFINITIONS AND  
METHODS OF CONTRACEPTION  
 
CONTRACEPTION GUIDANCE  FOR  MALE  PARTICIPANTS  WITH  PARTNER(S) OF  
CHILD BEARING POTENTIAL.  
Appropriate patient -centered counseling of adolescent trial subjects about contraception and 
sexual health topics should be provided, includi ng acceptable, highly effective methods as 
described below.  
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION 
Highly  effective methods  of contraception have a failure rate of < 1% when used consistently  and 
correctly.  Female  partners  of male  subjects,  who are WOCBP,  are expected  to use one of the 
highly  effective methods of contraception  listed  below.  Male  subjects  must  inform  their female  
partners  who are WOCBP  of the contraceptive requirements  of the protocol and are expected  
to adhere to using  contraception  with their partner.  Contraception  methods  are as follows:  
1. Progestogen only hormonal contraception  associated  with inhibition  of ovulation.  
2. Hormonal methods  of contraception  including oral contraceptive pills containing 
combined  estrogen  + progesterone, vaginal  ring, injectables,  implants  and intrauterine  
devices (IUDs) such as Mirena® 
Male participants  with female partners  of childbearing potential  are eligible  to participate  if they 
agree to the following during the treatment  and until the end  of relevant  systemic  exposure. 
• Inform  any and all partner(s) of their participation  in a clinical drug study and the need to 
comply  with contraception instructions as directed  by the investigator. 
• Males  who are sexually  active with WOCBP  must  agree to  follow  instructions for method(s) 
of contraception  for the duration of treatment  with study treatment(s)  plus 5 half-lives of the 
study treatment  [RO7239361; 50 days]  plus 90 days (duration of sperm  turnover) for a total of 
140 days (5 months)  post- treatment completion.  
• Azoospermic males are exempt from contraceptive requirements ; however, use of condom in 
male subjects (including azoospermic males) who are sexually  active  with a pregnant partner is 
required . 
• Male participants  must  be willing  to refrain  from  sperm  donation during the entire  study  and 
for 5 half-lives of study  treatment  plus 90 days (duration of sperm  turnover)  140 days after 
dosing has been completed.  
 
 
2. COLLECTION OF PREGNANCY INFORMATION  
Guidance for collection  of Pregnancy  Information  and outcome  of pregnancy  on the Pregnancy 
Surveillance Form is provided in Section 9.2.5  and the Appendix for Adverse Events and Serious  
Adverse  Events Definitions  and procedures for Evaluating, Follow -up and Reporting . 
 